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Status epilepticus (SE) is a life-threatening neurologic emergency 
occurring when the brain is in an unrelenting state of seizure activity. 
Approximately 40% of people who encounter a single event of SE go on to 
develop epilepsy, characterized by spontaneously occurring seizures. While the 
exact mechanisms underlying seizure origin are not understood, at a 
fundamental level seizures initiate due to an imbalance between inhibitory and 
excitatory neurotransmission.  We explored the impact of SE and the 
development of epilepsy on GABAA receptor mediated inhibitory 
neurotransmission and kainate receptor (KAR) mediated excitatory 
neurotransmission. 
Stiripentol (STP), a positive allosteric modulator of the GABAA receptor, 
was found to terminate both brief and prolonged SE with the development of less 
pharmacoresistance than is observed with the benzodiazepine (BZD), diazepam 
(DZP). In addition STP, but not DZP, retained its ability to potentiate both phasic 
and tonic GABAergic transmission post-SE. These findings are supported by 
previous studies demonstrating that the actions of STP do not require the BZD-
sensitive γ2-containing GABAARs which are internalized during prolonged SE. 
These data demonstrate that prolonged SE significantly impacts the 
pharmacological profile of GABAA receptors and potential therapeutics. 
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KARs densely populate the hippocampal mossy fiber – CA3 pathway 
where they mediate a portion of excitatory neurotransmission. Significant 
alterations in KAR subunit expression in the dentate gyrus and CA3 regions were 
observed in animals at 5, 60 and 200 day post-SE. These changes were dynamic 
and region specific. In agreement with observed alterations in subunit 
expression, KAR-mediated neurotransmission was significantly reduced at 
mossy fiber – CA3 synapses in epileptic animals. In addition, synaptic integration 
by KARs during repetitive stimulation was also significantly impaired. These data 
demonstrate that SE significantly impacts KAR-mediated excitatory 
neurotransmission. 
Together these studies provide new insight into the impact of SE and the 
development of epilepsy on both GABAA and KAR-mediated neurotransmission. 
The observed alterations following SE may contribute to the generation of 
seizures or may be compensatory mechanisms to reduce the likelihood of 
seizure initiation. Furthermore, these findings demonstrate the dramatic 
alterations observed in the diseased brain and emphasize the importance of 
acknowledging these differences for the development of effective therapeutics.
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 1.1 SIGNIFICANCE 
 
Epilepsy is the fourth most common neurological disorder after migraine, 
stroke and Alzheimer’s disease. The prevalence of the disorder is greater than 
that of autism spectrum disorders, cerebral palsy, multiple sclerosis and 
Parkinson’s disease combined (Epilepsy Foundation, 1993). Despite the 
magnitude of the disease-awareness, understanding and treatment of epilepsy 
are severely limited. Epilepsy is characterized by the presence of recurring, 
unprovoked abnormal synchronous brain activity that results in the disruption of 
normal brain function (Briggs and Galanopoulou, 2011). The World Health 
Organization has estimated that at least 65 million people worldwide, or nearly 
1% of the population, are afflicted with a type of epilepsy syndrome (England et 
al., 2012). Several precipitating events are linked to the development of epilepsy, 
including trauma, stroke and tumors (Chang and Lowenstein, 2003). However, 
epilepsy is considered the most challenging long-term consequence associated 
with status epilepticus (SE), as nearly 40% of people who endure a single event 
of SE develop epilepsy (Hesdorffer et al., 1998).   
Status epilepticus is a neurologic emergency, characterized as a seizure 
that lasts longer than 5 minutes, or when two seizures occur without complete 
 
2 
recovery between them (Epilepsy Foundation, 1993). SE occurs with an 
incidence of 100,000 – 160,000 people per year in the United States (Manno, 
2003), and results in death in approximately 20% of patients (Theodore et al., 
1994). While SE affects people of all ages, it is considered the most common 
neurologic condition in childhood with an incidence of 10 – 27 per 100,000 
children ranging from 1 month to 15 years of age, with the majority of events 
occurring in children less than four years of age (DeLorenzo et al., 1996; 
Hesdorffer et al., 1998; Coeytaux et al., 2000; Chin et al., 2006; Govoni et al., 
2008). Both the etiology (Huff and Fountain, 2011) and duration of SE 
dramatically impacts the prognosis, with a longer duration of SE correlated to 
increased morbidity and mortality (Pellock et al., 2004).  
Through a combination of anti-epileptic drugs (AEDs) and/or brain 
surgery, adequate control of seizures is obtained in nearly 60% of patients 
(Jacobs et al., 2009). However, nearly 20 – 40% of patients diagnosed with 
epilepsy will develop refractory status epilepticus (RSE), and will be unable to 
manage their seizures with available AEDs (French, 2007).  Patients suffering 
from RSE have increased hospitalization and more frequent medical 
complications (Mayer et al., 2002). There are a wide variety of factors that 
contribute to the development of RSE, including age of onset, seizure etiology, 
infection, as well as genetic and environmental factors (French, 2007). In 
addition, in both SE-experienced patients (Grigorenko et al., 1997; Mathern et al., 
1998; Loup et al., 2000; Das et al., 2012; Houser et al., 2012) and animal models 
of SE (Lason et al., 1997; Mikuni et al., 1999; Porter et al., 2006; Goodkin et al., 
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2008; Sun et al., 2009; Rajasekaran et al., 2012), both inhibitory and excitatory 
receptor populations are altered, a consequence of SE that may dramatically 
impact the effectiveness of prescribed AEDs and contribute to RSE. Despite 
these changes, little is known about how these alterations in receptor populations 
affect receptor pharmacology and neuronal signaling in the SE-experienced 
brain.  Understanding these alterations is crucial to being able to develop 
effective therapies for the treatment of status epilepticus and the progression to 
spontaneously occurring seizures. 
At the core of status epilepticus is the inability of the inherent cellular 
mechanisms to terminate seizure activity (Coulter and DeLorenzo, 1999). These 
sustained seizure events can yield devastating consequences including 
becoming refractory to available AEDs and the increased risk for the 
development of epilepsy.  
The following studies provide new evidence regarding how status 
epilepticus alters hippocampal inhibitory and excitatory receptor populations, and 




The International League Against Epilepsy and the International Bureau of 
Epilepsy have defined epilepsy as a disorder of the brain characterized by an 
enduring predisposition to the generation of epileptic seizures. In addition 
neurobiological, cognitive, psychological and social consequences associated 
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with the disease have been identified. In accordance with a variety of diagnostic 
tests, the diagnosis of epilepsy requires the occurrence of at least one epileptic 
seizure, defined as a transient occurrence due to abnormal, excessive or 
synchronous brain activity (Fisher et al., 2005). Epilepsy is a heterogeneous 
disease with no obvious geographic, racial or social boundaries. Despite its 
diversity, epilepsy tends to be more frequent within the African American 
population, slightly more common in men than women, and is more commonly 
diagnosed in infants and adults over 65 years of age (Theodore et al., 2006). 
Epilepsy is believed to affect nearly 65 million people worldwide, and may affect 
as many as 2.8 million Americans (England et al., 2012). In the United States the 
total annual hospital charges billed for the treatment of epilepsy totaled nearly $3 
billion (Vivas et al., 2012). However the annual economic burden of the disease, 
including lost employment, wages and productivity, has been estimated at $17.6 
billion. In addition to the economic burden, the diagnosis of epilepsy carries with 
it an increased risk for the development of social stigma and severe 
comorbidities. 
 
1.2.1 EPILEPSY STIGMA 
The earliest written description of seizure disorders dates back to nearly 
2000 B.C. in the region known as Mesopotamia, while the first medical 
documentation of the disease was crafted by Hippocrates in 400 B.C. 
(Magiorkinis et al., 2010). Despite the vast amount of time in which people have 
known about epilepsy the lack of understanding and knowledge about the 
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disease led people to believe that seizures were the result of demonic 
possession, sin and even lunacy. Despite the efforts of modern scientific and 
medical research to cast light on the disease many of the original social stigmas 
continue to impact epilepsy patients, caregivers and family members. In addition, 
patients who feel they experience the stigma often report increased levels of 
depression and anxiety, reduced self-esteem, and an overall decrease in quality 
of life (Jacoby and Austin, 2007). In addition to the social stigma associated with 
the disease, people suffering from epilepsy have difficulty obtaining driver’s 
licenses, proper medical insurance, and face limited job opportunities as careers 
in teaching, medicine, and police or fire enforcement may be restricted (Jacoby 
and Austin, 2007). In order to reduce the stigma associated with epilepsy the 
scientific community must join efforts with the millions of people suffering from 
seizure disorders and begin to raise public awareness and knowledge about the 
disease.  
 
1.2.2 COMORBIDITIES OF SEIZURE DISORDERS 
 While people suffering from epilepsy continue to face the stigma 
associated with their disease they are also at risk for a myriad of moderate to 
severe psychiatric, cognitive and behavioral comorbidities. For decades it was 
believed that these comorbid conditions were side-effects of the seizures, 
however more recent data suggest that some conditions may precede the 
seizures. In addition, control of seizures through available AEDs may not 
alleviate the symptoms associated with the comorbid conditions. Comorbidities 
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associated with seizure disorders require adequate attention as these conditions 
may be more severe and debilitating than the seizures themselves. Alterations in 
comorbidities are also observed during the progression of epilepsy and have 
been correlated with age of onset, seizure frequency and duration of seizures 
(Jacobs et al., 2009). 
 Psychiatric and cognitive comorbidities are commonly observed in patients 
suffering from seizure disorders. Diagnosis of psychiatric comorbidities including 
depression, anxiety, mood disorders and attention-deficit hyperactivity disorder 
are increased in epileptic patients (Lin et al., 2012). Of these conditions 
depression is the most common with some studies reporting upwards of 55% of 
patients suffering from depressive like symptoms (Jackson and Turkington, 
2005). Depression is not a uniform comorbidity in epilepsy, as it appears to be 
more common in complex partial (temporal lobe) seizures, than in generalized 
seizure disorders (Jackson and Turkington, 2005). In addition to depressive 
symptoms, suicide is also increased from 1.4% in the non-epileptic population to 
nearly 5% in epileptic patients (Jackson and Turkington, 2005). 
 As observed with psychiatric comorbidities, the impact of seizures on 
cognition appears to be related to seizure etiology, frequency, duration and 
severity (Saling et al., 1993; Jones-Gotman, 2000; Helmstaedter and Kurthen, 
2001; Jokeit and Ebner, 2002; Aldenkamp and Arends, 2004; Dodrill, 2004). In 
addition cognitive impairments are more prevalent in patients suffering from 
temporal (van Rijckevorsel, 2006) and frontal lobe epilepsies (Hernandez et al., 
2003). Commonly reported symptoms include impairments in memory, attention 
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and a general mental slowness (van Rijckevorsel, 2006). More recently, it has 
become evident that impaired cognitive abilities may precede the development of 
epilepsy, as studies have demonstrated academic underachievement in children 
(Austin et al., 2001; Dunn et al., 2002; Oostrom et al., 2003; Hesdorffer et al., 
2004; Berg et al., 2005) as well as adults (Hesdorffer et al., 2000; Hesdorffer et 
al., 2006) prior to seizure onset. Furthermore, commonly prescribed AEDs may 
initiate comorbid side-effects or exacerbate existing symptoms, as they have 
been shown to negatively impact cognition, as well as increase depression, 
anxiety and nervousness (Bootsma et al., 2006; Meador, 2006; Schmitz, 2006; 
Gomer et al., 2007). 
 
1.2.3 SEIZURE CLASSIFICATION 
In April of 1964, led by Henri Gastaut, several European branches of the 
International League Against Epilepsy met to develop an international 
classification of epileptic seizures. This initial system has been continuously 
amended and improved as knowledge and understanding of epilepsy and 
differences in seizure types emerged. In 1981 a detailed version of the 
classification system, which included seizure video and electroencephalogram 
(EEG) recordings, was approved by the General Assembly of the International 
League Against Epilepsy and has become the hallmark for seizure classification 
by clinicians.  
As approved in 1981, seizures can be classified into two broad categories, 
partial (also referred to as focal) and generalized seizures. Partial seizures 
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account for approximately 60% of new cases of epilepsy (Hauser et al., 1991), 
and generally only impact a specific region of the brain. Depending upon the 
brain region affected symptoms may impact motor, cognitive, sensory, or 
autonomic abilities. Partial seizures are further classified depending upon 
alterations in consciousness. Consciousness is not altered in simple partial 
seizures; however it is lost during complex partial seizures, also referred to as 
temporal lobe or psychomotor seizures. These types of seizures occur in about 
35% of patients, who have no memory of the event and usually report feelings of 
confusion and tiredness following the seizure event (Kammerman and 
Wasserman, 2001). Given that partial seizures occur in a specific region of the 
brain, they do have the ability to spread throughout the brain, a term referred to 
as secondary generalization. 
The second seizure category is referred to as generalized seizures 
(primary generalized) and account for approximately 40% of epilepsy cases 
(Hauser et al., 1991).  Unlike partial seizures, which are focal in nature, 
generalized seizures affect the entire brain, specifically the motor cortex and 
involve a loss of consciousness and impaired memory of the event. Six types of 
generalized seizures have been described. However, the most common is the 
grand-mal (tonic-clonic) seizure, which accounts for about 25% of all generalized 
seizures. Other types of generalized seizures include petit-mal (absence), 
myoclonic, clonic, tonic, and atonic. Each of the six types of generalized seizures 
is accompanied by distinct physical characteristics and movements by the patient 
(Kammerman and Wasserman, 2001).  
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 Both partial and generalized seizures are considered self-limiting, as they 
will terminate within seconds to minutes of onset. However a separate category 
of seizures exists, those referred to as continuous seizures or SE. Similar to self-
limiting seizures, SE can also be divided into two broad categories; general 
convulsive SE (GCSE) and non-convulsive SE (NCSE). GCSE is the most 
common form of SE, associated with higher morbidity and mortality and 
characterized by continuous, rhythmic movements. In contrast, NCSE manifests 
as confusion, psychosis without overt alterations in motor activity. Patients with 
GCSE or NCSE will demonstrate bilateral impairments on EEGs, however due to 
the lack of physical manifestations in NCSE an EEG is required for this 
diagnosis. Figure 1.1 serves as a modified diagram illustrating the different 
seizure categories discussed.  
The current project will focus on general convulsive status epilepticus and 
the progression to spontaneously occurring seizures. 
 
1.3 STATUS EPILEPTICUS 
 Status epilepticus (SE) is classically defined as the occurrence of two or 
more seizures without recovery of consciousness or 30 minutes of continuous 
seizure activity. However, due to the seriousness of SE more recent literature 
has reduced this time to merely 5 minutes of seizure activity (Huff and Fountain, 
2011). Unlike more classic seizure disorders, SE represents the inability of 
inherent cellular mechanism to terminate the seizure (Coulter and DeLorenzo, 








Figure 1.1. Seizure classification. Two broad categories of seizures 
exist, those that are self-terminating and those that are sustained, referred to as 
status epilepticus (SE). Self-terminating seizures can be further classified into 
partial and generalized seizures. Partial seizures are localized to a particular 
brain region whereas generalized seizures can affect the entire cortex. These 
categories are further identified based upon behavioral consequences including 
loss of consciousness. Partial seizures can spread to more severe generalized 
seizures. Sustained seizures, SE, can be subdivided into non-convulsive SE 
(NCSE) and generalized convulsive SE (GCSE). Additional types of SE exist but 










SE is composed of both an activation and a maintenance phase (Mazarati et al., 
1998). The proposed phases of SE are likely regulated by the several different 
receptor populations which can mediate excitatory and inhibitory 
neurotransmission. 
In the United States there are approximately 150,000 cases of SE each 
year (Chapman et al., 2001), of which at least 50% are diagnosed as the more 
severe GCSE. SE is associated with nearly a 20% mortality rate, a figure even 
higher in cases of RSE (Aminoff and Simon, 1980; Towne et al., 1994). In 20 – 
40% of patients a single SE event eventually leads to the development and 
diagnosis of epilepsy (Hesdorffer et al., 1998; Sankar et al., 2000). While 50% of 
SE cases occur in patients with no known seizure disorder, a previous diagnosis 
of epilepsy does significantly increase the risk of SE (Hesdorffer et al., 1998), 
with approximately 15% of epilepsy patients experiencing an episode of SE 
during their lifetime (Trinka et al., 2012). While risk factors for the development of 
SE are limited it is acknowledged that one factor is age, as approximately 40% of 
SE patients are under 2 years of age and the greatest incidence of SE occurs in 
adults over 60 years of age (Shinnar et al., 1997). Additional risk factors include 
possible genetic factors and lower socioeconomic standing.  
There are two general categories of underlying causes of SE, acute and 
chronic. Acute etiology includes an imbalance in electrolytes, drug toxicity, 
infection of the central nervous system (CNS), cerebral trauma, etc., while more 
chronic etiologies include a pre-existing seizure disorder, alcoholism, cerebral 
tumors or lack of AED compliance (Trinka et al., 2012). Understanding the 
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possible origin for the development of SE greatly influences potential treatment 
protocols for the patient. 
 
1.3.1 SEIZURE MECHANISMS 
 At a basic level seizures initiate due to abnormal neuronal firing or 
imbalance within the inhibitory and excitatory systems of the brain. Due to the 
highly interconnected network of the brain, epileptiform activity in one area or 
within one population of neurons can easily spread to neighboring areas and may 
eventually alter transmission throughout the entire cerebrum.  The majority of 
seizures are considered self-limiting, in that within seconds to minutes the 
seizure will terminate without the need for intervention. However when a seizure 
does not self-terminate it may continue indefinitely, a neurologic emergency 
referred to as SE. The exact mechanism by which seizures terminate is not clear. 
It is postulated that mechanisms involved in seizure termination occur at the level 
of a single neuron or within a network of neurons, and that in some individuals 
these mechanisms may simply fail (Lado and Moshe, 2008).  
One of the most critical mechanisms involved in regulation of neuronal 
firing is proper regulation of the afterhyperpolarization (AHP) which occurs at the 
level of the single neuron. Action potential invasion into a neuron produces an 
increase in intracellular Ca2+ which activates voltage-gated K+ channels that 
allow for K+ to flow out of the cell. This efflux of K+ leaves the intracellular space 
more negatively charged and the cell hyperpolarizes, which prevents further 
excitability (Alger and Nicoll, 1980; Timofeev et al., 2004). Network regulation of 
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seizures includes depletion of synaptic glutamate which serves to limit burst 
activity (Staley et al., 1998), and acidification of both the intracellular and 
extracellular spaces due to the increase in CO2 levels during prolonged seizure 
activity (Chesler and Kaila, 1992). Network synchronization, a hallmark of 
seizures, is partly regulated by interneuronal gap junctions (Mancilla et al., 2007). 
The acidification during a seizure also results in the decoupling of these gap 
junctions, which serves to limit neuronal discharge and network synchronization 
(de Curtis et al., 1998). There are many different mechanisms that serve to limit 
seizure activity, any number of which could be altered resulting in prolonged 
status epilepticus. 
 
1.3.2 TREATMENT OF REFRACTORY STATUS EPILEPTICUS 
 A major component to successful termination of SE is the ability of the 
patient to receive rapid treatment. It has been demonstrated that treatment even 
prior to arrival at a hospital is critical (Pellock et al., 2004). In a study 
investigating seizure treatment it was determined that over half of patients who 
were not successfully treated prior to a hospital were twice as likely to require 
intensive care (Alldredge et al., 2001). Fast and effective treatment of SE is so 
essential that standard treatment algorithms have been developed that indicate 
the hierarchy of available drugs (Pellock et al., 2004). In agreement with clinical 
studies indicating the need for pre-hospital treatment of SE, treatment algorithms 
begin with conventional antiepileptic drugs (AEDs) including benzodiazepines 
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(BZDs) and advance to the use of barbiturates and even anesthesia in extreme 
cases.  
 BZDs, including diazepam, are considered the first line of treatment of SE. 
To achieve the highest rate of seizure termination BZDs should be administered 
within minutes of seizure onset. One rationale for immediate treatment is that 
while BZDs are considered the safest of the available AEDs they have been 
shown to lose effectiveness during the progression of SE (Walton and Treiman, 
1988; Kapur and Macdonald, 1997; Jones et al., 2002; Grosenbaugh and Mott, 
2013).  Patients who develop pharmacoresistance to BZDs and other 
medications may develop RSE. Despite adequate treatment with available AEDs 
nearly 45% of patients with SE will develop RSE, which brings with it an 
increased risk for a variety of neuropathological consequences including death in 
nearly 25% of cases (Mayer et al., 2002; Holtkamp et al., 2005; Rossetti et al., 
2005). In cases of RSE when available AEDs are ineffective patients are often 
put into medically induced comas through exposure to a variety of anesthetics 
(Knake et al., 2009). 
 Chapter 3 will explore the use of stiripentol, a novel AED, for the treatment 
of BZD-refractory status epilepticus. 
 
1.4 THE HIPPOCAMPUS 
The term ‘hippocampus’, derived from the Greek word for seahorse, was 
first coined by anatomist Giulio Cesare Aranzi in 1587. Investigation into this 
newly discovered structure continued and by the mid 1900’s it was evident that 
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the early neuroanatomists such as Camillo Golgi, Karl Schaffer, and Santiago 
Ramon y Cajal, where incredibly accurate in their initial description and depiction 
of this region. In fact a rendering of the hippocampus by Ramon y Cajal in his 
book Histologie du Systeme Nerveux (1911) is widely used today. Despite a 
rapidly growing understanding of the anatomy and structure of the hippocampus 
the function of this region was not as clear. This changed in 1957 with the patient 
H.M. who underwent a bilateral mesial temporal lobectomy in which his 
hippocampus, among other limbic structures, was removed in an attempt to cure 
his epilepsy. The studies and observations of H.M. by William Scoville and 
Brenda Milner (Scoville and Milner, 1957) concluded that while the surgery was 
successful in reducing the seizures, the patient was left with global amnesia. This 
was the first time a direct link between memory and the hippocampus had been 
detected as prior to this event the hippocampus was believed to be involved in 
the limbic ‘emotional’ circuitry of the brain.  
The connection between the hippocampus and memory is nearly 
universally agreed upon, despite discrepancies regarding its precise role.  
However, it is generally accepted that the hippocampus is critical for both 
declarative memory and spatial memory (Burgess et al., 2002). Declarative, or 
explicit, memory is thought to include both episodic memory which is the capacity 
to remember personal experiences, as well as semantic memory which involves 
factual knowledge related to meanings and general concepts. As the name would 
indicate, spatial memory involves encoding information regarding one’s spatial 
orientation and environment. Consistent with the understanding of the 
 
16 
hippocampus’s role in spatial memory is the presence of hippocampal ‘place 
cells’ that encode an animal’s location independent of its orientation (O'Keefe, 
1976; Wilson and McNaughton, 1993; Muller et al., 1994). In addition to encoding 
specific types of information the hippocampus is also involved in memory 
retrieval. While research in this area is complicated it is believed that damage to 
the hippocampus, including lesions, sclerosis or atrophy, results in the inability to 
form new memories (anterograde amnesia), as well as difficulty recalling events 
just prior to the injury (temporally graded retrograde amnesia) (Squire, 1992; 
Hodges, 1994; Squire and Alvarez, 1995). 
The importance and central role for the hippocampus in learning and 
memory is without question. In accordance, hippocampal atrophy or sclerosis is a 
hallmark of many diseases linked to severe cognitive impairment, including 
Alzheimer’s disease (Jack et al., 1999; Wang et al., 2006), schizophrenia 
(Heckers, 2001), and as is the focus of this document, epilepsy (Chang and 
Lowenstein, 2003). The ability to develop therapeutics for the treatment of these 
diseases and their severe comorbidities (i.e. cognitive impairment) likely lies 
within our understanding of the hippocampus. As this region is highly organized 
and relatively encapsulated its anatomical structure and circuitry in the healthy 
brain has been well characterized. 
 
1.5 HIPPOCAMPAL ANATOMY AND CIRCUITRY 
The hippocampal formation lies deep within the mesial temporal lobes and 
is just one of several brain structures located within the limbic system. The 
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hippocampal formation contains several brain structures including the 
presubiculum, parasubiculum, entorhinal cortex (EC), subiculum, dentate gyrus 
(DG), and hippocampus proper. The hippocampus proper is composed of three 
distinct cellular subdivisions; CA1, CA2 and CA3, where ‘CA’ comes from the 
term cornu ammonis or Ammon’s horn.  Most commonly, and throughout this 
document, the term hippocampus refers collectively to the dentate gyrus and to 
areas CA1, CA2, and CA3. 
A unique feature of the hippocampus is the highly organized and 
unidirectional flow of information.  This feature is apparent in what is referred to 
as the ‘trisynaptic circuit’. The EC is considered the first step in this circuit as the 
axons from cells in the EC project into the dentate gyrus through the perforant 
path.  The axons of the principal cells within the dentate gyrus are called mossy 
fibers which then connect the dentate gyrus to area CA3. In turn, the CA3 
pyramidal cells serve as the major source of input into area CA1 through the 
Schaffer collaterals. Finally CA1 projections exit the hippocampus as they enter 
the subiculum (Figure 1.2).  This trisynaptic pathway emphasizes the concept 
that the major source of input into the hippocampus comes from within the 
hippocampus itself.  
 
1.5.1 DENTATE GYRUS ANATOMY AND CIRCUITRY 
The dentate gyrus (DG) is the first hippocampal structure to receive input 
directly from the entorhinal cortex and is classically comprised of three distinct 





              
 
Figure 1.2. Hippocampal organization and the trisynaptic pathway.  
Transmission from layer II of the entorhinal cortex (EC) enters the dentate gyrus 
(DG) through the perforant pathway (1. green). Signaling continues from the DG 
into area CA3 via the mossy fiber pathway (2. blue). From area CA3 signaling 
persists into area CA1 (3. red) before exiting the hippocampus through the 
subiculum (Sub) and terminating in layer V of the EC. In addition, layer III of the 
EC can directly synapse in area CA1, creating the temporoammonic pathway, 
and the perforant pathway can terminate directly in area CA3 (not shown).  
This study will explore the impact of SE on transmission from the perforant 





the molecular layer, stratum moleculare. This layer is subsequently divided into 
the inner and outer-layers, each receiving slightly different inputs from the EC. 
The principal cells of the DG are termed granule cells and form a very dense 
cellular layer, stratum granulosum. The cell layer located between regions CA1 
and CA3 is termed the suprapyramidal blade, while the layer opposite of this, 
which extends beneath area CA3 is the infrapyramidal blade. The U-shaped 
structure of these blades encompasses the polymorphic layer, commonly 
referred to as the hilus, which serves as the third layer of the dentate gyrus.  
Dentate granule cells (DGCs) are formed within the ventricular 
germinative layer of the hippocampus, located near area CA1.  During embryonic 
development newly generated DGCs can migrate directly to stratum granulosum, 
or into a second germinative layer located in the hilus prior to entering stratum 
granulosum. Later during postnatal development and during the process of 
neurogenesis, newly generated DGCs enter the granule cell layer through the 
hilar germinative layer. The morphology of granule cells is highly conserved, 
despite differences in how they may enter the cell body layer and which blade of 
the DG they are located along.  Granule cells display spiny dendrites that project 
toward the superficial portion of the molecular layer, with the dendrites 
terminating near the hippocampal fissure. The majority of granule cell axons, 
termed mossy fibers, project to area CA3, while axon collaterals innervate mossy 
cells located in the hilus. Mossy cells reside in the hilar region of the DG, and 
have axons that project to both the ipsilateral and contralateral inner molecular 
layer (associational/commissural pathways). In addition, the proximal dendrites of 
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the mossy cells are covered in large complex spines called thorny excrescences 
that serve as the termination site for the mossy fibers. These neuroanatomical 
projections within the dentate gyrus are illustrated in Figure 1.3.  
 
1.5.2 CA3 ANATOMY AND CIRCUITRY 
Similar to the dentate gyrus, areas CA1 – 3 are comprised of principal cells and 
are composed of several distinct cellular layers. While the principal cells of the 
DG are called granule cells, in areas CA1 – 3 they are referred to as pyramidal 
cells (i.e. CA3 pyramidal cells). In each of these regions pyramidal cells are very 
tightly packed to form the pyramidal cell layer, stratum pyramidale (SP). Located 
deep to the pyramidal cell layer is stratum oriens (SO), which contains several 
types of interneurons. SO also contains the CA3 – CA3 associational fibers, 
which provide input from CA3 neurons to other CA3 neurons in the same 
hemisphere, as well as a portion of the Schaffer collaterals that connect CA3 and 
area CA1. Directly above the CA3 pyramidal cell layer is stratum lucidum (SL), 
which is composed of mossy fibers originating in the DG. Stratum lucidum, 
meaning “clear layer” is appropriately named, as the unmyelinated mossy fibers 
and lack of cells within this layer contribute to its translucent appearance. 
Superficial to SL is another distinct cellular layer referred to as stratum radiatum 
(SR). In areas CA2 and CA1, SR is located directly above the pyramidal cell 
layers, as CA3 is the only region to contain stratum lucidum. Similar to SO, SR 
also contains interneurons, CA3 – CA3 associational fibers and a portion of the 







Figure 1.3. Anatomical projections of the dentate gyrus.  Dentate 
granule cells (black circles) reside in the dentate granule cell layer and have 
dendrites that extend into the molecular layer (purple). The axons of granule cells, 
termed mossy fibers (blue) travel through the hilus and terminate in area CA3 
stratum lucidum. Mossy fibers can also synapse on hilar mossy cell dendrites 
(green), which extend throughout the hilar region. The axons of mossy cells (red) 






area CA1. The most superficial layer of the hippocampus is stratum lacunosum-
moleculare (SLM), which is the thin layer in which fibers from the entorhinal 
cortex terminate and serves as the home for several different types of 
interneurons.  
Pyramidal cells, like DGCs, originate in the ventricular germinative layer of 
the hippocampus and migrate into their respective regions during embryonic 
development. Mature pyramidal cells located in area CA3 (as well as CA2 and 
CA1) are composed of a cell body which lies within the pyramidal cell layer, basal 
dendrites that extend into stratum oriens and apical dendrites that extend to 
stratum lacunosum-moleculare, near the hippocampal fissure. The axons of 
these cells bifurcate and often send a branch of the axon back towards the soma 
of the neuron. In area CA3 these axon collaterals project to areas CA1 – CA3 of 
both the ipsilateral and contralateral hemispheres, referred to as the 
associational and commissural pathways, respectively. In addition to these 
abundant projections, a smaller number of CA3 axon collaterals also terminate 
within the hilar region of the DG. Together, this extensive network of excitatory 
CA3 projections is believed to make up approximately 80% of all 
intrahippocampal synapses (Amaral and Witter, 1989). These complex 
neuroanatomical projections through area CA3 are depicted in Figure 1.4. 
 
1.5.3 MOSSY FIBER PATHWAY 
Projections stemming from area CA3 pyramidal cells overwhelmingly 










Figure 1.4. Anatomical projections of area CA3. CA3 pyramidal cells 
(black triangles) reside in the pyramidal cell layer. The apical dendrites of these 
pyramidal cells extend into stratum lacunosum-moleculare while the basal 
dendrites extend into stratum oriens (green). Collateralized axons of CA3 
pyramidal cells extend through stratum oriens before terminating in area CA1 
creating the Schaffer collaterals (red). Axons also give rise to associational 
(purple) and commissural (black) projections between the ipsilateral and 
contralateral hippocampi, respectively. Mossy fibers, comprised of large en 
passant terminals (blue fibers and circles), originate from dentate granule cells 
and synapse on the large thorny excrescences located on the apical dendrite of 







that the dentate gyrus effectively communicate with area CA3. The manner in 
which this occurs is through the mossy fiber pathway, first documented in the late 
1800s (Golgi, 1886; Sala, 1891). In rats, each of the approximately one million 
granule cells (approximately 15 million in humans) produces a single mossy fiber 
that travels into area CA3 through stratum lucidum. Prior to entering area CA3 
each mossy fiber gives rise to roughly 7 collaterals that synapse onto hilar mossy 
cells which mediate both inhibitory and excitatory transmission. A distinct 
characteristic of mossy fibers is that unlike any other hippocampal principal cell, 
granule cells have more than one type of terminal along their axons (Ramón y 
Cajal, 1911). The first type is the large terminals that occur along the length of 
the axon and so were given the name ‘en passant’ meaning ‘in passing’.  Each 
mossy fiber is believed to contain approximately 15 of these large (3 – 8 µM in 
diameter) en passant terminals, also referred to as mossy fiber expansions. Each 
expansion forms highly complex and intertwined connections with the thorny 
excrescences located on hilar mossy cells and the proximal dendrites of CA3 
pyramidal cells. Furthermore, a single mossy fiber expansion can make as many 
as 37 synaptic contacts with a single dendrite from a CA3 pyramidal cell. 
However, typically these large expansions do not contact two different spines on 
a single dendrite and thus do not contact two different pyramidal cells. In addition 
to the large en passant terminals that synapse onto mossy cells and CA3 
pyramidal cells, mossy fibers also contain smaller en passant terminals and 




The expansiveness and intricacy of the mossy fiber pathway allows for a 
single granule cell to communicate with up to 15 CA3 pyramidal cells, and with a 
single CA3 pyramidal cell receiving input from nearly 72 dentate granule cells. 
Furthermore, as DGCs are continuously generated through the process of 
neurogenesis, each newly formed granule cell also generates a newly formed 
mossy fiber. Thus the mossy fiber pathway would be highly plastic and 
undergoing constant reorganization. The unique ability for the dentate gyrus and 
CA3 to communicate via the mossy fiber pathway has drawn considerable 
attention in an attempt to understand its role in hippocampal synaptic 
transmission. 
 
1.6 MOSSY FIBER SYNAPTIC PLASTICITY 
 Synaptic transmission at the mossy fiber – CA3 synapse is predominately 
regulated by the excitatory neurotransmitter glutamate. Glutamate is contained in 
vesicles located within the presynaptic terminal which upon release activate 
postsynaptic glutamate receptors such as NMDA, AMPA and/or kainate 
receptors. These synapses have the ability to modify their strength and efficacy 
through an activity-dependent manner, a phenomenon referred to as synaptic 
plasticity. Synaptic plasticity is a hallmark of the mossy fiber – CA3 synapse and 
is believed to be essential in the ability to form memories, a function of the 
hippocampus as a whole. Activity at these synapses can either enhance or 
depress synaptic transmission, alterations can persist for milliseconds to minutes 
(short-term plasticity) or may continue for hours or days and in some cases may 
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become permanent (long-term plasticity). Two components of short-term 
plasticity include paired pulse facilitation and frequency facilitation. The strength 
of this form of plasticity is a distinguishing characteristic of the mossy fiber – CA3 
synapse and will be discussed in detail. 
 
1.6.1 SHORT-TERM PLASTICITY 
 The process of neurotransmission is initiated when an action potential 
(AP) invades the presynaptic terminal resulting in its depolarization.  This 
depolarization allows for voltage-gated Ca2+ channels to open and Ca2+ to enter 
the presynaptic terminal. The increase in the internal Ca2+ concentration initiates 
a process in which presynaptic vesicles fuse with the membrane and release 
their contents (i.e. glutamate) into the synapse to active post-synaptic receptor 
populations. If two APs occur close in time (milliseconds), the second AP may 
result in enhanced transmitter release, due to the build-up of residual Ca2+ in the 
presynaptic terminal, a phenomenon referred to as paired-pulse facilitation (PPF) 
(Katz and Miledi, 1968; Zucker, 1989). The ratio of PPF, or paired pulse 
depression (PPD) is inversely related to the presynaptic release probability 
(Dobrunz and Stevens, 1997). A synapse that demonstrates PPF would be 
suggestive of a low basal release probability in that a second stimulus is required 
to increase both internal Ca2+ stores and subsequent transmitter release.  The 
mossy fiber – CA3 synapse has a low probability of transmitter release (Jonas et 
al., 1993; Lawrence et al., 2004), and as would be expected demonstrates PPF.  
However, PPF at this synapse is 2 – 3x greater than what is observed at other 
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synapses in the brain (Salin et al., 1996).  
 A second form of short-term plasticity is frequency facilitation, in which low 
stimulus frequencies enhance synaptic transmission and synaptic strength. 
Increasing the frequency of stimulation at the mossy fiber – CA3 synapse from a 
basal 0.05Hz to 0.2Hz stimulation dramatically increases the amplitude of the 
post-synaptic event, while the parameters do not impact the 
associational/commissural (A/C) input into CA3 (Salin et al., 1996). In addition, 
the maximal facilitation at the CA3 – A/C pathway was about 125%, whereas the 
mossy fiber synapse potentiation was nearly 600% (Salin et al., 1996). Similar to 
the high level of PPF, the mossy fiber – CA3 synapse also demonstrates 
dramatically enhanced frequency facilitation compared to other synapses. 
 The characteristic low basal transmitter release probability is likely 
responsible for the high level of both PPF and frequency facilitation that is 
observed at the mossy fiber – CA3 synapse in comparison to other synapses. 
This dramatic difference is one reason in which this synapse has been 
extensively studied. For synaptic integration to occur DGCs and mossy fibers 
need to fire at similar frequencies. However, DGCs fire at very low frequencies 
(Jung and McNaughton, 1993). The broad frequency in which mossy fibers can 
function allows them to fire in a manner in which they can process information in 
the relevant range of granule cells. This strengthens the network activity between 





1.7 ALTERATIONS IN HIPPOCAMPAL CIRCUITRY IN EPILEPSY 
The relationship between seizures and damage to the hippocampus has 
been known since the early 1800s. In patients suffering from seizure disorders 
researchers noted neuronal loss and a hardening of the mesial temporal lobe, 
the area encompassing the hippocampus (Bouchet and Cazauvieilh, 1825).  This 
hardened, or sclerotic, hippocampus is observed in 50 – 70% of patients and 
includes sizeable cell loss within areas CA1 and CA3 of the hippocampus 
(Margerison and Corsellis, 1966). In addition to the dramatic cell loss in those 
regions, a smaller amount of cell loss has been detected in the dentate gyrus, 
hilus and presubiculum (Corsellis and Bruton, 1983; Mathern et al., 1997).  
Within the last two decades, the  abnormal growth of  mossy fiber axons into the 
supragranular region of the dentate gyrus, as opposed to area CA3, has also 
been identified (Tauck and Nadler, 1985; Represa et al., 1987; Sutula et al., 
1989; Houser et al., 1990; Babb et al., 1991; Sutula and Dudek, 2007). The 
aberrant formation of these axons is referred to as ‘mossy fiber sprouting’ and is 
now considered a hallmark of seizure disorders. In addition, these newly 
sprouted mossy fibers form functional synapses believed to create a recurrent 
excitatory network within the hippocampus (Sutula et al., 1988; Cronin et al., 
1992; Wuarin and Dudek, 1996). 
 Several different animal models of epilepsy exist, each producing distinct 
anatomical alterations. However, the lithium-pilocarpine and pilocarpine models 
used in the proposed set of experiments remain the most relevant models to the 
human disease (Curia et al., 2008). The mechanism of SE induction by 
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pilocarpine is through activation of the cholinergic system, as pilocarpine is a 
muscarinic agonist and atropine, a muscarinic antagonist, blocks pilocarpine-
induced SE (Clifford et al., 1987). However, once induced it is believed that the 
continuation and maintenance of SE is through a glutamatergic mechanism 
(Nagao et al., 1996; Smolders et al., 1997). As has been observed during the 
course of the current experiments a high dose of pilocarpine (390 mg/kg) does 
not always result in production of SE. To enhance the actions of pilocarpine, 
lithium chloride can be administered nearly 24 hours prior to pilocarpine 
treatment. In addition to increasing the effectiveness of pilocarpine, pre-
administration of lithium chloride also significantly reduces the amount of 
pilocarpine needed to induce SE (Honchar et al., 1983; Clifford et al., 1987; 
Morrisett et al., 1987). 
The prolonged SE that follows administration of pilocarpine (with or 
without administration of lithium chloride) brings with it an increased risk of 
mortality but it also initiates a severe and widespread cellular loss that persists 
for up to months following the event and eventually leads to tremendous 
neurodegeneration within the hippocampus and surrounding limbic regions. 
(Turski et al., 1983; Turski et al., 1984; Leite et al., 1990; Cavalheiro, 1995). In 
the present study, by 60 days post induction of SE, animals demonstrated nearly 
a 20% loss of both CA1 and CA3 pyramidal cells and a nearly 40% loss of hilar 






Figure 1.5. Neuronal cell loss in animals 60d post-SE. A. 
Representative images of NeuN labeling from sham (left) and pilo-treated (right) 
animals 60 days post treatment. B. Optical density measurements from NeuN 
labeling in four hippocampal regions. 1. CA1: 81.5 ± 4.0% of control, n = 7 – 9 2. 
CA3: 83.0 ± 2.9% of control, n = 7 – 9 3. DG: 93.3 ± 2.5% of control, n = 8 – 9 4.  





In addition to cell specific neuronal loss, the pilocarpine model also 
produces similar mossy fiber sprouting that is observed in patients with seizure 
disorders (Figure 1.6) (Turski et al., 1983; Turski et al., 1984; Leite et al., 1990; 
Cavalheiro, 1995; Sutula et al., 1998; Buckmaster and Dudek, 1999). The 
pilocarpine model is also associated with increased levels of astrocytes (Figure 
1.7) (Garzillo and Mello, 2002; Binder and Steinhauser, 2006), a characteristic 
not as widely noted in epilepsy patients. Overall the anatomical alterations 
observed within the hippocampus of both humans and animals demonstrate the 
dramatic impact that seizures have on the network organization and functionality 
of the hippocampus. 
 The pilocarpine model provides an excellent animal model for studying 
status epilepticus and the development of epilepsy, however there are some 
disparities that should be acknowledged.  One important consideration is the age 
in which the event occurs. As stated previously, SE is most common in children 
and precipitating injuries are also more common in childhood (Mathern et al., 
2002). However the anatomical and physiological alterations associated with SE 
are difficult to reproduce in animals younger than about 21 days of age (Curia et 
al., 2008). Additionally, human epilepsy is often associated with more brief and 
focal seizures. These patients demonstrate limited, asymmetric brain damage 
and likely appear healthy in other neurological aspects. However the pilocarpine 
model of SE is composed of a prolonged generalized status epilepticus event. 
Animals exhibit more widespread, bilateral brain damage, both cognitive and 







Figure 1.6. ZnT-3 labeling of mossy fiber sprouting in animals 60 and 
200d post-SE. A., C. ZnT-3 labeling in a sham-treated animal at the 200 day 
time point, demonstrates robust labeling throughout mossy fibers and the hilar 
region. In animals 60d (D.) and 200d post-SE (B, E.) robust ZnT-3 labeling is 
observed within the inner molecular of the dentate gyrus (white arrows) indicative 












Figure 1.7. Increase in GFAP labeling of astrocytes in animals 60 and 
200 days post-SE. A., C. Minimal GFAP labeling in the hippocampus and area 
CA3 in a sham-treated animal at the 200 day time point. In animals 60d (D.) and 
200d post-SE (B, E.) robust GFAP labeling is apparent within area CA3. GFAP 
expression was significantly increased in area CA1, CA3 and DG at 5d, 60d and 








consideration is the evidence that the site of spontaneous seizure generation in 
pilocarpine-treated animals is not the same as epilepsy patients (Mello and 
Covolan, 1996; Harvey and Sloviter, 2005; Sloviter et al., 2007). Differences in 
the site of seizure initiation may be due to differential neuronal damage or basic 
hippocampal circuitry. Despite the differences between the pilocarpine model and 
human epilepsy, this model is widely used and yields reproducible alterations 
sufficient for studying the epileptic condition.  
 
1.8 GABA 
γ-Aminobutyric acid (GABA) was originally synthesized in 1883, however it 
was not until 1950 that it was identified to be an integral part of the mammalian 
central nervous system (Petroff, 2002). The brain and spinal cord contain an 
abundance of GABA, whereas trivial amounts are found in peripheral tissue such 
as the liver, spleen and heart. GABA is synthesized by the alpha-decarboxylation 
of glutamate by the enzyme L-glutamic acid decarboxylase (GAD) and its 
cofactor pyridoxal phosphate (Petroff, 2002). GABA is an inhibitory 
neurotransmitter responsible for mediating the preponderance of inhibition within 
the brain. Three distinct forms of the GABA receptor exist; GABAA receptors 
which mediate fast synaptic neurotransmission (Sieghart and Sperk, 2002; 
Rudolph and Mohler, 2004), GABAB receptors responsible for mediating slow 
metabotropic actions (Couve et al., 2000; Bettler and Tiao, 2006), and GABAC 
receptors which mediate fast synaptic current in the retina (Bormann and 
Feigenspan, 1995).  
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1.8.1 GABAA RECEPTORS 
 GABAA receptors (GABAARs) are members of the ligand-gated ion-
channel superfamily, which also includes nicotinic acetylcholine receptors, 5-
hydroxytryptamine 3 receptors and glycine receptors (Unwin, 1989; Barnard et 
al., 1998). GABAARs are heteropentamers with each available subunit containing 
a large extracellular amino-terminal domain, four transmembrane domains (TM), 
a large intracellular domain between TM3 and TM4, and a smaller extracellular 
carboxy-terminal domain. The large amino-terminus serves as the binding site for 
GABA as well as other compounds such as benzodiazepines, and the large 
intracellular loop provides a site for receptor modulation via protein interactions 
and post-translational modifications (Jacob et al., 2008). At this time 18 different 
GABAAR subunits have been identified and divided into seven different subunit 
classes, some with additional members: α (1 – 6), β (1 – 3), γ (1 – 3), δ, ε (1 – 3), 
θ, and π. 
 While many different subunit combinations are possible, the majority of 
functional GABAARs are comprised of two α subunits, two β subunits and one γ 
subunit; although the γ subunit can be replaced by the δ, ε, θ, or π subunit 
(McKernan and Whiting, 1996; Rudolph and Mohler, 2004). The large amino-
terminus of the subunit regulates the assembly of particular subunits.  
Unassembled or misfolded proteins, as well as homomeric subunits are 
degraded in the endoplasmic reticulum (ER) (Gorrie et al., 1997; Bedford et al., 
2001). Receptors that survive the ER are trafficked to the Golgi apparatus where 
they are packaged into vesicles, transported and inserted into the plasma 
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membrane. Several factors aid in the translocation of receptors out of the ER, 
including GABAA receptor-associated protein (GABARAP) which interacts with 
the intracellular domain of the γ subunit (Wang et al., 1999), and N-
ethylmaleimide-sensitive factor (NSF) a protein involved in intracellular vesicle 
fusion (Kittler et al., 2001; Zhao et al., 2007). Once inserted into the plasma 
membrane the β (1 – 3) and /or γ2 subunit of the GABAAR directly bind to a 
particular subunit of a clathrin-adaptor protein 2 (AP2) complex. This interaction 
initiates the clathrin-dependent endocytosis, the major mechanism by which 
receptors are internalized and recycled (Kittler et al., 2000).  
 GABAA receptor subunits are ubiquitously expressed throughout the brain, 
however the one focus of this document is on GABAARs within the dentate gyrus. 
Within this region of the adult hippocampus GABAAR subunits α1, α2, α4, β3, γ2, 
and δ are most highly expressed, followed by the β1subunit, α3, α5, β2 and γ3 
subunits are weakly expressed, and nearly undetectable levels of γ1 subunit are 
observed (Sperk et al., 1997). Expression of these subunits is also 
developmentally regulated not only within the dentate gyrus but also throughout 
the hippocampus and other brain regions (Laurie et al., 1992). GABAAR subunits 
are targeted to different regions along the plasma membrane where they impart 
distinct physiological and pharmacological properties, including agonist affinity.  
 
1.8.2 FUNCTION OF HIPPOCAMPAL GABAA RECEPTORS 
Upon invasion of an action potential, presynaptic GABA is released in high 
concentrations into the synaptic cleft where it binds to the postsynaptic GABAA 
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receptor. Binding of the ligand allows for negatively charged Cl- ions to flow 
through the channel pore and into the cell. The increase in Cl- ions allows for the 
inside of the cell to become more negatively charged and the cell hyperpolarizes. 
This hyperpolarization increases the threshold for an action potential and 
ultimately reduces neurotransmission.  
As previously stated the majority of inhibitory neurotransmission is 
mediated by the GABAA receptor, and the particular subunit composition of the 
receptor imparts distinct characteristics. Synaptically located GABAARs mediate 
fast phasic inhibition (Rudolph and Mohler, 2004), whereas extrasynaptic 
receptors mediate tonic inhibition (Brunig et al., 2002). In addition to influencing 
the localization of the receptor the subunit composition dramatically influences 
receptor pharmacology. GABAARs are modulated by a variety of compounds 
including benzodiazepines, barbiturates and neurosteroids. The BZD sensitivity 
of the GABAAR has been well studied, particularly in relation to seizure disorders, 
and will be discussed in detail in Chapter 3. Generally, seizures may result from 
a reduction in GABAAR-mediated inhibition in the brain (Jacob et al., 2008), thus 
understanding the precise manner in which these receptors regulate 
neurotransmission is essential.  
 
1.8.3 PHASIC INHIBITION 
 The presynaptic release of GABA yields high, millimolar concentrations 
within the synaptic cleft (Mody et al., 1994) which binds to the synaptically 
located GABAARs and produces an inhibitory post-synaptic current (IPSC). 
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IPSCs regulate the rapid and precise, and near-synchronous, phasic inhibition. 
Studies have demonstrated that the high concentration of GABA within the cleft 
dissipates, either through re-uptake or diffusion, with a time constant of 100 – 
500 µs (Overstreet et al., 2000; Mozrzymas et al., 2003; Mozrzymas, 2004). As 
opposed to mass quantities, GABA can also be released by a single synaptic 
vesicle. This spontaneously occurring event, results in a miniature inhibitory post-
synaptic current (mIPSC). Phasic inhibition is typically mediated by GABAARs 
composed of α1, 2, 3 or 5 subunits together with β and γ subunits (Rudolph and 
Mohler, 2004). Most notable for synaptically located GABAARs is the presence of 
the γ2 subunit, which is essential for the synaptic clustering of GABAARs (Essrich 
et al., 1998). 
 
1.8.4 TONIC INHIBITION 
 In addition to the well-characterized rapid phasic inhibition, it is recognized 
that ionotropic receptors may also mediate a slower form of transmission (Mody, 
2001), including a tonic activation of the receptor. As opposed to synaptically 
located GABAARs that interact with millimolar concentrations of GABA, the 
extrasynaptic receptors must have a higher affinity for GABA, as the 
concentration in the extracellular space is likely within the micromolar range 
(Nyitrai et al., 2006). In addition to their high affinity, extrasynaptic receptors must 
demonstrate little desensitization (Mtchedlishvili and Kapur, 2006; Glykys and 
Mody, 2007), a process by which receptor channels close despite the continued 
presence of agonist bound to the receptor. The tonic activation of extrasynaptic 
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GABAARs would be significantly reduced if the receptors became desensitized to 
the sustained presence of extrasynaptic GABA. Tonic inhibition is generally 
mediated by GABAARs composed of α4 or 6 subunits, together with β and δ 
subunits (Barnard et al., 1998). Most notable for extrasynaptic receptors is the 
presence of the δ subunit, which is exclusively located in the extrasynaptic 
membrane (Nusser et al., 1998; Wei et al., 2003).  
 
1.9 GABAA RECEPTORS IN EPILEPSY 
 At a fundamental level seizures result from an imbalance between the 
excitatory and inhibitory transmission within the brain. While several 
glutamatergic receptors, including kainate receptors which will be discussed 
later, regulate excitatory neurotransmission, the GABAA receptor is responsible 
for regulating the majority of the inhibitory tone in the brain. Studies have 
demonstrated that both the trafficking of GABAA receptors as well as their subunit 
composition is altered in animal models and patients with seizure disorders such 
as status epilepticus and temporal lobe epilepsy (for review see, Jacob et al., 
2008). 
 One pharmacological consequence of SE is alterations in the surface 
expression of GABAA receptor subunits. Subsequently these alterations impact 
receptor pharmacology and even the network physiology. It has been shown that 
during the progression of SE the surface expression of the γ2 and β2/3 GABAA 
receptor is significantly reduced, while other receptor subunits such as the 
extrasynaptic δ subunit remain constant (Goodkin et al., 2008). This finding 
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supported the pharmacological observation that SE patients and animal models 
of SE develop pharmacoresistance to BZDs (Walton and Treiman, 1988; Kapur 
and Macdonald, 1997; Jones et al., 2002; Grosenbaugh and Mott, 2013). BZDs, 
such as diazepam, bind to the GABAAR at a specific allosteric site, located at the 
interface of α1, α2, α3, or α5 and the γ2 subunit (Sigel, 2002). Activation of the 
BZD-binding site results in a prolonging or increase in GABAAR-mediated 
synaptic current (Otis and Mody, 1992). The sensitivity of the GABAAR to BZDs 
is conferred by the presence of the γ1 - 3 subunit (Sieghart and Sperk, 2002), 
which is significantly reduced during SE, and thus explains reduced efficacy in 
patients. In addition, alterations in pharmacological changes in the subunit 
expression can also impact the network physiology of the brain. Given that 
extrasynaptic δ-containing GABAAR subunits remain functional during SE, the 
increase in extracellular GABA during prolonged SE (Naylor et al., 2005), is able 
to produce an increase in the overall tonic inhibitory tone of the network (Naylor 
et al., 2005; Grosenbaugh and Mott, 2013).  As GABAA receptors mediate the 
majority of the inhibitory neurotransmission within the cerebrum, it is critical to 
understand how SE alters their subunit expression and the subsequent 
alterations on receptor pharmacology and physiology. 
 
1.10 GLUTAMATE RECEPTORS 
 Two classes of receptors, ionotropic and metabotropic, are responsible for 
mediating excitatory neurotransmission within the CNS. Ionotropic receptors, 
commonly referred to ligand-gated ion channels, are responsible for mediating 
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the fast neurotransmission that occurs at the synapse. Specific binding of a 
ligand or neurotransmitter to the receptor results in a conformational shift 
allowing for the flow of ions (i.e. Na+, Ca2+, K+, Cl-) through the channel. Three 
distinct classes of excitatory ionotropic receptors have been established- α-
amino-3-hydroxy-S-methylisoxazole-4-propionic acid (AMPA), N-methyl-D-
aspartate (NMDA), and kainate (KA). In contrast to ionotropic receptors are 
metabotropic receptors which activate a second-messenger system, following 
binding of a ligand or neurotransmitter. Unlike ionotropic receptors which always 
mediate excitatory neurotransmission, the second-messenger system associated 
with metabotropic glutamate receptors (mGluRs) allows them to regulate either 
inhibitory or excitatory neurotransmission. Eight different mGluRs (mGluR1-8) 
have been identified and classified into three distinct groups (Group 1 – III). Of 
particular interest is the ability of kainate receptors (KARs) to mediate both 
ionotropic and metabotropic transmission, however the focus of the proposed 
experiments will be on the ionotropic action of KARs.  
 
1.10.1 KAINATE RECEPTOR ASSEMBLY AND LOCALIZATION 
Kainate receptors (KARs) were identified as a separate class of ionotropic 
glutamate receptors based on their sensitivity to the agonist kainate (kainic acid), 
a naturally occurring compound found in seaweed. Studies conducted throughout 
the early 1990's concluded the presence of five distinct kainate receptor subunits, 
GluK1 – 5 (Hollmann and Heinemann, 1994), which form functional tetramers.  
Each of the available KAR subunits contains a large extracellular amino-terminal 
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domain, involved in subunit assembly, followed by the extracellular ligand binding 
domain. The membrane region is composed of three transmembrane domains 
(TM1, TM3, TM4) and a re-entrant P-loop (TM2), which does not fully span the 
membrane. The M4 domain gives way to the intracellular carboxy-terminus of the 
subunit (Mayer, 2006).  
GluK1 – 5 subunits are divided into two families based on their sequence 
homology, functionality and agonist affinity. GluK1 – 3 subunits (Bettler et al., 
1990; Egebjerg et al., 1991; Bettler et al., 1992; Sommer et al., 1992) and GluK4 
– 5 subunits (Werner et al., 1991; Herb et al., 1992; Sakimura et al., 1992) are 
each about 70% identical within their family, but share only a 40% identity with 
each other. In addition to differences in the sequence homology of the two 
groups, GluK1 – 3 subunits can form functional homomeric receptors (Egebjerg 
et al., 1991; Sommer et al., 1992; Schiffer et al., 1997), while GluK4 – 5 subunits 
must be co-expressed with GluK1 – 3 (Werner et al., 1991; Herb et al., 1992). 
Binding assays from recombinant KARs have demonstrated that GluK4 – 5 
subunits have  significantly higher agonist affinity than do the GluK1 – 3 subunits 
(Monaghan and Cotman, 1982; Monaghan et al., 1989). In addition to the 
differences between GluK1 – 3 and GluK4 – 5 subunits, GluK1 and GluK2 are 
also subject to mRNA editing that alters Ca2+ permeability and sensitivity to 
intracellular polyamines (Sommer et al., 1991; Rosenthal and Seeburg, 2012). 
Furthermore, two membrane proteins that interact with KAR subunits were 
identified, Neuropilin and Tolloid-like 1 and Neuropilin and Tolloid-like 2 (Neto1 
and Neto2, respectively) (Zhang et al., 2009; Straub et al., 2011b; Tang et al., 
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2011). These proteins have been shown to dramatically alter the basic properties 
of KARs (Copits et al., 2011; Straub et al., 2011a; Fisher and Mott, 2012, 2013).  
KARs composed of GluK2/GluK5 subunits are believed to be the most 
prominent within the brain (Petralia et al., 1994), thus the majority of studies 
investigating KAR assembly and trafficking have focused on these two subunits. 
One check-point involved in proper receptor assembly is the occupancy of the 
ligand-binding site. Recombinant studies have demonstrated that mutations that 
reduce agonist affinity results in the subunits being retained within the ER and 
not inserted into the plasma membrane (Mah et al., 2005; Gill et al., 2009; Fisher 
and Housley, 2013). For homomeric GluK2 receptors, glutamate binding 
promotes proper folding resulting in a conformational change that is essential for 
assembly and trafficking of the receptor (Gill et al., 2009). The GluK5 subunit was 
found to contain several ER retention motifs that prevented surface expression 
unless this subunit was bound to a GluK1 – 3 subunit (Gallyas et al., 2003; Ren 
et al., 2003), a process that promotes formation of heteromeric receptors. 
Furthermore it was recently determined that agonist binding to the GluK5 subunit 
alone was sufficient to promote the formation of heteromeric GluK2/5 subunits 
(Fisher and Housley, 2013). Together these studies demonstrate the complexity 
of receptor assembly and trafficking as well as represent a key role for both the 
GluK2 and GluK5 subunits.  
Early studies have conclusively demonstrated that mRNA for a portion of 
kainate receptor subunits is expressed throughout the brain and spinal cord 
(Wisden and Seeburg, 1993; Bahn et al., 1994; Bettler and Mulle, 1995).  Similar 
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results were noted in the hippocampus, in which mRNA for all of the KAR 
subunits was also observed, however the expression within the hippocampus 
varies between regions and cell types. Furthermore, the mossy fiber – CA3 
synapse was the first hippocampal region shown to utilize kainate receptors 
(Castillo et al., 1997; Vignes and Collingridge, 1997). In this region the CA3 
pyramidal cells, as well as dentate granule cells, show elevated mRNA levels for 
GluK2, GluK4 and GluK5. GluK3 mRNA appears to be restricted to dentate 
granule cells, while interneurons predominately express GluK1, in addition to 
GluK2 – 3 (Bahn et al., 1994; Bureau et al., 1999; Paternain et al., 2000; Darstein 
et al., 2003).  
Variability in subunit localization, differences in the biophysical properties 
of the subunits and regulation by Neto1 and Neto2 make it difficult to study KARs 
in vivo. Furthermore, these differences become more apparent when attempting 
to use pharmacological agents to activate or block the receptor, as each subunit 
may behave differently to agonists and antagonists. As a result of this variability 
the role of KARs in regulating excitatory neurotransmission, specifically within the 
diseased brain, is not fully understood. 
 
1.11 FUNCTION OF HIPPOCAMPAL KAINATE RECEPTORS 
 Kainate receptors are ubiquitously expressed in the brain and 
hippocampus (Wisden and Seeburg, 1993), and are heavily expressed 
throughout the mossy fiber – CA3 pathway.  Specifically, KARs have been 
localized on postsynaptic CA3 pyramidal cells, on the presynaptic terminals of 
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the mossy fibers and on the mossy fiber axons extending from dentate granule 
cells. At these sites KARs regulate specific forms of excitatory 
neurotransmission, and given the relationship between the CA3 region and the 
generation of seizures (Lothman et al., 1991; Ben-Ari and Cossart, 2000), KARs 
pose an interesting avenue to explore.  
 
1.11.1 POSTSYNAPTIC KAINATE RECEPTORS 
Throughout the brain the majority of glutamatergic transmission is 
mediated by postsynaptic AMPA and NDMA receptors, while excitatory 
transmission mediated by KARs is limited to only a few synapses in the brain 
(Cossart et al., 1998; Frerking et al., 1998; Li and Rogawski, 1998; Kidd and 
Isaac, 1999; Li et al., 1999; Bureau et al., 2000). KARs located on postsynaptic 
CA3 cells regulate transmission originating from presynaptic mossy fiber 
terminals, but not inputs from the A/C fibers (Castillo et al., 1997; Vignes and 
Collingridge, 1997). At the mossy fiber – CA3 synapse postsynaptic KARs are 
activated by synaptically released glutamate which generates an excitatory 
postsynaptic current (EPSC) (Cossart et al., 2002). The KAR-mediated EPSC 
has two characteristic features; a small amplitude, approximately 10% of the total 
peak observed for AMPA receptors, and significantly slower deactivation kinetics 
(Castillo et al., 1997; Vignes and Collingridge, 1997; Frerking et al., 1998; Kidd 
and Isaac, 1999).  
As stated previously, the mossy fiber – CA3 synapse is likely comprised of 
receptors composed of GluK2, GluK4 and GluK5 subunits, which would heavily 
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impact agonist affinity as well as the decay kinetics of the response. Heteromeric 
receptors, presumed to be more common, containing the GluK4 or GluK5 subunit 
would have significantly higher affinity for glutamate than would homomeric 
GluK2 receptors (Monaghan and Cotman, 1982; Monaghan et al., 1989). In 
addition, the GluK5 subunit confers a slower decay than does the GluK4 subunit 
(Contractor et al., 2003). While many studies suggest that GluK2/5-containing 
receptors are the principal KAR at the mossy fiber – CA3 synapse, it remains 
possible that the chief receptor at this synapse is in fact comprised of the 
GluK2/4 subunit combination. However lack of selective and reliable KAR 
antagonists have limited the understanding of precisely which KAR subunits 
regulate the majority of transmission at this synapse. 
 Relative to the much larger AMPA receptor-mediated currents, the 
characteristic slow decay and small amplitude of the KAR-mediated EPSC may 
have little impact on excitatory transmission. However, the slow decay allows for 
KAR-mediated EPSCs to develop a large depolarization envelope at frequencies 
as low at 3Hz (Frerking and Ohliger-Frerking, 2002). In addition, the summation 
produced by KARs has a more global and consistent impact on membrane 
activity than do AMPA receptors which produce substantial variability (Frerking 
and Ohliger-Frerking, 2002). Collectively, while the postsynaptic KAR-mediated 
EPSC may be significantly smaller than that observed by the AMPA receptors, 
the significant levels of depolarization and temporal summation that are observed 




1.11.2 PRESYNAPTIC KAINATE RECEPTORS 
 Initial studies exploring KAR subunit localization suggested that the 
majority of subunits may actually be restricted to the presynaptic mossy fiber, as 
opposed to the postsynaptic CA3 cell (Agrawal and Evans, 1986; Represa et al., 
1987). In support of the heavily presynaptic localization of KARs was the finding 
that selective destruction of the mossy fibers results in a dramatic decrease in 
high affinity [3H] kainate binding, whereas it remains chiefly intact following 
destruction of the CA3 pyramidal cells (Represa et al., 1987). It is now well 
known and accepted that presynaptic KARs regulate neurotransmission, and in 
fact do so in a bidirectional manner, at both excitatory and inhibitory synapses 
(Lerma, 2003). Furthermore, presynaptic KARs are heavily implicated in the 
short-term synaptic plasticity which was discussed in section 1.6.1.  
 Presynaptic regulation of glutamate release has been extensively studied 
at the mossy fiber – CA3 synapse where KARs modulate release in a bimodal 
manner. Several studies have confirmed that low nanomolar concentrations of 
kainate facilitate glutamate release, while larger concentrations depress release 
(Contractor et al., 2000; Lauri et al., 2001; Schmitz et al., 2001a). In addition to 
regulating transmitter release there is substantial evidence that presynaptic 
KARs also act as autoreceptors that sense synaptically released glutamate and 
subsequently increase glutamate release (Contractor et al., 2001; Lauri et al., 
2001; Schmitz et al., 2001b).   
The exact mechanism by which presynaptic KARs regulate transmitter 
release is unknown. However, similar to the postsynaptic KARs, quantal release 
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of glutamate is also sufficient to activate presynaptic KARs (Contractor et al., 
2001; Schmitz et al., 2001b), which increases release from internal Ca2+ stores 
and promotes subsequent transmitter release (Lauri et al., 2003; Scott et al., 
2008). However, other studies have proposed that released glutamate 
depolarizes the presynaptic terminal to facilitate release (Kamiya and Ozawa, 
2000; Schmitz et al., 2000; Schmitz et al., 2001b; Schmitz et al., 2001a; Schmitz 
et al., 2003). Regardless of its action, presynaptic KARs are heavily involved in 
short-term synaptic plasticity, predominately in the frequency-dependent 
facilitation that is a hallmark of the mossy fiber – CA3 synapse. Despite the lack 
of availability of specific KAR subunit antagonists, the use of some antagonists 
coupled with genetically modified mice have demonstrated that presynaptic 
mossy fibers are likely composed predominately of GluK2 (Contractor et al., 
2001; Schmitz et al., 2003; Breustedt and Schmitz, 2004) and GluK3 (Pinheiro et 
al., 2007) subunits. 
 
1.11.3 MOSSY FIBER KAINATE RECEPTORS 
 In addition to their localization on postsynaptic CA3 pyramidal cells and 
presynaptic mossy fiber terminals, KARs are also located along mossy fiber 
axons where they regulate axonal excitability (Kamiya and Ozawa, 2000; 
Schmitz et al., 2000; Mott et al., 2008). Similar to the biphasic actions on 
transmitter release, low agonist concentrations facilitate axon excitability while 
higher concentrations suppress excitability (Kamiya and Ozawa, 2000; Schmitz 
et al., 2000; Mott et al., 2008). KARs located along the mossy fiber axons are 
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sensitive to both synaptically released glutamate as well as glutamate located in 
the extracellular space (Contractor et al., 2003; Schmitz et al., 2003). It is 
believed that KARs located on mossy fiber axons are predominately composed 
of GluK2, GluK4 and GluK5 subunits (Wisden and Seeburg, 1993). In a GluK4 
knockout mouse it was observed that the amount of axon excitability normally 
produced by low nanomolar concentrations of kainate was significantly reduced 
(Catches et al., 2012), suggestive of a role for GluK4-containing KARs in 
regulating mossy fiber axon excitability. Alterations in KAR sensitivity and 
regulation of mossy fiber axon excitability would affect neuronal transmission and 
communication between the dentate gyrus and area CA3, as well as alter 
synaptic plasticity at the mossy fiber – CA3 synapse.  
  
1.12 KAINATE RECEPTORS IN EPILEPSY 
 Kainate receptors have prominently been implicated in seizure disorders 
[for review see, (Ben-Ari and Cossart, 2000; Vincent and Mulle, 2009; Contractor 
et al., 2011; Lerma and Marques, 2013)], but have also been linked to a variety 
of diseases (Lerma and Marques, 2013). In particular, alterations in KAR subunit 
expression have been observed in psychiatric conditions including anxiety, 
depression and schizophrenia (Lerma and Marques, 2013), all disorders with 
increased prevalence in epilepsy (Jacobs et al., 2009). Systemic administration 
of kainate has been used for decades as a reliable animal model of epilepsy and 
produces similar pathologies as seen with human epilepsy (Nadler, 1981; Ben-
Ari, 1985). Following administration of kainate, animals develop limbic seizures 
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followed by a latent period of epileptogenesis and finally the development of 
persistent spontaneously recurring seizures (Ben-Ari, 1985; Leite et al., 1990; 
Cavalheiro et al., 1991). In addition GluK1-selective antagonists block 
pilocarpine-induced seizures (Smolders et al., 2002), and genetic knockout of the 
GluK2 subunit significantly reduces seizure susceptibility (Mulle et al., 1998). 
As described earlier, the aberrant sprouting of mossy fiber axons in the 
DG has become an anatomical hallmark of seizures in both human and animal 
models. This newly formed circuit predominately regulates excitatory glutamate 
transmission (Buckmaster et al., 2002), and it was recently determined that newly 
formed KARs partly regulate this transmission (Epsztein et al., 2005). KARs have 
also been linked to the excitotoxicity that occurs in epilepsy (Vincent and Mulle, 
2009). Specifically, KARs are densely located in area CA3, a cellular region that 
is highly susceptible to excitotoxicity (Nadler et al., 1978). Furthermore, KARs 
have also been linked to pyramidal cells in layer III of the medial entorhinal 
cortex, a region that rapidly degenerates due to excitotoxic cell death following 
administration of kainate (Du et al., 1995; West et al., 2007).  
Alterations in hippocampal KAR subunit expression have also been 
examined in patients with seizure disorders (Grigorenko et al., 1997; Mathern et 
al., 1998; Li et al., 2010; Das et al., 2012). Despite a true consensus, possibly 
due to the type of seizure disorder, duration of the disease and therapeutics, 
these studies clearly demonstrate that KAR subunit expression is altered in the 
epileptic brain. Animal models have also demonstrated dramatic changes in KAR 
subunits, findings that persist despite differences in the seizure model utilized 
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(Lason et al., 1997; Tandon et al., 2002; Zhang et al., 2004; Ullal et al., 2005; 
Porter et al., 2006). However, while a minimal number of studies have addressed 
these alterations even fewer have addressed changes in KAR subunit expression 
that occur during the progression of the disease (Ullal et al., 2005). Furthermore, 
the majority of these studies examined alterations in KAR mRNA expression 
within the hippocampus as a whole. Given that KAR subunit localization is not 
uniform within the hippocampus, there is reason to believe that alterations in the 
epileptic brain would be region specific and that protein levels would provide 
more relevant information than mRNA. Despite the evidence linking KARs to 
epilepsy, currently there are no antiepileptic drugs that target KARs. This may be 
partially due to the limited understanding of KAR-mediated expression and 
physiology in the epileptic brain, two areas examined in the current document. 
 Chapters 4 – 6 will explore alterations in KAR subunit expression and the 
functional impact of those changes on mossy fiber – CA3 neurotransmission and 
hippocampal axon excitability.  
 
1.13 SIGNIFICANCE REVISITED 
 
Status epilepticus is a neurologic emergency characterized by the inability 
of inherent cellular mechanisms to terminate seizure activity. The occurrence of a 
single SE event leads to the development of epilepsy in upwards of 40% of 
patients, making the development of epilepsy the most challenging long-term 
consequence associated with SE. Currently available AEDs are successful in 
treating SE in approximately 60% of patients. However this leaves a large portion 
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of the patient population suffering from uncontrolled SE, thus increasing their risk 
for the development of epilepsy and associated comorbidities. This project 
undoubtedly demonstrates that the ability to develop safe and effective 
therapeutics for the treatment of SE and seizure disorders lies within the 
understanding that a single SE event can drastically alter the brain.  
The overarching hypothesis of this project is that status epilepticus and 
the development of epilepsy produce striking alterations in GABAA and kainate 
receptor populations. Furthermore, these alterations significantly impact receptor 







2.1 ANIMAL MODEL OF STATUS EPILEPTICUS 
 
 The ability to understand the epileptic brain and to develop therapeutics is 
dependent upon the use of animal models. These models must as closely as 
possible replicate the distinct anatomical and physiological alterations seen in the 
human disease including sclerosis and cell loss. When exploring potential 
models several features are identified that are similar to the human pathology. 
Some of these features include the appropriate seizure phenotype 
(convulsive/non-convulsive), similar neuropathological consequences, chronic 
hyperexcitability and appropriate responsiveness to AEDs. Commonly used 
animal models fall into five distinct categories; electrical, chemical, thermal, in 
vitro, and refractory (Reddy and Kuruba, 2013). 
The current study will utilize a chemical model involving administration of 
pilocarpine and lithium-pilocarpine to initiate status epilepticus followed by a 
period of epileptogenesis and eventually the development of spontaneously 
recurring seizures. As discussed in section 1.7 both of these models very closely 
replicate the hippocampal injury associated with human epilepsy.  
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2.1.1 ANIMAL CARE AND USE 
All animal care and use procedures were carried out in accordance with 
protocols written under the guidance of the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals and approved by the Institutional Animal 
Care and Use Committee at the University of South Carolina. Male Sprague-
Dawley rats were purchased from Harlan, and housed at 1 – 3 rats per cage with 
ad libitum access to food and water. Rats were housed in a climate controlled 
facility with a light/dark cycle of 12/12 hours.   
 
2.2 LITHIUM PILOCARPINE MODEL OF STATUS EPILEPTICUS 
Young male Sprague-Dawley rats (15 – 23 days; Harlan, Indianapolis, IN) 
received intraperitoneal (i.p.) injections of lithium chloride (127 mg/kg) followed 
15 – 20 hours later by scopolamine methyl bromide (2 mg/kg). Status epilepticus 
was then induced 15 – 30 minutes later by injection with pilocarpine 
hydrochloride (60 mg/kg). As pilocarpine is a muscarinic agonist, scopolamine is 
pre-administered in order to block peripheral muscarinic receptors and ensure 
selectivity of pilocarpine. Following pilocarpine injections, rats were observed 
continuously for the occurrence of behavioral seizures and were scored based 
upon the Racine scale (Racine, 1972) (Table 2.1). Diazepam (DZP, 0.3 – 100 
mg/kg) or stiripentol (STP, 10 – 1000 mg/kg) was administered either at the 
onset of the first stage 3 seizure (brief SE) or 45 minutes after the first stage 3 
seizure (prolonged SE; pSE). This experimental protocol of the lithium 
pilocarpine (Li-Pilo) model was used in Chapter 3 when exploring the actions of 
 
55 
STP and DZP on behavioral SE and GABAergic neurotransmission.  
 
 
Table 2.1. Racine scale of epileptic seizures  
 
 
2.3 PILOCARPINE MODEL OF STATUS EPILEPTICUS 
Adult male Sprague-Dawley rats (37 – 47 days; Harlan, Indianapolis, IN) 
received intraperitoneal (i.p.) injections of scopolamine methyl bromide and 
terbutaline hemisulfate (2 mg/kg) followed 30 – 45 min by pilocarpine 
hydrochloride (390 mg/kg). In addition to administration of scopolamine to block 
peripheral muscarinic receptors, animals also received terbutaline which acts as 
a bronchodilator to prevent respiratory depression associated with prolonged SE. 
Following pilocarpine injection, rats were observed continuously for the 
occurrence of behavioral seizures and were scored on the Racine scale (Racine, 
1972) (Table 2.1).  Approximately 75% of rats experienced a seizure score of 5 
Score Observed Motor Behavior 
0 Normal behavior (exploring, walking, grooming, etc.) 
1 Immobility, staring ‘curled up’ posture 
2 
Automatisms  
(Chewing, head bobbing, twitching, wet-dog shakes) 
3 Forelimb/hindlimb myoclonic jerking, head tremor 
4 Rearing and whole-body clonus 
5 Rearing and falling over; loss of posture 
6 
Tonic-clonus seizures with tonic forelimb flexion/extension, 
whole-body clonus 
7 Wild-running with bouncing; death 
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on the Racine scale. Animals that did not exhibit SE after 45 mins were given an 
additional ‘booster’ of pilocarpine (200 – 300 mg/kg). Nearly 90% of animals 
receiving a pilocarpine ‘booster’ experienced sufficient SE. After 2 hours of status 
epilepticus, DZP (25 mg/kg) was administered intraperitoneally. This group of 
animals served as the ‘pilo’ group. In order to limit physical distress and any 
peripheral effects of pilocarpine animals received additional doses of the 
scopolamine/terbutaline cocktail approximately one-hour into SE as well as upon 
termination of SE with DZP.   A separate group of animals was treated 
identically, but received saline (390 mg/kg) instead of pilocarpine hydrochloride. 
This group of animals served as the ‘sham’ group. Approximately 1 – 2 hours 
after seizures were terminated animals received a subcutaneous dose of the 
scopolamine/terbutaline cocktail (2 mg/kg), lactated Ringer’s solution (2 mL), and 
rat chow that had been softened and sweetened in high sucrose water. Animals 
that did not enter SE were excluded from the study.  
All animals were housed overnight in the animal facility and checked as 
early as possible on the following day to determine if they had successfully 
recovered from treatment (normal posture, movement and activity levels). 
Animals still experiencing side-effects from treatment (lethargy, immobility) were 
given additional subcutaneous injections of lactated Ringer’s solution and the 
scopolamine/terbutaline cocktail and placed on a heating pad. For animals who 
endured the first night post-treatment the survival rate was nearly 100%.  This 
experimental protocol was used in Chapters 4 – 6 to explore alterations in 
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kainate receptor subunit expression and kainate receptor-mediated 
electrophysiological alterations in the epileptic brain. 
Video monitoring of animals a minimum of 30 days post-treatment 
confirmed the appearance of spontaneously occurring seizures in pilocarpine 
treated animals. In addition, by approximately 60 days post-SE animals began to 
demonstrate neuronal cell loss and the appearance of mossy fiber sprouting.  
 
2.4 DETERMINATION OF BRAIN-PLASMA STP CONCENTRATION 
Brain and plasma concentrations of STP were determined in four separate 
groups of male Sprague-Dawley rats: 1) naïve juvenile (20 – 27 days old), 2) 
prolonged SE-experienced juvenile (20 – 21 days old), 3) naïve adult (62 – 63 
days old) and 4) prolonged SE-experienced adult (61 days old). Fifteen minutes 
following i.p. administration of 300 mg/kg STP, naïve and prolonged SE rats were 
anesthetized and decapitated in order to collect brain and blood samples.  Trunk 
blood was collected in 6 mL sodium heparin lined BD vacutainers and 
centrifuged for 10 min at 2000 rpm at 4°C to collect blood plasma. Brains were 
removed and rapidly frozen on dry ice. Brain tissue and plasma were stored at         
-80°C until use. 
Brain and plasma concentrations of STP were measured by high-
performance liquid chromatography (HPLC) with ultraviolet detection. For plasma 
analysis 100 µl of internal standard (2 µg of AB1191 per mL of 50/50 
methanol/H2O) and 50 µL of 50/50 methanol/H2O with 2 mL of tert-Butyl methyl 
ether were added to a 50 µL plasma sample. Following agitation for 15 min, 
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decantation and freezing in a dry ice/acetone bath, the organic layer was 
transferred and evaporated to dryness under nitrogen at 45°C.  
For brain tissue analysis, 100 µL of internal standard (50 µg of AB1191 
per mL of 50/50 methanol/H2O) and 50 µL of 50/50 methanol/H2O with 2 mL of 
H2O were added to the weighed brain sample and mixed. A 0.5 mL volume of 
homogenate was extracted with 3 mL of pentane. Following agitation for 15 min, 
decantation and freezing in a dry ice/acetone bath, the organic later was 
transferred and evaporated to dryness under nitrogen at 45°C. 
Residues from plasma and brain samples were reconstituted with 200 µL 
of mobile phase (acetonitrile/H2O; 60/40) and used for HPLC analysis. UV 
detection was accomplished at 264 nm with a limit of sensitivity of 0.5 µg/mL for 
plasma and 0.45 µg/g or 0.35 µg/g in juvenile and adult brain respectively. The 
concentration levels of STP in plasma (µg/mL) and brain (µg/g) were expressed 
as total drug concentration. The coefficients of variations for intra- and inter-
assays were 0.2 – 13% and 3 – 14% respectively. 
 
2.5 INTRODUCTION TO BRAIN SLICE ELECTROPHYSIOLOGY 
Neuronal function is based on the ability of cells to integrate and 
propagate electrical signals such as action potentials. Electrophysiology is the 
study of this electrical activity within the brain and provides detailed information 
on the functionality of individual neurons and networks of neurons. In the 1950’s 
Henry McIlwain developed the brain slice preparation and demonstrated the 
ability of brain slices to retain their metabolic activity as well as their cellular 
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membrane potentials (Mc et al., 1951; McIlwain and Buddle, 1953; Li and Mc, 
1957; Yamamoto and McIlwain, 1966). These studies set the foundation for brain 
slice electrophysiology by demonstrating that neurons could be kept alive in an 
artificial setting while their electrical properties were explored. 
 In vitro brain slice electrophysiology can be conducted on many, if not all, 
brain regions. However successful experiments are dependent upon quality 
slices which are defined by the ease and reliability in which the tissue is 
prepared, the visibility of structural landmarks and the extent in which fibers and 
synaptic fields are observed within the slice (Lynch and Schubert, 1980). In 
regards to these properties, one structure in particular lends itself to the 
technique of brain slice electrophysiology, the hippocampus. The hippocampus is 
a region that can be easily removed from the brain without the need for a 
microscope. In addition once sectioned, little to no magnification is needed to 
visualize its unique structure composed of pyramidal and granule cell layers. 
Furthermore, the laminar organization of the hippocampus allows for properly 
sectioned slices to contain cell bodies, dendrites and axons which often extend 
throughout the slice (Lynch and Schubert, 1980). Together these properties of 
the hippocampus increase the ease of experiments as well as provide the ability 
to study individual intrinsic cell properties (whole-cell electrophysiology), as well 
as extracellular network activity (field-potential electrophysiology).  The following 
sections will detail the concept and methods used for both whole-cell and field-




2.6 WHOLE-CELL ELECTROPHYSIOLOGY 
Patch clamp electrophysiology is an intracellular recording technique that 
allows for the study of ion flow through a single channel and was first 
demonstrated in 1976 by Erwin Neher and Bert Sakmann (Neher and Sakmann, 
1976), who in 1991 won the Nobel Prize in Physiology or Medicine. Several 
different configurations of this technique exist, one of which is whole-cell 
recording. To acquire a whole-cell configuration a glass electrode is placed on 
the surface of a cell and mild suction is then applied to rupture the membrane, 
allowing for a diffusional exchange of the contents of the cell cytoplasm and the 
glass pipette (Figure 2.1). The whole-cell configuration produces a convenient 
method to directly apply substances into the cell in order to study the electrical 
currents and properties from the entire cell. 
Whole-cell electrophysiology is used to study the movement of electrically 
charged ions, commonly through voltage-gated or ligand-gated channels. The 
GABAA receptor is selectively permeable to negatively charged Cl
- ions. When 
the receptor is open, Cl- ions flow into the cell creating a more negative 
intracellular environment. This hyperpolarization of the cell brings it further away 
from the threshold of firing an action potential (~-40mV) and thus reduces 
neuronal firing. The postsynaptic current produced by activation of GABA 
receptors is referred to as an inhibitory postsynaptic current (IPSC). In contrast,  
glutamatergic receptors such as kainate or AMPA are permeable to Na+ and K+ 
ions. When these receptors are open, the concentration gradient maintained by a 







Figure 2.1. Schematic of whole-cell recording configuration. One of several 
configurations of patch-clamp electrophysiology. A glass electrode filled with 
experiment-specific internal solution is applied to the surface of a cell. Slight 
suction is applied to rupture the cell membrane allowing the contents of the 
electrode and the cell to easily diffuse. Schematics of receptor complexes, 
including Cl-, Na+ and K+ are expressed on the surface of the cell. In addition the 






intracellular environment. If this depolarization of the cell is sufficient it will fire an 
action potential. Thus activation of these glutamatergic receptors, in contrast to 
GABAergic receptors, generally increase neuronal firing, and produce an 
excitatory postsynaptic current (EPSC). 
 
2.6.1 EXPERIMENTAL PROTOCOL FOR WHOLE-CELL RECORDINGS  
Chapter 3- Transverse 300 µm thick slices from isoflurane-anesthetized 
animals were cut using a vibratome (Leica VT1000S, Nussloch, Germany). Brain 
slices were prepared in cold (4°C), oxygenated (95% O2 / 5% CO2) sucrose-
based ‘cutting’ artificial cerebrospinal fluid (aCSF) that contained (in mM):  248 
sucrose, 2 KCl, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose, 0.5 CaCl2 and 5 MgS04 
(350 mOsm).  Slices were incubated for approximately one hour at room 
temperature in oxygenated (95% O2 / 5% CO2) aCSF containing (in mM): 125 
NaCl, 2.7 KCl, 1.25 NaH2PO4, 25 NaHCO3, 10 glucose, 0.5 CaCl2 and 5 MgSO4, 
0.02 D-APV and 1 kynurenic acid (pH 7.4; 305-312 mOsm).  
Currents were recorded from dentate granule cells located in the infra-
pyramidal blade of the dentate gyrus, visually identified with infrared-differential 
interference contrast optics. Currents were recorded using a Multiclamp 700A 
amplifier (Molecular Devices, Sunnyvale, CA) and filtered at 1 kHz. Currents 
were digitized using a Digidata 1440A A-D board (Molecular Devices, Sunnyvale, 
CA) and analyzed using pClamp10 software. GABAA IPSCs were evoked by 
stimulation in stratum moleculare of the dentate gyrus near the recording 
electrode. Stimuli were 0.1ms, cathodal, monophasic, rectangular constant 
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current pulses (10 – 100 μA) delivered through monopolar, platinum-iridium 
stimulating electrodes (FHC Inc., Bowdoin, ME). IPSCs and miniature excitatory 
post-synaptic currents (mEPSCs) were recorded using borosilicate glass 
electrodes ( resistance 5 – 8 MΩ) filled with an internal solution containing (in 
mM): 130 D-Gluconic Acid, 130 CsOH, 7CsCl, 10 HEPES, 3 QX-314, 2 MgATP, 
0.3 Na2GTP, yielding a chloride reversal potential of -42 mV. Miniature inhibitory 
post-synaptic currents (mIPSCs) and tonic currents were recorded using an 
internal solution containing (in mM): 140 CsCl, 10 HEPES, 3 QX-314, 4 MgATP, 
0.3 Na2GTP, yielding a chloride reversal potential of 0 mV. Voltage-clamp 
recordings were made at a holding potential of -20 mV for evoked IPSCs, -60mV 
for tonic currents and mIPSCs, and -70mV for mEPSCs. Input and series 
resistance were monitored throughout the experiment and recordings in which 
either changed significantly were discarded.   
 Miniature IPSCs (mIPSCs) were pharmacologically isolated using the 
glutamate receptor antagonists, D-2-amino-5-phosphopentanoic acid (D-APV, 
50μM), or 5-methyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5,10-imine 
maleate (MK-801, 10 μM) and 6-cyano-7-nitroquinoxaline-2,3-dione disodium salt 
(CNQX, 50 μM), plus the addition of tetrodotoxin (TTX, 1 μM) for mIPSCs and 
tonic current.  Bicuculline methochloride (Bic, 20 μM) was added at the end of 
each experiment to confirm that the recorded IPSCs were mediated by GABAA 
receptors. mEPSCs were isolated using 30 μM bicuculline methochloride and 1 




Chapter 5- Animals were deeply anesthetized with isoflurane and 
transcardially perfused with a sucrose-based aCSF fluid containing (in mM): 248 
sucrose, 2 KCl, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose, 2.4 pyruvate, and 1.3 
ascorbic acid (345 – 351 mOsm) for approximately 2 min. The brain was then 
rapidly removed and transverse 300 µM thick slices were cut using a vibratome 
(Leica VT1000S, Nussloch, Germany). The same sucrose-based solution was 
also used to prepare brain slices, with the addition of (in mM): 0.02 D-APV and 1 
kynurenic acid, and exclusion of pyruvate and ascorbic acid (pH 7.4; 305 – 312 
mOsm).  Slices were incubated for approximately one hour in room temperature 
oxygenated (95% O2 / 5% CO2) NaCl-based aCSF solution containing (in 
mM):125 NaCl, 2.8 KCl, 1.0 NaH2PO4, 26 NaHCO3, 10 glucose, 0.5 CaCl2 and 5 
MgSO4, 0.02 D-APV and 1 kynurenic acid (pH 7.4; 300 – 310 mOsm).  
Currents were recorded from dentate granule cells visually identified with 
infrared-differential interference contrast optics. Recordings were performed 
using a Multiclamp 700A amplifier (Molecular Devices, Sunnyvale, CA) and 
filtered at 1 kHz. Currents were digitized using a Digidata 1440A A-D board 
(Molecular Devices, Sunnyvale, CA) and analyzed using pClamp10 software.  
EPSCs were recorded using borosilicate glass electrodes (resistance 4 – 
6 MΩ) filled with an internal solution containing (in mM): 130 D-Gluconic Acid, 
130 CsOH, 5 CsCl, 10 HEPES, 5 CsBAPTA, 2 MgCl2, 0.5 CaCl2, 2 MgATP, 0.3 
NaGTP. Voltage-clamp recordings were made at a holding potential of -70mV 
with input and series resistances monitored throughout the experiment. Currents 
were evoked with borosilicate glass pipettes (resistance 2 – 3 MΩ) filled with 10 
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µM domoate dissolved in external recording solution. Every 60 seconds, a 50 ms 
puff was applied approximately 70 µM from the dentate granule cell body using a 
Pneumatic PicoPump (PV800, World Precision Instruments, Sarasota, FL). 
EPSCs were pharmacologically isolated in an antagonist cocktail 
containing bicuculline methochloride (Bic, 15 µM), [(2S)-3-[[(1S)-1-(3,4-
Dichlorophenyl)ethyl]amino]-2-hydroxypropyl](phenylmethyl)phosphinic acid 
hydrochloride (CGP55845, 1 µM), MK-801 (10 µM), plus the addition of 
tetrodotoxin (TTX, 1 µM). KAR-mediated currents were isolated using 1-(4-
Aminophenyl)-3-methylcarbamyl-4-methyl-3,4,-dihydro-7,8-methylenedioxy-5H-
2,3-benzodiazepine hydrochloride (GYKI 53655, 50 µM)  remaining current was 
blocked by application of CNQX (100 µM).  
 
2.7 FIELD POTENTIAL ELECTROPHYSIOLOGY 
In contrast to whole-cell electrophysiology which occurs intracellularly, 
field-potential electrophysiology is performed extracellularly. Once the tissue is 
prepared a stimulating electrode is placed in the tissue in order to sufficiently 
active a population of neurons. In contrast to recording from a single neuron, field 
potential electrophysiology allows the researcher to record the activity of a 
population of neurons by placing the recording electrode within a cell body layer, 
or within the dendrites or axons of the neuronal population. Activation of these 
neurons results in a summation of the extracellular potentials creating either a 
field inhibitory postsynaptic potential (fIPSP) or a field excitatory postsynaptic 
potential (fEPSP).  
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 Due to the fact that these recordings are extracellular, the placement of 
the recording electrode, relative to the stimulating electrode is crucial in order to 
properly interpret of the data.   Relative to the electrode, neuronal activation can 
create what is denoted as an extracellular sink or source. The flow of positively 
charged ions into a cell or dendrite leaves the extracellular space more negative, 
creating an extracellular sink. In order to maintain electroneutrality the sink is 
balanced by an extracellular source comprised of an efflux of positively charged 
ions into the extracellular space. Field potential recordings in the mossy fiber – 
CA3 synapse are at particular risk for improper electrode placement, as the CA3 
region contains mossy fibers input as well as the associational/commissural 
fibers. Pure stimulation of the mossy fibers, elicited through activation of dentate 
granule cells, would evoke an extracellular sink in area CA3 stratum lucidum. 
However, if the placement of the recording electrode was not precise an 
extracellular source evoked from the CA3 A/C fibers would contaminant the 
response. The overall response would be a fEPSP comprised of both a 
downward sink and upward source. Thus in experiments involving the mossy 
fiber – CA3 synapse steps were taken to ensure pure mossy fiber stimulation and 
recording.   
 
2.7.1 EXPERIMENTAL PROTOCOL FOR FIELD POTENTIAL RECORDINGS 
Animals were deeply anesthetized with isoflurane and transcardially 
perfused with a sucrose-based aCSF solution containing (in mM): 248 sucrose, 2 
KCl, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose, 2.4 pyruvate, and 1.3 ascorbic acid 
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(345 – 351 mOsm) for approximately 2 min. The brain was then rapidly removed 
and transverse 500 µM thick slices were cut using a vibratome (Leica VT1000S, 
Nussloch, Germany). The same sucrose-based solution was also used to 
prepare brain slices, with the addition of (in mM): 0.02 D-APV and 1 kynurenic 
acid, and exclusion of pyruvate and ascorbic acid (pH 7.4; 305 – 312 mOsm).  
Slices were prepared in cold (4ºC), and incubated for 30 min in heated (37ºC), 
oxygenated (95% O2 / 5% CO2) sucrose-based aCSF.  After 30 min incubation in 
heated sucrose-based aCSF slices were gradually transitioned to a room-
temperature oxygenated (95% O2 / 5% CO2) NaCl-based solution containing (in 
mM): 125 NaCl, 2.8 KCl, 1.0 NaH2PO4, 26 NaHCO3, 10 glucose, 0.5 CaCl2 and 5 
MgSO4, 0.02 D-APV and 1 kynurenic acid (pH 7.4; 301 – 307 mOsm).  
Following a minimum of 30 min incubation slices were placed in a 
submerged chamber that was continuously perfused with the warm, oxygenated 
(31 – 34 ºC; 95% O2 / 5% CO2) NaCl-based solution containing (in mM): 125 
NaCl, 2.7 KCl, 1.25 NaH2PO4, 25 NaHCO3, 10 glucose, 0.5 CaCl2 and 5 MgSO4 
(pH 7.4; 301 – 307 mOsm). Stimuli were 0.1 ms, cathodal, monophasic, 
rectangular constant current pulses delivered through monopolar, platinum-
iridium stimulating electrodes (FHC Inc., Bowdoin, ME) referenced to a bath 
ground. fEPSPs and antidromic spikes were recorded through a borosilicate 
glass electrode (resistance 2 – 3 MΩ) filled with external recording aCSF. Two 
separate stimuli paradigms were used, 1) Mossy fiber – CA3 fEPSPs were 
evoked in the dentate gyrus granule cell layer every 30 sec and recorded in CA3 
stratum lucidum. Mossy fiber fEPSPs were characterized by their large paired 
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pulse facilitation (Salin et al., 1996) and inhibition by the group II-selective 
metabotropic glutamate receptor (mGluR) agonist (2S,2’R,3’R)-2-(2’3’-
Dicarboxycyclopropyl) glycine (DCG-IV, 1 µM) (Kamiya et al., 1996). 2) 
Recurrent mossy fiber fEPSPs in the dentate gyrus were evoked in the inner 
one-third of the molecular layer every 60 sec and recorded in the granule cell 
layer (Epsztein et al., 2005). Stimuli recorded in both CA3 and dentate gyrus 
were evoked at 50% of the maximal response determined though an input-output 
(I/O) curve. Antidromic population spikes were evoked in two distinct pathways. 
1) Mossy fibers were stimulated in CA3 stratum lucidum and the response was 
recorded in the dentate granule cell layer. 2) CA3 axons were stimulated in 
stratum radiatum and the response was recorded in the CA3 pyramidal cell layer. 
Figure 2.2 depicts each of the four experimental paradigms utilized in Chapters 5 
and 6. 
Both antidromic spikes and fEPSPs were pharmacologically isolated in an 
antagonist cocktail containing bicuculline methochloride (Bic, 20 µM) and MK-801 
(10 µM). AMPA receptor mediated transmission was blocked by application of 
GYKI53655 and remaining KAR-mediated transmission was blocked by 
application of (S)-1-(2-Amino-2carboxyethyl)-3-(2-carboxythiphene-3-yl-methyl)-
5-methylprimidine-2,4-dione (UBP310, 3 µM) or (S)-1-(2-Amino-2-carboxyethyl)-
3-(2-carboxy-5-phenylthiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione 










Figure 2.2. Experimental paradigms for field potential 
electrophysiology. Blue electrodes: MF – CA3 fEPSPs were elicited by 
stimulation of the mossy fibers and recorded in CA3 stratum lucidum. To limit 
activation of the recurrent A/C pathway stimulation of the mossy fibers originated 
near the dentate granule cell layer. Green electrodes: Recurrent mossy fiber 
collaterals were activated by stimulation of the inner one-third of the molecular 
layer and recorded in the dentate granule cell layer. Purple electrodes: The 
mossy fiber antidromic spike was elicited through stimulation of the mossy fibers 
in CA3 stratum lucidum and recorded in the dentate granule cell layer. Red 
electrodes: CA3 antidromic spikes were produced by stimulation of the CA3 








2.8 WESTERN BLOT ANALYSIS 
 The technique of western blotting (i.e. protein blotting, immunoblotting) 
was first developed during the late 1970’s and has become a widely used tool to 
determine the presence and abundance of particular proteins (MacPhee, 2010). 
Western blotting begins with successful extraction and isolation of a particular 
lysate followed by separation onto a polyacrylamide gel through electrophoresis. 
The proteins are then transferred onto a membrane and probed with antisera to 
detect the presence of particular proteins. Determining the proper antisera can 
require several preliminary runs as both polyclonal and monoclonal antisera are 
available, each bringing its own advantages and disadvantages. However, a 
chief difference between the antisera is their specificity for an individual protein of  
interest. Once the appropriate antisera is bound to the protein, its relative 
expression can be determined through processes such as enhanced 
chemiluminescence (ECL). The peroxidase conjugated secondary antisera 
serves to oxidize the luminol substrate within the ECL to emit light which is then 
captured onto film and measured using densitometry.  In general, western 
blotting is a widely used and acceptable technique to determine relative 
expression and abundance of proteins. The following sections describe in detail 
the western blotting protocol utilized in Chapter 4 to determine differences in 
kainate receptor subunit abundance within specific brain regions following 





2.8.1 MEMBRANE PREPARATION 
Animals were anesthetized, the brain removed, and immediately placed 
on dry ice.  Brains were cut at 100 µM on a freezing microtome (Microm, Waldorf, 
Germany). Punches from prefrontal cortex, amygdala and striatum were 
collected, while hippocampi were removed and micro-dissected into dentate 
gyrus (DG), CA1 and CA3 regions.  Microdissected regions collected from the 
hippocampus are outlined in Figure 2.3.  All tissue collections were immediately 
placed in ice-cold homogenization buffer (0.32 M sucrose, 2mM EDTA, 2mM 
EGTA, 20mM HEPES, pH 7.6, containing 1:100 protease and phosphatase 
inhibitor cocktails (Sigma, St. Louis, MO). The samples were then homogenized 
and centrifuged for 10 min at 500 x g at 4ºC to remove the nuclear fraction.  The 
supernatant containing the total membrane fraction was centrifuged at 31,000 x g 
for 30 min at 4ºC.  The resulting pellet, crude plasma membrane, was re-
suspended in phosphate buffered saline (PBS) and stored at -80ºC prior to use. 
Protein concentrations were determined by using the Bradford method utilizing 
BSA (Bovine Serum Albumin, Thermo Scientific) as a standard. Linear 
regression analysis was performed in Microsoft Excel to extrapolate the unknown 
protein concentration. 
 
2.8.2 SDS-PAGE AND ANTIBODY DEVELOPMENT 
Aliquots of 2 – 10 µg of crude plasma membrane proteins were denatured 








 Figure 2.3. Microdissected hippocampal regions for western blot 
analysis. Hippocampal sections 100 µM thick were microdissected into Green, 
1. Dentate gyrus Blue, 2. CA3 and Red, 3. CA1 regions prior to homogenization 
and processing for western blot analysis. This process allowed for increased 











mercaptoethanol. Samples were then heated at 95ºC for 5 min and loaded into 
pre-cast polyacrylamide gels (4 – 15%). Running buffer (in mM: 25 Tris, 240 
Glycine, 0.1% SDS) was added to the appropriate tank, BioRad mini PROTEAN-
Tetra or BioRad Criterion, and run using the BioRad Power Pack HC for at least 
30 min at 175 – 200 V. Following sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) protein separation, proteins were transferred to 
polyvinylidene fluoride (PVDF) membranes using the BioRad Trans-Blot SD 
Semi-Dry Transfer Cell.  Protein transfer was completed using the BioRad Power 
Pack HC for 30 min at 25V. Transfer buffer contained (in mM): 25 Tris, 192 
Glycine, and 20% methanol. All equipment was acquired from Bio-Rad 
Laboratories, Inc.  
Following transfer, PVDF membranes were blocked in tris-buffered saline 
(TBS) plus 5% non-fat dry milk for 60 min at room temperature.  PVDF 
membranes were incubated with primary antisera (in TBS/5% non-fat dry milk) 
overnight at 4ºC with gentle shaking. Primary antibodies are listed in Table 2.2. 
Normalization for protein loading was performed using a mouse monoclonal 
primary antibody selective for β-actin. Following overnight incubation membranes 
were washed with TBS plus 0.05% Tween 20 (TBS-T) and incubated in 
peroxidase-labeled, species-specific secondary antibodies.  PVDF membranes 
were washed with TBS-T and developed using enhanced chemiluminescence 
reagents (ECL, Pierce) as described by the manufacturer. Images were captured 
on Kodak BioMax XAR film and optical densitometric analysis was performed 
using ImageJ 1.47v (National Institutes of Health, USA).  
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 The art of immunohistochemistry (i.e. immunostaining) was first 
demonstrated in the mid 1930’s, and the first study was published in the mid 
1940’s (Matos et al., 2010).  Since this time the technique has evolved into a 
commonly used method used to determine the specific expression patterns of 
proteins, enzymes or peptides within cells and tissue samples.  In order to 
generate reproducible and reliable immunohistochemical data, several 
preliminarily experiments may be required to determine the appropriate type of 
tissue fixation, sectioning, storage, antisera and analysis. Following tissue 
fixation, commonly utilizing paraformaldehyde, tissue may be immediately 
sectioned and stored for several days while antibody detection is performed.  
Other commonly used techniques involve cryoprotecting the tissue which allows 
for more long-term storage while analysis is conducted. In addition, antigen  
retrieval steps may be performed which serve to uncover antigenic sites which 
may have been shielded during fixation or through handling of the tissue. One 
must also consider the ability of the antisera to permeate the tissue and/or cell 






GluK2/3 Millipore; 04-921 1:8,000 
GluK4 SantaCruz; sc8916 1:200 
GluK5 Millipore; 06-315 1:8,000 
GFAP Cell Signaling; 3670 1:8,000 
β-Actin Sigma; A5441 1:50,000 
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100, can be utilized to increase the permeability and penetration of the antisera. 
In general, the protein of interest and the available antisera will often dictate the 
types of fixation, sectioning and storage of the tissue samples. The use of 
immunohistochemistry in determining protein localization and expression 
patterns is widely used and simply requires that the protocol be amended to the 
particular protein of interest. The following sections describe in detail the 
immunohistochemical protocol used in Chapter 4 to determine alterations in 
kainate receptor subunit expression within the hippocampus following 
pilocarpine-induced status epilepticus.  
 
2.9.1 PERFUSION AND TISSUE FIXATION 
Rats were deeply anesthetized using the anesthetic isoflurane.  Once 
anesthetized, a lateral incision to the lower abdomen was made which extended 
upwards to expose the chest cavity and the heart.  A hemostatic clamp was 
placed on the descending vena cava to prevent perfusate flow to the lower 
extremities.   A 20 x ½ gauge needle attached to the perfusion pump was 
inserted through the apex of the left ventricle and held firmly in place with a 
hemostat. Once inserted, the right atrium was clipped to allow perfusate flow. Ice 
cold, oxygenated (95% O2 / 5% CO2) 0.05M PBS (pH 7.4) was perfused at 
approximately 60mL/min for 4 – 5 min, followed by the ice cold fixative (0.1M 
phosphate buffer / 4% paraformaldehyde), for approximately 20 min. Whole 
brains were removed and blocked to remove olfactory lobes and cerebellum. The 
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remaining portion of the brain was post-fixed at 4ºC for 3 hours in tissue fixative 
and then transferred to 0.1M phosphate buffer (PB) until sectioned. 
Brains were sectioned at 50 µM-thick coronal sections on a vibratome 
(Leica VT1000S, Nussloch, Germany). Sectioning was performed in 0.1M PB 
and sections were stored at 4 ºC in 0.1M PB and 0.1% sodium azide to inhibit 
bacterial growth until used for immunohistochemical processing. 
 
2.9.2 IMMUNOPEROXIDASE 
Free floating tissue sections were transferred from 0.1M PB/0.1% sodium 
azide to TBS (0.08M Tris Base, 0.42M Tris Hydrochloride, 1.54M NaCl) for 
approximately 40 minutes (4 x 10 min). Tissue was then exposed to an antigen 
retrieval step in which sections were placed for 5 min in a Na+-Citrate buffer (10 
mM Na-Citrate) heated to 85ºC. Following the 5 min incubation sections were 
cooled at room temperature for 5 – 10 min and returned to TBS solution for 
approximately 40 min (4 x 10 min) to remove excess Na+-Citrate buffer. Antigen 
retrieval was performed prior to labeling with GluK2/3, GluK4 and GluK5 labeling 
only. Tissue was then treated with a methanolic peroxide (90 mL TBS, 10 mL 
100% methanol, 2 mL 30% hydrogen peroxide) rinse for 15 min at room 
temperature. This step was performed to reduce endogenous peroxidase in the 
tissue which aids in reducing background exposure during development. 
Following the methanolic peroxide step, tissue was then rinsed for 30 min (3 x 10 
min) in TBS, and then blocked for 1 hour in solution containing TBS, 3 – 5% 
donkey serum, and 0.1 – 0.2% Triton-X-100 (TBS+). The concentration of 
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donkey serum and Triton-X-100 is dependent upon the primary antibody; see 
Table 2.3 for further detail. Once blocking was complete the tissue was 
transferred to TBS+ containing the primary antibody of interest at the appropriate 
concentration. Tissue was gently rocked overnight at room temperature. 
Following incubation with the primary antibody, tissue was rinsed for 30 min in 
TBS (3 x 10 min), and incubated for 1.5 hour at room temperature in the 
appropriate biotinylated secondary antibody in TBS+ (1:1,000, Jackson 
ImmunoResearch). Tissue was then rinsed again for 30 min in TBS (3 x 10 min) 
and incubated for 1 hour in TBS containing 0.1 – 0.2% Triton-X-100 and 
horseradish peroxidase-conjugated streptavidin (1:1600, Jackson 
ImmunoResearch). Following the tertiary incubating tissue was rinsed for 50 min 
in TBS (5 x 10 min) and developed using nickel ammonium sulfate/cobalt 
chloride intensified diaminobenzidine (DAB, Sigma, St. Louis, MO; 0.025% DAB, 
50% TBS, 50% Nickel-Cobalt). Reaction was initiated by the addition of 0.3% 
hydrogen peroxide. Development time was determined on one slice from a 
sham-treated animal and the appropriate development time was used for both 
sham and pilocarpine-treated tissue.  Development times were dependent upon 
the primary antibody in use.  
 
2.9.3 SLIDE PREPARATION AND ANALYSIS 
Free floating tissue sections were mounted on slides with a 0.15% gelatin 
solution and allowed to dry overnight. Once dry, tissue went through a serial 
dehydration step with increasing concentrations of ethanol (50%, 70%, 95%, 
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100%, 100%; 3 min/bath) followed by two, 10 min incubations in Xylene. Slides 
were immediately cover-slipped using cover glass and DPX mounting solution 
(Sigma, St. Louis, MO) and allowed several days to dry prior to analysis and 
long-term storage. Analysis of immunohistochemical data was performed on 
MCID Elite 7.0 analysis system (Imaging Research, Inc., St. Catharines, 
Canada). 
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2.10 STATISTICAL ANALYSIS 
Electrophysiological data was analyzed using pClamp10 (Molecular 
Devices, Sunnyvale, CA), Origin7.5 (OriginLab, Northampton, MA), GraphPad 
Prism (v. 4.00, GraphPad Software, San Diego, CA) and Mini Analysis 6.0 
(Synaptosoft, Inc., Decatur, GA). Statistical significance was determined using 
one-way analysis of variance (ANOVA) with post-hoc Bonferroni tests or the 
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Student’s t-test, with α < 0.05. Values are depicted as the mean ± standard error 
of the mean (SEM). 
Data collected from western blot analysis and immunohistochemistry was 
analyzed using MCID ELITE 7.0 (Imaging Research, Inc., St. Catharine’s, 
Canada) or ImageJ 1.47V (National Institute of Health, USA). Optical density 
measurements were obtained using a standard curve. Data depicting changes in 
KAR subunit expression were obtained by averaging data collected from a 












Benzodiazepines (BZDs) are the first-line therapy for the treatment of 
status epilepticus (SE) and reduce seizure activity by enhancing GABAA 
receptor- mediated inhibition. However, clinical studies have revealed that nearly 
35% of patients suffering from SE are refractory to BZDs (Mayer et al., 2002). 
While many factors could contribute to this pharmacoresistance, clinical and 
animal studies have demonstrated that the likelihood of a patient responding to 
BZDs decreases as the duration of SE increases. Sensitivity to BZDs requires 
the presence of γ2-containing GABAA receptors (Mayer et al., 2002; Sieghart and 
Sperk, 2002). However, following the onset of SE, these BZD sensitive, γ2-
containing receptors are internalized (Goodkin et al., 2008). This internalization 
reduces the number BZD-sensitive receptors on the membrane surface, and thus 
during prolonged SE the efficacy of BZDs is significantly reduced. While BZD-
sensitive receptors are internalized during SE, other populations of BZD-
insensitive GABAA receptors, such as those containing α4 and δ subunits, remain  
________________________________________ 
1Stiripentol is anticonvulsant by potentiating GABAergic transmission in a model 
of benzodiazepine-refractory status epilepticus. Grosenbaugh, D.K., and Mott, 
D.D. 2013. Neuropharmacology. 67: 136-143.  
Reprinted here with permission of publisher. 
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functional (Goodkin et al., 2008).   
Stiripentol (STP, Diacomit) is an anticonvulsant drug approved for use in 
Europe for the treatment of severe myoclonic epilepsy in infancy (Dravet 
syndrome). Typically, STP is co-administered with other anti-epileptic drugs 
(AEDs) as it has been shown to increase their efficacy through inhibition of 
several hepatic cytochrome P450 enzymes (Tran et al., 1997). However, several 
animal models have demonstrated that STP may provide anticonvulsant effects 
when administered alone via enhancement of GABAergic inhibition (Poisson et 
al., 1984; Quilichini et al., 2006). In support of this finding, Fisher (2009) reported 
that STP is a positive allosteric modulator of GABAA receptors containing any of 
the α, β or γ-subunits, with greatest activity at α3 or δ-containing receptors.  
 The subunit selectivity profile of STP suggests its ability to potentiate both 
phasic and tonic GABAergic inhibition.  In addition, STP may retain this ability to 
potentiate GABAergic inhibition during prolonged SE when γ2-containing, BZD-
sensitive, GABAA receptors have been internalized. The goal of the current 
project was to determine the ability of STP to terminate SE in BZD-resistant rats, 
and to understand the mechanism by which STP may be anticonvulsant.  
 
3.2 HYPOTHESIS  
STP has been previously demonstrated to potentiate GABAA receptors 
composed of any of the α, β, or δ-subunits. Given that during status epilepticus 
GABAA receptors containing α4 and δ subunits remain functional, we 
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hypothesize that STP will remain effective during prolonged SE when seizures 
have become resistant to benzodiazepines.   
 
3.3 MATERIAL AND METHODS 
3.3.1 BEHAVIORAL EXPERIMENTS  
Male Sprague-Dawley rats (15 – 24, and 57 – 63 days old) received 
intraperitoneal (i.p.) injections of lithium-chloride (LiCl, 127 mg/kg) followed 15 – 
20h later by scopolamine methyl bromide (2 mg/kg). Status epilepticus was then 
induced after 15 – 30 min by injection with pilocarpine (60 mg/kg). Diazepam 
(DZP; 0.3 – 100 mg/kg) or stiripentol (STP; 10 – 1000 mg/kg) was administered 
either at the onset of stage 3 seizures (brief SE) to assess its effect on brief 
behavioral convulsions or 45 min after stage 3 seizure onset (prolonged SE; 
pSE) to assess its effect during prolonged seizures. Behavioral seizure scores 
were recorded throughout the course of SE. Seizure scores reported in this study 
correspond to scores 15 min following administration of STP or DZP.  
 
3.3.2 DETERMINATION OF STP CONCENTRATIONS 
Four separate groups of male Sprague-Dawley rats: 1) naïve juvenile (20 
– 27 days old), 2) prolonged SE-experienced juvenile (20 – 21 days old), 3) naïve 
adult (62 – 63 days old) and 4) prolonged SE-experienced adult (61 days old), 
were used to determine brain and plasma concentrations of STP. Fifteen minutes 
following i.p. administration of 300 mg/kg STP, naïve and prolonged SE rats were 
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anesthetized and decapitated in order to collect brain and blood samples. A 
detailed description is provided in Chapter 2.4. 
   
3.3.3 WHOLE-CELL RECORDINGS 
Transverse (300 µM thick) hippocampal slices were prepared from 5 – 65 
day old rats as described in Chapter 2.6. Rats were either naïve or had 
experienced prolonged SE, in which slices were prepared 45 min after the first 
stage 3 seizure. Animals were selected for slice experiments only if they had an 
average seizure score between 3 and 4 during the prolonged SE.  
 GABA IPSCs were evoked by stimulation in stratum moleculare of the 
dentate gyrus near the recording electrode. IPSCs were pharmacologically 
isolated using the glutamate receptor antagonist D-APV (50 µM), or MK-801 (10 
µM), and CNQX (50 µM), plus the addition of tetrodotoxin (TTX, 1 µM) for 
miniature IPSCs (mIPSCs) and tonic current. Bicuculline methochloride (20 µM) 
was added at the end of each experiment to confirm that the recorded IPSCSs 
were mediated by GABAA receptors. Miniature EPSCs (mEPSCs) were isolated 
using 30 µM bicuculline methochloride and 1 µM TTX. Drugs were perfused for a 
minimum of 20 min in order to obtain a stable baseline.  
  Stiripentol was a generous gift from Biocodex. Scopolamine methyl 
bromide, pilocarpine, kynurenic acid, diazepam, clobazam and all salts were 
purchased from Sigma Chemical Company (St. Louis, MO). D -APV, MK-801, 
CNQX, flumazenil, tetrodotoxin and bicuculline methochloride were purchased 
from Ascent Scientific (Princeton, NJ). For behavioral experiments all drugs were 
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made fresh on the day of the experiment and dissolved in 0.9% saline, except for 
STP which was dissolved in 20% propylene glycol and 80% ethanol. All drugs 
were administered via i.p. injection. For electrophysiological experiments drugs 
were bath applied in the perfusion medium. Drugs were diluted from frozen 
stocks in water except STP, DZP and clobazam which were diluted from frozen 
stocks in dimethyl sulfoxide (DMSO). The final concentration of DMSO in working 
solutions was less than 0.3%. 
 
3.4 RESULTS 
 3.4.1 STP TERMINATION OF BRIEF BEHAVIORAL SE IS AGE DEPENDENT 
 Behavioral convulsions began approximately 3 min after injection of 
pilocarpine. Behavioral seizures progressed through stages, as previously 
described in Table 2.1. Stage 3 behavioral convulsions, characterized by forelimb 
clonus without rearing and falling began approximately 20 min after 
administration of pilocarpine. Treatment with stiripentol at the start of stage 3 
seizures was effective in reducing seizures at doses above 10 mg/kg with a dose 
of 1000 mg/kg terminating seizures in all tested animals (n = 4). In contrast, 
treatment with vehicle alone (20% propylene glycol/80% ethanol) did not reduce 
seizures. Dose-response analysis was performed on young rats (15 – 23 days 
old) by administration of STP (10 – 1000 mg/kg) at the onset of stage 3 seizures 
and yielded an ED50 of 100 (58.1 – 171.8) mg/kg; Figure 3.1A. To determine the 
age-dependence of this effect, STP was also tested in adult animals (61 – 63 





Figure 3.1. STP and DZP both terminate brief behavioral convulsions. 
The anticonvulsant effect of STP and DZP on brief SE was compared in young 
(15 – 23 days old) and adult (59 – 63 days old) male rats. Seizure scores in the 
presence of STP or DZP were expressed as a percentage of the seizure score at 
the same time point from animals that did not receive drug.  A. STP dose-
dependently reduced seizure score in young (closed squares, n = 5 – 10) and 
adult animals (open triangles, n = 5 – 9). The anticonvulsant effect of STP in 
adult animals was shifted significantly to the right. B. DZP dose-dependently 
reduced seizure score in young (closed squares, n = 4 – 19), and adult animals 






the right (ED50 = 377.6 (256.4 – 555.9) mg/kg; Figure 3.1A). The confidence 
intervals of the ED50 did not overlap, indicating a real difference in the STP 
potency with maturation, as previously reported (Cao et al., 2012). In 
comparison, the 95% confidence intervals for DZP in both young (21 – 23 days 
old; ED50 = 3.1 (2.2 – 4.2) mg/kg; Figure 3.1B) and adult (59 – 63 days old; ED50 
= 4.2 (2.2 – 7.8) mg/kg; Figure 3.1B) rats did overlap, indicating no real 
difference in the ED50 for DZP during maturation. These findings indicate that, 
like DZP, STP is able to terminate brief SE in the Li-Pilo model. 
 
 
3.4.2 PHARMACORESISTANCE DEVELOPS TO DZP BUT NOT STP DURING 
PROLONGED SE 
As with status epilepticus in humans, seizures in the Li-Pilo model become 
pharmacoresistant to DZP during prolonged SE (Walton and Treiman, 1988; 
Kapur and Macdonald, 1997; Jones et al., 2002). In agreement, we found that in 
young (15 – 23 days old) animals the ED50 for DZP increased about 14 fold when 
it was administered 45 min after the first stage 3 behavioral seizure (ED50 = 3.1 
(2.2 – 4.2) mg/kg after brief SE; ED50 = 43.1 (33.0 – 56.0) mg/kg after prolonged 
SE; Figure 3.2A,B). In contrast, we observed no real difference in the ED50 for 
STP during prolonged SE (ED50 = 100 (58.1 – 171.8) mg/kg after brief SE; ED50 
= 216.3 (136.8 – 342.0) mg/kg after prolonged SE; Figure 3.2A,B). Similarly, in 
adult (57 – 63 days old) animals the ED50 for DZP increased 11 fold after 
prolonged SE (ED50 = 4.2 (2.2 – 7.8) mg/kg after brief SE; ED50 = 47.2 (33.2 – 






Figure 3.2. Less pharmacoresistance develops to STP than to DZP 
following prolonged SE. SE was induced in young (15 – 23 days old, top 
panels) and adult (57 – 63 days old, bottom panels) male rats. DZP or STP was 
administered at different doses at the onset of the first stage 3 behavioral 
convulsion (closed squares) or 45 min following the first stage 3 convulsion 
(closed circle) and the dose response curve measured. ED50 values for 
anticonvulsant effect of DZP (left panel, n = 3 – 19) and STP (right panel, n = 5 – 
29) during brief (Brief) and prolonged SE (pSE) in A. young rats and C. adult 
rats. Fold change in ED50 for DZP and STP during prolonged SE relative to brief 








different (ED50 = 377.6 (256.4 – 555.9) mg/kg after brief SE; ED50 = 397.2 (290.4 
– 544.5) mg/kg after prolonged SE; Figure 3.2C,D). 
 
3.4.3 BRAIN-PLASMA STP 
We next wanted to determine if alterations in the bioavailability of STP 
during maturation or prolonged SE affected its apparent efficacy. To address this 
possibility, we measured plasma and brain concentrations of STP following 
administration of 300 mg/kg STP. An initial pilot study in young rats (23 – 27 days 
old, n = 4 – 5), showed that exposure to brief seizure activity modified neither 
STP plasma levels nor the brain/plasma ratios compared to animals that did not 
experience any seizure activity. To further explore this, a larger study of 43 
animals was then carried out. This study revealed that STP plasma concentration 
was not different in juvenile (96 ± 4.1 µg/mL) or adult (86.8 ± 3.6 µg/mL, p > 0.05) 
animals (Table 3.1). The brain/plasma ratio of STP was also not different 
between juvenile (0.98 ± 0.04) and adult (0.91 ± 0.04) animals (p = 0.41) and 
was similar to that previously reported in adult animals (Shen et al., 1990; Shen 
et al., 1992; Arends et al., 1994). Following prolonged SE, neither the plasma 
concentration (100.7 ± 11.4 µg/mL, p = 0.67) nor the brain/plasma ratio (1.01 ± 
0.09, p = 0.72 compared to naïve animals) changed in juvenile animals (Table 
3.1). In contrast, in adult animals the brain/plasma ratio for STP decreased by 
approximately 20% following prolonged SE (naïve: 0.91 ± 0.04, post-SE: 0.70 ± 




Table 3.1. Plasma and brain concentrations of STP 
  *p < 0.05 
 
3.4.4 STP POTENTIATES EVOKED GABAA RECEPTOR MEDIATED IPSCS 
Given the ability of STP to potentiate GABAA receptors (Quilichini et al., 
2006; Fisher, 2009), we hypothesized that STP acted as an anticonvulsant in SE  
by enhancing GABAergic inhibition. To test this hypothesis we characterized the 
effects of STP on GABAA receptor mediated currents in dentate granule cells.  
The effect of STP on evoked  IPSCs in dentate granule cells in young (20 
– 26 day old) naïve animals was examined in the presence of glutamate 
antagonists (CNQX, 50 µM and D-APV, 50 µM) to block AMPA/kainate and 
NMDA receptors, respectively. Bicuculline methochloride (20 µM) completely 
blocked this IPSC, indicating that it was mediated by GABAA receptors. DZP (1 
µM) increased its decay time (145.6 ± 10.4% of control, n = 5; p < 0.01; Figure 
3.3), further confirming that it was mediated by GABAA receptors. STP (100 µM) 
had no effect on the IPSC rise time (10 – 90% rise time: 118 ± 11% of control, n 
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Figure 3.3. STP prolongs IPSC decay in an age-dependent manner. A. 
Left, Sample IPSC waveforms from 5 – 7 and 60 – 65 day old animals in the 
absence (CON) and presence of 100 µM STP (STP). Right, Concentration 
response curves showing the effect of STP on the 50% decay time of the evoked 
IPSC in the three age groups tested; postnatal day 5 – 7 (closed squares, n = 4 – 
7), postnatal day 20 – 25 (closed circles, n = 5 – 9) and postnatal day 60 – 65 
(closed triangles, n = 4 – 8). B. Plot of the EC50 and 95% confidence intervals for 









significantly prolonged the IPSC decay (156 ± 8.9% of control, n = 9; p < 0.01; 
Figure 3.3), in agreement with a previous report (Quilichini et al., 2006). This 
increase in decay time was concentration dependent (EC50 = 103 µM (85 – 126 
µM), n = 5 – 9). While STP had no effect on IPSC amplitude at lower 
concentrations, at the highest concentration tested (700 µM) STP significantly 
reduced IPSC amplitude (62.5 ± 4.6%, n = 6; p < 0.001).  
Since the anticonvulsant effect of STP was age-dependent, we compared 
the ability of STP to prolong IPSC decay time in animals of different ages (5 – 8 
days old, 20 – 26 days old, and 59 – 65 days old; Figure 3.3A). STP potentiated 
IPSCs in granule cells from animals that were postnatal 5 – 8 days to a greater 
extent than it potentiated IPSCs in animals from either of the other two age 
groups (Figure 3.3B). The ability of STP to produce greater potentiation of IPSCs 




3.4.5 ACTION OF STP IS INDEPENDENT OF THE BZD SITE ON THE GABAA 
RECEPTOR 
Stiripentol is approved in Europe for use as add-on therapy in Dravet 
Syndrome, and is commonly administered with the 1,5-benzodiazepine, 
clobazam (CLB) (Chiron et al., 2000; Ng and Collins, 2007). We investigated 
whether CLB and STP act through a common site on the GABAA receptor by 
measuring whether a maximally effective concentration of CLB occluded the 
effect of STP. STP alone prolonged IPSC decay time (153.3 ± 15.2% of control, 
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p < 0.001). CLB maximally potentiates GABAA currents at a concentration of 
about 10 µM (Nakamura et al., 1996). At this concentration CLB alone also 
significantly prolonged IPSC decay time (187.4 ± 17.8% of control, p < 0.001; 
Figure 3.4A). Application of STP (100 µM) in the presence of CLB (10 µM) 
significantly increased the IPSC decay time beyond that of CLB alone (350.8 ± 
38.2% of control, p < 0.001; Figure 3.4A), suggesting that these drugs act at 
separate loci.  
 In further support of this conclusion, we found that the benzodiazepine-site 
antagonist flumazenil (FMZ) had no effect on IPSC decay time (94.3 ± 3% of 
control, p > 0.05), but blocked IPSC prolongation produced by 1 µM DZP (85.7 ± 
3.2%, p > 0.05) and 10 µM CLB (96.5 ± 4.6%, p > 0.05; Figure 3.4B). However, 
FMZ did not prevent IPSC prolongation by STP (200.5 ± 18.3%, p < 0.001; 
Figure 3.4B). In agreement with Quilichini et al. (2006), these findings support the 
conclusion that STP does not interact with the BZD site of the GABAA receptor. 
 
 
3.4.6 GABAERGIC POTENTIATION BY STP REMAINS EFFECTIVE FOLLOWING 
PROLONGED SE  
The ability of STP to retain anticonvulsant potency during prolonged SE 
could be explained by the continued ability of the drug to potentiate the IPSC 
during SE. To investigate this possibility we compared the effect of STP on 
IPSCs in dentate granule cells from naïve animals and from animals that had 
experienced 45 min of continuous seizure activity (Figure 3.5A). STP (100 µM) 






Figure 3.4. STP potentiation of GABAergic transmission is 
independent of the BZD-binding site. A. STP (100 µM, n = 7; ***p < 0.001) and 
CLB (10 µM, n = 7; ***p < 0.001) increased the 50% decay time of the evoked 
IPSC. Co-application of STP (100 µM) and CLB (10 µM) significantly enhanced 
decay time compared to control (n = 8; ***p < 0.001) as well as compared to 
either STP (###p < 0.001) or CLB alone (##p < 0.01). B. FMZ (10 µM) alone did 
not alter IPSC decay time (n = 10; p > 0.05), but blocked potentiation by DZP (1 
µM, n = 4) or CLB (10 µM, n = 4). In contrast, STP (100 µM, n = 4) continued to 










Figure 3.5. STP continues to potentiate phasic GABAergic 
transmission following prolonged SE. A. Left, Sample traces from naïve and 
prolonged SE-experienced animals demonstrate similar potentiation by 100 µM 
STP. Right, STP (100 µM) similarly potentiates IPSC decay in both naïve (gray 
bar, n = 9) and prolonged SE-experienced animals (black bar, n = 4). B. Left, 
Sample traces from naïve and prolonged SE-experienced animals demonstrate a 
lack of potentiation by 300 nM DZP in prolonged SE-experienced animals. Right, 
Potentiation of IPSC decay by DZP (300 nM) following prolonged SE (black bar, 
n = 10) is significantly (*p < 0.05) reduced compared to naïve animals (gray bar, 






(naïve: 156 ± 8.9%, p < 0.01; prolonged SE: 180.2 ± 12.5%, p < 0.001). The 
extent of potentiation in both conditions was not different (p = 0.15). In contrast, 
IPSC potentiation by DZP (300 nM) was significantly reduced in granule cells 
from animals that had experienced prolonged SE (naïve: 147.0 ± 9.7%; 
prolonged SE: 117.0 ± 7.2%, p < 0.05; Figure 3.5B). This reduction in DZP 
potency during SE agrees with previous reports (Walton and Treiman, 1988; 
Kapur and Macdonald, 1997). These findings demonstrate that STP, but not DZP 
retains potency following prolonged SE and suggests that the continued ability of 
STP to potentiate GABAergic IPSCs underlies its ability to remain effective 
during prolonged SE.  
 
 
3.4.7 STP, BUT NOT DZP, REMAINS EFFECTIVE IN POTENTIATING TONIC 
CURRENT FOLLOWING PROLONGED SE 
Tonic inhibition in the dentate gyrus is mediated by GABAA receptors 
containing α4 and δ subunits as well as those containing α5 and γ2 subunits 
(Zhang et al., 2007). The ability of STP to act at receptors containing these 
subunits (Fisher, 2009) suggests that potentiation of tonic GABA currents may 
contribute to the anticonvulsant effect of STP. We examined the effect of STP on 
tonic GABA current in dentate granule cells in young (21 – 23 days old) naïve 
animals. Tonic currents were studied in the presence of 50 µM CNQX, 50 µM D-
APV/10 µM MK-801, and 1 µM TTX to block AMPA/kainate receptors, NMDA 
receptors and Na+ channels, respectively. Tonic currents were blocked by 
bicuculline methochloride (20 µM), indicating that they were mediated by GABAA 
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receptors. As predicted, STP (100 µM) significantly potentiated the tonic current 
(185.5 ± 22.6%, p < 0.01). We then compared the effect of STP on tonic current 
in naïve animals to that in animals that had experienced prolonged SE (naïve: 
20.4 ± 3 pA, n = 10; prolonged SE: 36.6 pA, n = 9; p < 0.05; Figure 3.6A), a 
finding in agreement with a previous study (Naylor et al., 2005). Despite the 
increase in tonic current, STP still potentiated this current following prolonged SE 
(175.4 ± 23.8%, p < 0.05) by a similar amount to that in naïve animals (p = 0.76; 
Figure 3.6A). By comparison, DZP (1 µM) potentiated tonic GABA current (155.3 
± 18%, p < 0.05) in granule cells in naïve animals, likely by acting on α5/γ2-
containing GABAA receptors (Zhang et al., 2007). However, following prolonged 




3.4.8 STP RETAINS ITS ABILITY TO POTENTIATE MIPSCS FOLLOWING 
PROLONGED SE 
STP can increase GABA release by acting presynaptically on inhibitory 
terminals (Quilichini et al., 2006) and this action could contribute to both the 
ability of STP to prolong the IPSC decay and the anticonvulsant effect of the 
compound. We examined the presynaptic action of STP by measuring its effect 
on the frequency of miniature IPSCs (mIPSCs). Spontaneous mIPSCs were 
recorded in the presence of glutamate antagonist (CNQX, 50 µM and D-APV, 50 
µM) and TTX (1 µM), to block Na+ channels. In young animals (19 – 26 days old) 





Figure 3.6. STP, not DZP, continues to enhance tonic GABAergic 
inhibition following prolonged SE. A. Left, Sample traces from naïve and 
prolonged SE-experienced animals demonstrate similar potentiation of tonic 
GABAA currents by 100 µM STP. Tonic GABAA current is blocked by 30 µM 
bicuculline (BIC). Right, STP (100 µM) similarly potentiates tonic GABAA currents 
in naïve (gray bar, n = 6) and prolonged SE-experienced animals (black bar, n = 
5). B. Left, Sample traces demonstrate that DZP (1 µM) potentiates tonic GABAA 
current in dentate granule cells in naïve animals and that this potentiation is lost 
following prolonged SE. Right, DZP (1 µM) enhances tonic GABAA current in 
naïve animals (gray bar, n = 4), but does not potentiate this current following 








but increased both the frequency (131.5 ± 5.8%, p < 0.001) and the decay time of 
events (150.1 ± 12.1%, p < 0.01; Figure 3.7A). Similarly, in dentate granule cells 
from animals that had experienced prolonged SE, 100 µM STP continued to 
potentiate both the frequency (140.3 ± 13.6%, p < 0.05) and decay time (140.7 ± 
7.5%, p < 0.001) of the mIPSCs, without affecting mIPSCs amplitude (101.5 ± 
10.5%, p > 0.05; Figure 3.7A). These findings indicate that STP acts 
presynaptically to enhance GABA release and this effect does not change during 
prolonged SE. In contrast, in naïve animals DZP (1 µM) significantly potentiated 
the decay time (156.7 ± 8.2%, p < 0.001) of mIPSCs, without affecting mIPSC 
frequency (95.5 ± 9.6%, p > 0.05; Figure 3.7B), supporting the conclusion that its 
action was entirely postsynaptic on GABAA receptors. During prolonged SE, the 
effect of DZP on mIPSC decay (118.1 ± 3.8%, p < 0.001) was significantly 
reduced (Figure 3.7B).  
 The mechanism by which STP enhances GABA release is unknown. 
However, given its ability to act presynaptically, we also assessed whether it 
could enhance glutamate release. The effect of STP on glutamate release was 
measured by its ability to alter the frequency of spontaneous miniature excitatory 
post-synaptic currents (mEPSCs). mEPSCs were studied in the presence of the 
GABAA receptor antagonist bicuculline methochloride (30 µM) and TTX (1 µM). 
In young animals (19 – 26 days old) STP (100 µM) significantly increased 
mEPSC frequency (128 ± 4.5%, p < 0.001) without altering the amplitude of 





Figure 3.7. STP, not DZP, remains effective in potentiating mIPSCs 
following prolonged SE. A. Top, Sample waveforms from naïve and prolonged 
SE-experienced animals before and after application of 100 µM STP showing 
increased mIPSC frequency. Lower Left, Superimposed traces of averaged 
mIPSCs in the absence and presence of STP (100 µM) in naïve and prolonged 
SE (pSE) animals. Lower Right, STP (100 µM) similarly increased mIPSC 
frequency and decay time in both naïve (gray bars, n = 5) and prolonged SE-
experienced animals (black bars, n = 6). B. Top, Sample waveforms from naïve 
and prolonged-SE experienced animals before and after application of 1µM DZP, 
showing no change in mIPSC frequency. Lower Left, Superimposed traces of 
averaged mIPSCs in the absence and presence of DZP (1 µM) in naïve and 
prolonged SE (pSE) animals. Lower Right, DZP (1 µM) had no effect on mIPSC 
frequency in naïve (gray bar, n = 5) or prolonged SE-experienced animals (black 
bar, n = 6). DZP (1 µM) significantly prolonged SE-experienced mIPSC decay 
time in dentate granule cells from naïve animals (gray bar, n = 5).  Following 







Figure 3.8. Neither STP nor DZP alter mEPSCs following prolonged 
SE A. Top, Sample waveforms from naïve and prolonged SE-experienced 
animals before and after application of 100 µM STP, showing increased mEPSC 
frequency. Lower Left, Superimposed traces of averaged mEPSCs in the 
absence and presence of STP (100 µM) in naïve and prolonged SE (pSE) 
animals. Lower Right, STP (100 µM) significantly potentiated mEPSC frequency 
in naïve animals (gray bars, n = 5), but did not alter frequency following 
prolonged SE (black bars, n = 6), a significant difference from naïve animals (**p 
< 0.01). STP had no effect on mEPSC decay time in naïve or prolonged SE-
experienced animals. B. DZP (1 µM) did not alter mEPSC frequency or decay 
time in naïve (gray bars, n = 5) or prolonged SE-experienced animals (black 






mEPSC frequency was significantly reduced (p < 0.01). In contrast, DZP (1 µM) 
did not affect the frequency or decay time of mEPSCs in either naïve animals or 
prolonged SE-experienced animals (Figure 3.8B). These findings indicate that 
STP affects both inhibitory and excitatory transmission, but that its effects on 
inhibitory and excitatory terminals are differentially regulated during SE. 
 
3.5. DISCUSSION  
The results of this study suggest that STP may be effective in terminating 
prolonged SE, a time when seizures have become resistant to BZDs.  
Specifically, this study demonstrates that at therapeutically relevant 
concentrations STP terminates both brief and prolonged behavioral SE. These 
actions of STP are due to its enhancement of GABAA receptor mediated 
transmission, as STP acts both postsynaptically to prolong IPSC decay and 
presynaptically to enhance GABA release.  Despite a significant reduction in 
IPSC potentiation by DZP, the actions of STP on GABAergic transmission are 
preserved during prolonged SE. Postsynaptically STP potentiates both phasic 
and tonic GABAergic currents by acting on the GABAA receptor at a locus 
separate from the BZD site.  This study also demonstrated that the 
anticonvulsant effects of STP, as well as its effects on IPSC decay, are age-
dependent with greater effects in younger animals.  The results of this study 
suggest the potential for the use of STP in treatment of BZD-resistant SE. Figure 









Figure 3.9. Summary of changes in GABAA receptor pharmacology 
following prolonged-SE. In naïve animals BZD-sensitive γ2-containing 
GABAAR dominate the postsynaptic membrane. Extrasynaptic receptors are 
composed of a combination of γ2-containing and γ2-lacking GABARs. In 
prolonged-SE experienced animals (Post-SE), the γ2 subunit is internalized 
leaving mostly BZD-insensitive γ2-lacking GABAARs at synaptic and 
extrasynaptic sites. The pharmacological profile of STP preserves its 









3.5.1 STATUS EPILEPTICUS INDUCED RESISTANCE TO BZDS 
The initiation and maintenance of SE is regulated by GABAergic inhibition 
within the dentate gyrus and CA1 region of the hippocampus (Kapur and 
Lothman, 1989; Kapur et al., 1989).  Seizures become self-sustaining because  
with time seizures progressively reduce GABAA receptor-mediated inhibition in 
the hippocampus.  This reduction in GABAergic transmission leads to the 
development of further seizures.  BZDs, such as DZP, are anticonvulsant by 
potentiating γ2-containing GABAA receptor currents in this region.  However, the 
pharmacoresistance to BZDs during prolonged SE results from the rapid activity-
dependent decrease in surface expression of the BZD-sensitive γ2-containing 
GABAA receptors (Naylor et al., 2005; Goodkin et al., 2008).  In contrast, BZD-
insensitive GABAA receptors containing α4 and δ subunits are preserved 
(Goodkin et al., 2008).   
 
3.5.2 STP POTENTIATION OF BOTH PHASIC AND TONIC GABAERGIC INHIBITION 
The results of this study suggest that the ability of STP to remain effective 
during prolonged SE is due to its unique subunit selectivity profile.  STP is a 
positive allosteric modulator of GABAA receptors containing any of the α, β or γ 
subunits (Fisher, 2009). GABAA receptors containing α4 subunits can mediate 
phasic inhibition and remain at the membrane surface following prolonged SE.  
STP may retain its ability to potentiate phasic inhibition during prolonged SE by 
acting at receptors containing these subunits.  
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In addition to potentiating phasic inhibition, the results of this study 
demonstrate that STP strongly potentiates tonic inhibition. This finding is in 
support of its activity at δ-containing GABAA receptors (Fisher, 2009). The ability 
of STP to enhance tonic GABAA currents may have contributed to its 
anticonvulsant effect.  The continued effectiveness of STP on tonic inhibition 
during prolonged SE was likely due to the persistence of δ-containing GABAA 
receptors on the membrane surface (Goodkin et al., 2008). In contrast, DZP does 
not act at δ-containing receptors.  The observed potentiation of tonic GABAA 
current by DZP has been reported to occur through the activity of the drug at 
α5/γ2-containing extrasynaptic GABAA receptors (Zhang et al., 2007). However, 
this effect of DZP was lost during prolonged SE due to internalization of γ2-
containing receptors (Naylor et al., 2005). Thus, STP, not DZP, retained efficacy 
during prolonged SE. While it seems likely that STP potentiated tonic inhibition 
by acting at δ-containing GABAA receptors, the possibility that the presynaptic 
action of STP contributed cannot be excluded. The present data suggest that the 
ability of STP to remain effective during prolonged SE is likely due to its activity 
at BZD-insensitive GABAA receptors containing α4 and δ subunits as well as its 
presynaptic effect.  
 
3.5.3 EFFECTS OF STP ARE DEVELOPMENTALLY REGULATED 
 STP has been shown to act at all α subunits, however it has the highest 
activity at α3-containing GABAA receptors (Fisher, 2009). In rat, expression of the 
α3 subunit is strongly developmentally regulated. In embryonic and newborn 
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brain α3 subunits are expressed in most regions (Laurie et al., 1992).  However, 
with maturation α3 mRNA expression decreases becoming restricted to neurons 
primarily in the cortex and thalamus. The developmental loss of α3 subunit 
expression likely explains the observed age dependence in both the ability of 
STP to potentiate the IPSC and its anticonvulsant activity.  However, it is 
important to note that the developmental profile of α3 subunit expression in 
humans has not been reported.  Furthermore, the mechanism by which a 
developmental loss of α3 subunits could cause a shift in STP potency has not 
been explored. Further studies will be required to resolve these issues.  
 In the present study the ED50 for DZP to terminate SE and the extent of 
the rightward shift in the DZP ED50 during prolonged SE are in agreement with 
previous studies in the Li-Pilo model (Walton and Treiman, 1988; Kapur and 
Macdonald, 1997; Jones et al., 2002; Goodkin et al., 2003).  The observed shift 
in DZP ED50 was similar in both juvenile and adult animals. Under the same 
conditions, STP displayed markedly less pharmacoresistance than DZP at both 
developmental time points. However, in juvenile animals there was a slight trend 
for the STP ED50 to increase (~ 2 fold) after prolonged SE; a trend which 
disappeared in adult animals. This observation in juvenile animals may be 
explained by the developmental decrease in α3 subunit expression.  Thus, in 
juvenile animals the action of STP on α3-containing GABAA receptors may have 
accounted for a greater proportion of the drugs effect than in adult animals. 
Consequently, internalization of α3-containing GABAA receptors during SE would  




in juvenile than in adult animals.  
 
3.5.4 STP IS EFFECTIVE AT THERAPEUTICALLY RELEVANT CONCENTRATIONS 
STP is used clinically to treat Dravet Syndrome in children at doses that 
result in plasma concentration of 4 – 22 µg/mL (Farwell et al., 1993; Chiron et al., 
2000), a value that corresponds to approximately 16 – 90 µM.  The present study 
determined that in granule cells from 5 to 7 day old rats STP potentiated the 
IPSC with an EC50 of 45 µM, a value well within the established therapeutic 
range.  Previous studies examining the effects of STP have focused on its 
anticonvulsant effects in adult animals.  The concentrations of STP used in these 
reports are similar to those used in adult animals in the present study. For 
example, Shen et al. (1990) found that STP applied alone produced a maximal 
anticonvulsant effect in adult animals at concentrations above 120 µg/mL, 
equivalent to ~500 µM. In agreement, the present study reported that STP 
terminated SE in adult animals with an ED50 of 378 mg/kg, corresponding to a 
plasma concentration of approximately 110 µg/mL. In younger rats (20 – 25 days 
old), STP became more potent, terminating SE with an ED50 of 100 mg/kg.  This 
corresponds to a plasma concentration of 30 µg/mL, equivalent to ~120 µM. The 
concentration corresponding to this ED50 for the anticonvulsant effect of STP 
measured in vivo agreed well with the EC50 of 102 µM determined for STP 
prolongation of the IPSC in vitro from animals of the same age. The similarity 
between these values is consistent with the idea that potentiation of GABAergic 




3.5.5 STP ACTS AT A DISTINCT SITE ON THE GABAA RECEPTOR 
The site of action of STP on the GABAA receptor is not known.  The 
actions of STP on the IPSC were similar to those of BZDs in that they both 
prolonged the decay of the IPSC without increasing its peak amplitude.  
However, results of the present study, as well as previous work (Quilichini et al., 
2006; Fisher, 2009), indicate that STP acts at a distinct site on the GABAA 
receptor; a site separate from BZD binding sites as well as binding sites for 
neurosteroids and some anesthetics.  In support of this, the present study 
determined that the actions of STP were not blocked by a BZD site antagonist, 
and were additive with co-applied BZDs. This finding suggests a potential role for 
STP as add-on therapy with BZDs for the treatment of SE.  
The current study also reported that at concentrations above 300 µM, STP 
depressed the evoked IPSC.  This finding is consistent with the previous 
suggestion that STP acts as a partial agonist (Fisher, 2009). The ability of STP to 
directly activate the receptor may have contributed to the strong sedation 
produced by the drug at high doses.  Based on similarities to the actions of 
barbiturates, Quilichini et al. (2006) suggested that STP may act at the 
barbiturate site.  However, unlike barbiturates, STP did not increase the peak 
amplitude of the IPSC. Fisher (2009) also reported that the subunit dependence 
of STP is distinct from that of the barbiturates (Thompson et al., 1996), 
suggesting that STP acts at a unique site on the GABAA receptor.  Barbiturates 
and STP also differ in their activity at other sites. For example, barbiturates 
decrease glutamate release and block AMPA receptors (Ho and Harris, 1981; 
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Miljkovic and MacDonald, 1986), whereas the present study determined that STP 
enhanced glutamate release. STP also enhanced GABA release and this effect 
persisted during prolonged SE, suggesting that it could have contributed to the 
anticonvulsant effect of the drug. This presynaptic effect differentiates STP from 
both barbiturates and BZDs, further demonstrating the unique pharmacological 
profile of STP.  
 
3.6 SIGNIFICANCE 
The present study determined that STP increased GABA release, 
potentiated both phasic and tonic GABAergic currents and was anticonvulsant in 
the Li-Pilo model of SE. Most notably, STP remained effective during prolonged 
SE at a time when seizures had become pharmacoresistant to BZDs. The 
actions of STP were age-dependent with the greatest effect in younger animals.  
These findings suggest that STP may be effective in treatment of prolonged SE.  
The need for novel therapies for prolonged SE is highlighted by clinical studies 
showing that the majority of patients undergoing SE do not receive treatment 
within 30 min (Jordan, 1994; Pellock et al., 2004; Shinnar et al., 2008). Results of 
the present study suggest that STP, either alone or as add-on therapy, would be 





TEMPORAL ALTERATIONS IN KAINATE RECEPTOR SUBUNIT EXPRESSION 
FOLLOWING STATUS EPILEPTICUS 
 
4.1 INTRODUCTION 
 Alterations in both glutamatergic and GABAergic receptor populations 
have been identified in patients suffering from seizure disorders such as status 
epilepticus (SE) (Grigorenko et al., 1997; Mathern et al., 1998; Mathern et al., 
1999; Das et al., 2012; Houser et al., 2012). While some of these modifications 
can occur during a single SE event others emerge during the progression of the 
disease, representative of enduring alterations in receptor expression. The ability 
to develop effective therapeutics for the treatment of SE and epilepsy rests in our 
understanding of the diseased brain and the available receptor targets. 
 Kainate receptors (KARs) contribute to excitatory neurotransmission in the 
cerebrum, specifically throughout the hippocampus, a region central to the 
development of epilepsy (Chang and Lowenstein, 2003; Sloviter, 2005). In 
particular, KARs densely populate the mossy fiber – CA3 pathway, a region of 
the hippocampus prone to excitotoxicity and seizure development (Nadler et al., 
1978). KARs in this pathway are believed to be composed of GluK2/3, GluK4 and 
GluK5 receptor combinations (Darstein et al., 2003). KARs are also responsible 
for mediating a portion of the excitatory circuit that appears in the epileptic brain 
following the aberrant sprouting of mossy fibers into the inner molecular layer of 
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the dentate gyrus (DG) (Epsztein et al., 2005).  
In addition to the role of KARs in regulating neurotransmission, direct 
activation of the receptor via kainate has long been used as a model of SE and 
leads to the development of epilepsy (Nadler, 1981; Ben-Ari, 1985).  In 
agreement, knockout of the GluK2 subunit increases seizure threshold, 
demonstrating that low doses of kainate initiate seizures through GluK2-
containing KARs (Mulle et al., 1998; Fritsch et al., 2014). KARs have also been 
implicated in several comorbidities and possible disorders associated with 
epilepsy. Alterations in KAR subunit expression and localization have been 
observed in disorders with increased prevalence in epilepsy, including anxiety 
and depression (Catches et al., 2012; Lerma and Marques, 2013). Together, 
these studies create a framework in which the KAR could serve as a potential 
therapeutic target for the treatment of epilepsy and related comorbidities. 
Despite this potential relationship few studies have examined possible 
alterations in KAR subunit expression post-SE. Studies from patients with 
epilepsy have consistently demonstrated that KAR subunit expression is altered 
in the epileptic brain (Grigorenko et al., 1997; Mathern et al., 1998; Li et al., 2010; 
Das et al., 2012). However the observed changes in individual subunit 
expression remain inconsistent, likely due to differences in seizure etiology and 
treatment methods, as well as differences in the duration of the disorder.  In 
agreement with human studies, animal models of SE have also demonstrated 
that KAR subunit expression and localization is altered (Kamphuis et al., 1995; 
Porter et al., 1996; Lason et al., 1997; Tandon et al., 2002; Zhang et al., 2004; 
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Ullal et al., 2005; Porter et al., 2006). However, the literature on animal studies is 
also severely inconsistent, likely due to different animal models utilized as well as 
the lack of exploring region-specific changes.  
The goal of the current study was to explore how the expression of 
GluK2/3, GluK4 and GluK5 KAR subunits are altered at three distinct time-points 
following the induction of SE. Expression of the GluK1 subunit was not explored 
as its expression is essentially absent from postsynaptic neurons and is 
predominately expressed in hippocampal interneurons (Wisden and Seeburg, 
1993).  In addition, this study explored region specific alterations by examining 
tissue from microdissected DG, CA3 and CA1 hippocampal subfields. 
Together, the data collected from this study provide the first long-term, 
region-specific exploration of alterations in KAR subunit expression following the 
induction of SE and the development of epilepsy. 
 
4.2 HYPOTHESIS 
 Collectively, the scientific literature demonstrates that in both human and 
animal studies, KAR subunit expression and localization is altered following SE.  
Based on the limited human and animal studies, we hypothesize that distinct 
changes in KAR subunit expression will be observed within each of the three 
different hippocampal subfields explored. In addition, we postulate that these 





4.3 MATERIALS AND METHODS 
4.3.1 ANIMAL MODEL OF SE 
All animal care and use procedures were carried out in accordance with 
protocols written under the guidance of the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals and approved by the Institutional Animal 
Care and Use Committee at the University of South Carolina. Following induction 
of SE, rats were housed 1 per cage with ad libitum access to food and water. 
Rats were housed in a climate controlled facility with a light/dark cycle of 12/12 
hours. 
           SE was induced in adult male Sprague-Dawley rats (Harlan, Indianapolis, 
IN). Animals received intraperitoneal (i.p.) injections of scopolamine methyl 
bromide and terbutaline hemisulfate (2 mg/kg) followed 30 – 45 min later by 
pilocarpine hydrochloride (390 mg/kg). After 2 hours of continuous SE, seizures 
were terminated by diazepam (DZP, 25 mg/kg). This group of animals served as 
the ‘pilo’ group. A separate group of animals received identical treatment with the 
exception of receiving saline (390 mg/kg) instead of pilocarpine hydrochloride. 
This group of animals served as the ‘sham’ group. More detailed methods 
concerning induction of SE are described in Chapter 2.3. 
 
4.3.2 WESTERN BLOT ANALYSIS 
Animals 5, 60, and 200 days post-SE were anesthetized, the brain 
removed, and immediately placed on dry ice. Brains were sectioned at 100 µM 
on a freezing microtome (Microm, Waldorf, Germany). Tissue from hippocampal 
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regions- DG, CA3 and CA1, in addition to prefrontal cortex, amygdala and 
striatum were collected. Microdissected regions collected from the hippocampus 
are outlined in Figure 2.3.  Individual regions were homogenized with the 
resulting pellet resuspended in PBS and stored at -80°C prior to use.  
Aliquots of 2 – 10 µg of crude plasma membrane protein were loaded onto 
a 4 – 15% pre-cast polyacrylamide gel. Sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) was used to separate the proteins prior to being 
transferred to polyvinylidene fluoride (PVDF) membranes. Membranes were 
blocked with TBS + 5% non-fat dry milk for 60 min at room temperature followed 
by primary antibody incubation overnight at 4°C. Primary antibodies are listed in 
Table 2.2. Enhanced chemiluminescence reagents (ECL, Pierce) were used for 
antibody detection. Images were captured on Kodak BioMax XAR film and 
densitometric analysis performed using ImageJ 1.47v (National Institutes of 
Health, USA). More detailed methods concerning western blot analysis are 
described in Chapter 2.8. 
 
4.3.3 IMMUNOHISTOCHEMISTRY 
 Animals 60 and 200 days post-SE were anesthetized and perfused for 4 – 
5 minutes with ice cold, oxygenated (95% O2 / 5% CO2) PBS followed by ice cold 
4% paraformaldehyde for approximately 20 minutes. Whole brains were removed 
and post-fixed at 4°C in 4% paraformaldehyde or 3 hours and then transferred to 
0.1M PB until sectioned at 50 µM thick coronal sections on a vibratome (Leica, 
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VT1000S, Nussloch, Germany). Slices were stored at 4°C in 0.1M PB and 0.1% 
sodium azide until used for immunohistochemical processing.  
Free floating sections were washed for approximately 40 minutes in TBS.  
Tissue was then exposed to an antigen retrieval step in which sections were 
placed for 5 min in Na-Citrate buffer heated to 85°C and then cooled to room 
temperature for 5 – 10 min. Primary antibodies utilized for immunohistochemical 
analysis are listed in Table 2.3. Tissue was processed using a standard 
immunohistochemical protocol described in detail in Chapter 2.9, and then cover-
slipped using cover glass and DPX mounting solution (Sigma, St. Louis, MO). 
Slides were left to dry completely prior to analysis with MCID Elite 7.0 (Imaging 




4.4.1 ALTERATIONS IN KAR SUBUNIT EXPRESSION IN THE DENTATE GYRUS 
 As the first stop in the trisynaptic pathway, the DG serves to gate 
information entering the hippocampus from the entorhinal cortex (EC; Figure 1.2) 
(Henze et al., 2002; Acsady and Kali, 2007). This feature is critical in that it 
allows dentate granule cells (DGCs) to resist the propagation of seizures that 
may originate from the EC (Collins et al., 1983; Stringer and Lothman, 1989; 
Lothman et al., 1992).  However in human temporal lobe epilepsy, as well as the 
pilocarpine model of SE, dramatic alterations in the anatomy and circuitry of the 
DG have been observed. One such change involves the aberrant sprouting of 
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mossy fibers into the inner molecular layer of the DG (Figure 1.6) (Tauck and 
Nadler, 1985; Represa et al., 1987; Sutula and Dudek, 2007). This pathological 
sprouting creates a recurrent excitatory network between granule cells and likely 
serves to facilitate the synchronous firing of DGCs and promote seizure 
propagation (Tauck and Nadler, 1985; Gabriel et al., 2004; Timofeeva and 
Nadler, 2006). In addition, KARs have been shown to mediate a portion of this 
new excitatory network (Epsztein et al., 2005). We explored the impact of 
pilocarpine-induced SE on the KAR subunit expression within the DG, in hopes 
of shedding light on the subunit composition mediating this newly formed 
excitatory circuit in the epileptic brain.  
 We determined that expression of the GluK2/3 subunit is significantly 
reduced in the DG at 5 days post-SE (70.0 ± 5.2% of control, n = 7 – 8; p < 0.01) 
and remains significantly reduced at 60 and 200d post-SE (60d: 56.8 ± 7.1% of 
control, n = 8; p < 0.01; 200d: 71.1 ± 4.8% of control, n = 6 – 10; p < 0.001; 
Figure 4.1A).  Our observation that the GluK2/3 subunit is reduced shortly after 
SE is supported by a previous study in which GluK2/3 subunit expression was 
also decreased in the DG at 20 days following induction of SE (Porter et al., 
2006).  We failed to observe any alterations in GluK4 subunit expression at 5d 
(91.7 ± 9.1% of control, n = 7 – 8; p > 0.05) and 60d post-SE (93.8 ± 14.2% of 
control, n = 8; p > 0.05). However, by 200d post-SE a significant reduction in 
GluK4 expression was observed in the DG (63.1 ± 4.8% of control, n = 6 – 9; p < 
0.01); Figure 4.1B).The lack of change in GluK4 expression at 5 and 60d time-




 Figure 4.1. Alterations in KAR subunit expression in the dentate 
gyrus in animals post-SE. Western blot analysis of microdissected DG from 
animals 5d, 60d and 200d post pilocarpine-induced SE.  A. Expression of the 
GluK2/3 subunit was significantly reduced at all three time-points examined. B. 
GluK4 subunit expression was unchanged at 5d and 60d post-SE and 
significantly decreased by 200d post-SE. C. GluK5 subunit expression was 
initially decreased at 5d post-SE, recovered to baseline by 60d and was 
decreased at 200d post-SE. S, sham-treated; P, pilo-treated. n = 6 – 10; **p < 
0.01; ***p < 0.001, t-test.  
 
117 
was unaltered days to weeks following induction of SE (Kamphuis et al., 1995; 
Porter et al., 1996).   
We observed that the GluK5 subunit is significantly decreased at 5d post-
SE (69.2 ± 4.2% of control, n = 7; p < 0.01), and recovers to baseline by 60d 
(88.9 ± 5.5% of control, n = 7; p > 0.05). However, by 200d post-SE we observed  
another significant decrease in expression (74.7 ± 4.5% of control, n = 6 – 10; p 
< 0.01; Figure 4.1C). The observed decrease in GluK5 subunit expression within 
the DG following induction of SE disagrees with Porter et al. (2006), in which 
GluK5 expression was increased in DGCs at 20 days post-SE. This disparity may 
be attributed to differences in tissue preparation as Porter et al. (2006) utilized 
isolated DGCs and the current study employed microdissected DG which also 
contained portions of the supragranular layer and hilar interneurons.   
 To substantiate the above findings immunohistochemical analysis was 
performed on tissue collected from animals 60d post-SE (Figure 4.2). In 
agreement with previous studies, we observed that GluK2/3, GluK4 and GluK5 
subunit proteins were widely expressed throughout the DG, including robust 
labeling throughout the polymorphic layer and hilar interneurons (Wisden and 
Seeburg, 1993; Darstein et al., 2003). Of particular interest was the observation 
that GluK2/3 labeling within the molecular layer was not uniform, as was 
observed for GluK4 and GluK5 subunits. In contrast, GluK2/3 expression 
appeared higher in the outer molecular layer, creating a distinct separation 
between the inner and outer molecular layers of the DG.  In animals 60d post-




Figure 4.2. KAR subunit immunoreactivity in the hippocampus and 
DG in animals 60d post-SE. GluK2/3, GluK4 and GluK5 subunits exhibit distinct 
hippocampal labeling patterns. A. GluK2/3 expression was significantly reduced 
between Ai. sham-treated and Aii. pilocarpine-treated animals 60d post-SE. B. 
GluK4 immunoreactivity between Bi. sham-treated and Bii. pilocarpine-treated 
animals was unaltered within the DG. C. There was no change in GluK5 
immunoreactivity in the DG among Ci. sham-treated and Cii. pilocarpine-treated 
animals. ML, molecular layer; IML, inner molecular layer, DGCL, dentate granule 
cell layer. Scale bars: A – C, 200 µM; Ai – Cii, 100 µM. 
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three subunits, particularly GluK4 labeling which appears nearly absent. In 
support of western blot analysis demonstrating a decrease in GluK2/3 and GluK5 
expression in the DG, we observed that GluK2/3 and GluK5 labeling was 
dramatically reduced throughout the dentate granule cell layer. In addition, we 
noted that GluK2/3 labeling throughout the molecular layer appeared more 
uniform post-SE. This observation is suggestive of the idea that dendritic 
localization of the GluK2/3 subunit is altered post-SE, and may play a role in 
mossy fiber sprouting and KAR-mediated neurotransmission. 
 
4.4.2 ALTERATIONS IN KAR SUBUNIT EXPRESSION IN AREA CA3  
Hippocampal region CA3 is composed primarily of CA3 pyramidal cells 
and stratum lucidum (Figure 1.4). The well characterized mossy fiber – CA3 
pathway, the second synapse within the trisynaptic pathway, serves as the 
primary means of communication between the DG and area CA3 (Figure 1.2). 
This synapse has been referred to as the ‘detonator synapse’ in that input from a 
single mossy fiber is sufficient to fire a CA3 pyramidal cell (Urban et al., 2001).  
The strength of this mossy fiber input contributes to the highly susceptible nature 
of CA3 to epileptogenic activity and the associated excitotoxicity (Nadler et al., 
1978; Lothman et al., 1991; Ben-Ari and Cossart, 2000). The mossy fiber – CA3 
pathway was also the first synapse demonstrated to utilize KARs as a means of 
regulating excitatory neurotransmission (Castillo et al., 1997; Vignes and 
Collingridge, 1997). Immunohistochemical and electrophysiological analysis 
further revealed that KARs, likely composed of GluK2, GluK4 and GluK5 
 
120 
subunits, densely populate area CA3 contributing to transmission on mossy fiber 
axons, presynaptic mossy fiber terminals and postsynaptic CA3 pyramidal cells  
(for review see, Lerma and Marques, 2013).  Given the various avenues in which 
area CA3 may be implicated in seizures and the extensive role of KARs within 
this region, we explored how pilocarpine-induced SE and the development of 
epilepsy altered KAR subunit expression in area CA3.  
Similar to findings in the DG, we determined that at 5 days post-SE in area 
CA3 there is a significant decrease in GluK2/3 subunit immunoreactivity (57.0 ± 
5.6% of control, n = 7 – 8; p < 0.001). This decrease persists at both the 60 day 
(56.7 ± 6.3% of control, n = 7 – 8; p < 0.001) and 200 day time points (67.6 ± 
7.0% of control, n = 6 – 8; p < 0.01; Figure 4.3A). In contrast to the dramatic 
decrease in GluK2/3 expression, the GluK4 subunit remains unaltered at 5 days 
post-SE (91.3 ± 10.4% of control, n = 7 – 8; p > 0.05), but is significantly reduced 
by 60d (59.4 ± 3.4% of control, n = 7 – 8; p < 0.001) and remains reduced at 
200d post-SE (54.0 ± 7.1% of control, n = 6 – 10; p < 0.001; Figure 4.3B). In 
agreement, a decrease in GluK4 subunit expression in area CA3 was observed 
in a separate seizure model (Porter et al., 1996). Alterations in GluK5 subunit 
expression appear almost opposite to those of the GluK4 subunit in that 
expression is significantly decreased at 5d post-SE (63.1 ± 5.1% of control, n = 7 
– 8; p < 0.001), but returns to baseline by the 60 and 200d time-points (60d: 85.5 
± 8.1% of control, n = 8; p > 0.05; 200d: 82.9 ± 7.0% of control, n = 6 – 10; p > 
0.05; Figure 4.3C). The overall decrease in KAR subunit expression, particularly 




Figure 4.3. Alterations in KAR subunit expression in area CA3 in 
animals post-SE. Western blot analysis of microdissected CA3 from animals 5d, 
60d and 200d post pilocarpine-induced SE.  A. Expression of the GluK2/3 
subunit was significantly reduced at all three time-points examined. B. GluK4 
subunit expression was unchanged at 5d post-SE and was significantly reduced 
by 60d and 200d post-SE. C. GluK5 subunit expression was initially decreased at 
5d post-SE and recovered to baseline by 60d and 200d post-SE. S, sham-
treated; P, pilo-treated. n = 6 – 10; **p < 0.01; ***p < 0.001, t-test. 
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with a previous finding in which a significant decrease in 3H-kainate binding was 
observed in area CA3 following repeated injection of kainate (Tandon et al., 
2002).  
 The observed decrease in GluK2/3 and GluK4 subunit expression in area 
CA3 is supported by immunohistochemical analysis of animals 60d post-SE,  
 (Figure 4.4).  In agreement with previous studies we observed intense labeling 
of GluK2/3, GluK4 and GluK5 subunits within CA3 pyramidal cells and stratum 
lucidum (Wisden and Seeburg, 1993; Darstein et al., 2003). Labeling of GluK2/3 
and GluK5 was also observed in interneurons located in stratum radiatum and to 
a lesser degree stratum oriens, with no apparent interneuron labeling by GluK4. 
In support of western blot analysis at 60d post-SE, we observed a dramatic 
decrease in GluK2/3 and GluK4 labeling within individual CA3 pyramidal cells, as 
well as a reduction in labeling throughout stratum lucidum. Expression of the 
GluK5 subunit did not appear to change following SE, a finding also in support of 
western blot analysis.  
 
4.4.3 ALTERATIONS IN KAR SUBUNIT EXPRESSION IN AREA CA1 
Neurotransmission between area CA3 and CA1 via the Schaffer 
collaterals serves as the final synapse within the trisynaptic pathway (Figure 1.2). 
Epileptogenic activity that initiates in area CA3, or propagates to this area from 
the DG, likely spreads to hippocampal area CA1. While KAR subunits are 
localized in area CA1, particularly mRNA for the GluK2 and GluK5 subunits, and 




Figure 4.4. KAR subunit immunoreactivity in area CA3 in animals 60d post-
SE. Distinct KAR subunit labeling in area CA3. A. GluK2/3 subunit expression 
was reduced in SP and SL between Ai. sham-treated and Aii. pilocarpine-treated 
animals 60d post-SE. B. GluK4 immunoreactivity among Bi. sham-treated and 
Bii. pilocarpine-treated animals was noticeably reduced within SP and SL. C. No 
alteration in GluK5 immunoreactivity within area CA3 was observed between Ci. 
sham-treated and Cii. pilocarpine-treated animals. SR, stratum radiatum; SL, 




neighboring CA3 and DG  (Bahn et al., 1994; Bureau et al., 1999; Paternain et 
al., 2000; Darstein et al., 2003; Isaac et al., 2004). KARs have been shown to 
regulate excitatory current in CA1 interneurons (Cossart et al., 1998; Frerking et 
al., 1998) and as demonstrated by knockout studies, GluK2-containing KARs are 
capable of producing inward current in CA1 pyramidal cells (Bureau et al., 1999).  
Despite the availability of seemingly functional KARs in CA1, they have not been 
shown to contribute to synaptic transmission. However, applied kainate and 
synaptically released glutamate have been shown to act on second-messenger 
metabotropic KARs to inhibit the slow afterhyperpolarization (AHP) (Melyan et 
al., 2002; Melyan et al., 2004). Reduction of the slow AHP increases the ability of 
neurons to fire more rapidly and thus can contribute to the propagation of 
seizures through area CA1 (Robinson and Deadwyler, 1981; Ashwood et al., 
1986). While distinct from their role in CA3 and DG, KARs localized in CA1 may 
contribute to the spread of seizures. We investigated alterations in KAR subunit 
expression in area CA1 following pilocarpine-induced SE. 
In agreement with the immediate and persistent decrease observed in 
area CA3 and the DG, we determined that GluK2/3 subunit expression is 
significantly reduced in area CA1 at all three time points explored (5d: 59.8 ± 
9.2% of control, n = 8; p < 0.01; 60d: 59.2 ± 4.0% of control, n = 7 – 8; p < 0.01; 
200d: 63.4 ± 8.5% of control, n = 7 – 8; p < 0.01; Figure 4.5A). Alterations in 
GluK5 subunit expression are similar to those observed in area CA3 in that 








Figure 4.5. Alterations in KAR subunit expression in area CA1 in 
animals post-SE. Western blot analysis of microdissected CA1 from animals 5d, 
60d and 200d post pilocarpine-induced SE. A. Expression of the GluK2/3 subunit 
was significantly reduced at all three time-points examined. B. GluK5 subunit 
expression was initially decreased at 5d post-SE and recovered to baseline by 
60d and 200d post-SE. S, sham-treated; P, pilo-treated. n = 6 – 8; **p < 0.01; 





– 8; p < 0.001) and then recovers to baseline by 60d (97.3 ± 4.5% of control, n = 
6 – 8; p > 0.05) and 200d post-SE (87.2 ± 14.2% of control, n = 7 – 8; p > 0.05; 
Figure 4.5B). Western blot analysis utilizing a GluK4 antibody failed to produce a 
detectable signal on tissue collected from area CA1. 
 Immunohistochemical analysis of tissue collected 60d post-SE 
demonstrated robust labeling of GluK2/3 and GluK5 subunits Figure 4.6. We 
observed immunoreactivity of the GluK2/3 subunit throughout area CA1, 
including labeling in the somata and dendrites of pyramidal cells, as well as 
robust labeling of interneurons throughout stratum radiatum and stratum oriens 
(Figure 4.6A).  In agreement with mRNA expression, we observed the strongest 
immunoreactivity with GluK5 labeling throughout area CA1 (Wisden and 
Seeburg, 1993). In addition we observed GluK5 immunoreactivity throughout the 
dendrites of CA1 pyramidal cells, extending into stratum radium. GluK5 
expression was also noted in interneurons throughout stratum radiatum and 
stratum oriens (Figure 4.6C). Our observed expression of GluK2/3 and GluK5 
immunoreactivity throughout area CA1, including interneuron labeling, is in 
agreement with previous studies (Wisden and Seeburg, 1993; Paternain et al., 
2000; Christensen et al., 2004). In animals 60d post-SE we observed a decrease 
in GluK2/3 immunoreactivity in both CA1 pyramidal cells as well as the remaining 
interneurons, and no apparent difference in GluK5 immunoreactivity, findings in 
support of western blot analysis of CA1 tissue.  
It is worthwhile noting that while our GluK4 antibody failed to detect 




Figure 4.6. KAR subunit immunoreactivity in area CA1 in animals 60d 
post-SE. Distinct KAR subunit labeling in area CA1. A. GluK2/3 subunit 
expression was dramatically reduced in SP in Ai. sham-treated and Aii. 
pilocarpine-treated animals. B. GluK4 immunoreactivity among Bi. sham-treated 
and Bii. pilocarpine-treated animals was weak and did not appear to change 
post-SE. C. GluK5 immunoreactivity remained unaltered in Ci. sham-treated and 
Cii. pilocarpine-treated animals. SO, stratum oriens; SP, stratum pyramidale; SR, 




labeling of CA1 pyramidal cells in immunohistochemical analysis (Figure 4.6B).  
In support of our observation, previous studies have also reported the presence 
of GluK4 immunoreactivity in area CA1 (Fogarty et al., 2000; Darstein et al., 
2003; Vargas et al., 2013), but also see Wisden and Seeburg (1993). Based on 
immunohistochemical observations we did not observe any noticeable alterations 
in GluK4 immunoreactivity in area CA1 from animals 60d post-SE. Our ability to 
detect GluK4 in immunohistochemical analysis, but not through western blots, 
may be due to differences in tissue preparation and handling or antibody 
selectivity. 
 
4.4.4 REDUCTION IN GLUK2/3 SUBUNIT EXPRESSION IS RESTRICTED TO LIMBIC 
REGIONS 
We observed a significant decrease in GluK2/3 subunit expression in each 
of the three hippocampal regions explored- DG, CA3 and CA1. This decrease 
was apparent as early as 5 days post-SE and appeared to be permanent, as 
data collected from 60d and 200d post-SE also displayed a reduction in GluK2/3 
expression. We collected tissue from different brain regions from animals 60 
days post-SE to determine if the decrease in GluK2/3 subunit expression was 
part of a global reduction. We found that similar to hippocampal tissue, there was 
a significant reduction in GluK2/3 expression within the amygdala (68.2 ± 4.1% of 
control, n = 6; p < 0.01) and prefrontal cortex (PFC; 48.4 ± 7.4% of control, n = 5 
– 7; p < 0.05; Figure 4.7). In contrast, GluK2/3 subunit expression remained 






Figure 4.7. Reduction in GluK2/3 subunit expression is restricted to 
limbic regions. Western blot analysis of microdissected or punched tissue from 
sham or pilocarpine-treated animals 60d post-SE. GluK2/3 subunit expression is 
significantly reduced within limbic regions including the hippocampus (DG, CA3 
and CA1 regions), amygdala and prefrontal cortex. However GluK2/3 expression 
was not altered in other brain regions (striatum and cerebellum), demonstrating 
the impact of SE on GluK2/3 subunit expression throughout the limbic system. 
S,sham-treated; P, pilo-treated Amyg, amygdala; PFC, prefrontal cortex; Cb, 









0.05) and cerebellum (Cb; 116.3 ± 9.6% of control, n = 8; p > 0.05; Figure 4.7). 
These results demonstrate that GluK2/3 expression does not appear to be 
global, in that the observed reduction was restricted to structures involved in the 
limbic system- hippocampus, cortex and amygdala (Noebles et al., 2012). These 
limbic regions are tightly interconnected to memory formation as well as the 
emotional response of anxiety (Shin and Liberzon, 2010). The dramatic reduction 
in GluK2/3 subunit expression within these regions may be associated to 
comorbid conditions of cognitive impairment and increased levels of anxiety 
reported by patients (Jacoby and Austin, 2007). 
 
4.4.5 GFAP LABELING IS SIGNIFICANTLY INCREASED IN ANIMALS POST-SE 
 Many studies of epileptic tissue have explored alterations in neuronal cell 
loss and mossy fiber sprouting, while the role of reactive gliosis is fairly limited. 
Given that astrocytes are ubiquitously expressed throughout the CNS and play 
critical roles in regulating synaptic transmission, alterations in their expression in 
the epileptic brain may have dramatic consequences. Studies from both human 
and animal models of epilepsy have established that astrogliosis is significantly 
increased, even as early as one week post-SE (Babb et al., 1996; Schmidt-
Kastner and Ingvar, 1996; Binder and Steinhauser, 2006; Vargas et al., 2013). 
We determined that GFAP labeling of astrocytes was significantly increased in 
areas CA1, CA3 and DG at all three time-points examined (Figure 4.8). Within 
area CA1 we found a significant increase in GFAP labeling at 5d (206.4 ± 24.1% 




Figure 4.8. GFAP expression is increased in all hippocampal regions 
post-SE. Western blot analysis of microdissected A. CA1 B. CA3 and C. dentate 
gyrus from animals 5d, 60d and 200d post-SE demonstrate significant increase 
in GFAP labeling at all three time-points examined. S, sham-treated; P, pilo-





200d post-SE (181.0 ± 23.4% of control, n = 7; p < 0.05; Figure 4.8A). Similarly, 
a significant increase was observed in area CA3 at all three points explored (5d: 
161.3 ± 10.7% of control, n = 8; p < 0.01; 60d: 134.4 ± 11.8% of control, n = 8; p 
< 0.05; 200d: 187.2 ± 20.2% of control, n = 6 – 9; p < 0.05; Figure 4.8B). In 
agreement with the observed increases in CA1 and CA3, we saw significant 
increases in GFAP labeling throughout the DG at all time-points (5d: 189.7 ± 
23.1% of control, n = 6 – 7; p < 0.01; 60d: 133.2 ± 10.0% of control, n = 6 – 7; p < 
0.05; 200d: 170.0 ± 15.6% of control, n = 5 – 10; p < 0.05; Figure 4.8C). 
Immunohistochemical analysis of GFAP expression is depicted in Figure 1.7). 
While the dramatic increase in GFAP labeling throughout the hippocampus as 
early as 5d post-SE was shocking, it is in agreement with previous studies and 
emphasizes the potential impact that astrogliosis can have on neuronal signaling 
in the epileptic brain.  
 
4.5 DISCUSSION 
 The results of this study provide the first long-term examination of region-
specific changes in hippocampal KARs following pilocarpine induction of SE.  
These findings are summarized in Figure 4.9. We determined that as early as 5 
days post-SE there is a universal downregulation of the GluK2/3 subunit 
throughout the hippocampus. This decrease appears permanent as it was 
observed at both 60d and 200d time-points. In contrast to this dramatic reduction 
in GluK2/3 expression, the apparent decrease in GluK4 and GluK5 subunit 





Figure 4.9. Summary of region specific reductions in KAR subunit 




regarding alterations in KAR subunit expression, we also observed significant 
increases in GFAP labeling of astrocytes as early as 5 days post-SE in all three 
hippocampal regions examined. This increase in GFAP was consistently 
observed at 5d, 60d and 200d post-SE.  Our findings from western blot and 
immunohistochemical analysis definitively demonstrate that pilocarpine induced 
SE produces significant alterations in KAR subunit expression throughout the  
hippocampus and possibly throughout surrounding limbic regions.  
 
4.5.1 EPILEPTOGENESIS AND ASSOCIATED CHANGES IN HIPPOCAMPAL 
CIRCUITRY 
 We examined alterations in KAR subunit expression at three distinct time-
points following induction of SE. These points were chosen based on known 
alterations in hippocampal circuitry as well as the development of 
epileptogenesis following SE. Epileptogenesis refers to the interval between the 
occurrence of a brain insult, such as SE, and the development of spontaneously 
occurring seizures. It is widely believed that during this ‘latent period’ a host of 
changes occur that transform the healthy, non-epileptic brain into one 
characterized by recurring seizures (Herman, 2002; Loscher, 2002; Pitkanen, 
2002; Stables et al., 2002; Walker et al., 2002; Andre et al., 2007; Pitkanen et al., 
2007; Dichter, 2009b, a; Jacobs et al., 2009; Pitkanen and Lukasiuk, 2009; 
Pitkanen, 2010). The process of epileptogenesis has been well documented in 
the patient population, with the development of seizures occurring an average of 
7.5 years following the precipitating event (French et al., 1993). Several animal 
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models, including the pilocarpine model of SE utilized in the current study, have 
also been identified as producing periods of epileptogenesis. Following induction 
of SE through administration of pilocarpine animals typically experience a seizure 
free ‘latent period’ ranging from days to several weeks prior to the development 
of spontaneous recurring seizures (Walker et al., 2002; Stables et al., 2003; 
Morimoto et al., 2004; Curia et al., 2008).  
 Following the latent period and the beginning of spontaneous seizures 
both human and animal studies demonstrate the appearance of mossy fiber 
sprouting, which serves as an anatomical hallmark of epilepsy (Sutula et al., 
1989; Houser et al., 1990; Babb et al., 1991). As described in detail in Chapter 
1.7, aberrant mossy fibers synapse within the inner molecular layer of the DG, 
creating a new excitatory circuit partially mediated by KARs (Cronin et al., 1992; 
Wuarin and Dudek, 1996; Sutula et al., 1998; Epsztein et al., 2005). This well 
characterized occurrence can be seen as early as several days post-SE, but 
tends to plateau by 2 – 3 months post-SE (Mello et al., 1993; Okazaki et al., 
1995). In addition to mossy fiber sprouting neuronal cell loss and the proliferation 
of astrocytes is also evident within the first few weeks to months following SE 
(Corsellis and Bruton, 1983; Mathern et al., 1997; Garzillo and Mello, 2002; 
Binder and Steinhauser, 2006).  
 In regards to these dramatic alterations in hippocampal circuitry and 
anatomy following SE definitive time-points were examined in the current study. 
The 5d post-SE time-point corresponds to a time when animals have recovered 
from the precipitating SE insult, but are extremely unlikely to be experiencing 
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spontaneously occurring seizures. In contrast, by 60d post-SE animals have 
developed spontaneous seizures, and are likely reaching the height of mossy 
fiber sprouting, neuronal cell loss as well as astrocyte proliferation. In addition to 
these two distinct time-points we also explored alterations in KAR subunits in 
animals 200d post-SE. This point provides an extremely chronic view of epilepsy 
and is likely more similar to the human condition than earlier time-points.  
 
4.5.2 REDUCED KAR SUBUNIT EXPRESSION IN DG DESPITE MOSSY FIBER 
SPROUTING 
Mossy fiber sprouting into the inner molecular layer of the DG has become 
an anatomical hallmark of epilepsy in both humans and animal models (Tauck 
and Nadler, 1985; Represa et al., 1987; Sutula and Dudek, 2007). Previous 
studies, as well as those detailed in Chapter 5, have demonstrated that KARs 
mediate a portion of this newly formed excitatory circuit (Epsztein et al., 2005). 
Conflicting with these studies is the current observation that KAR subunit 
expression is significantly decreased within the DG in animals both 60d and 200d 
post-SE. Several factors could contribute to this apparent discrepancy. 
 In the present study western blot analysis was performed in 
microdissected hippocampal tissue. The section of tissue collected for each 
region is identified in Figure 2.3. In contrast to areas CA1 and CA3, which 
predominately contain pyramidal cell layers, the region collected for DG analysis 
also contains a large portion of the supragranular layer as well as area CA4. 
Therefore the observed alterations in DG samples may not be reflective of pure 
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dentate granule cells. Another possibility is that the observed reduction in KAR 
subunits is reflective of extrasynaptic KARs, whereas synaptic KARs, which 
contribute to the newly formed mossy fiber synapse, remain intact.  
 In addition, KAR subunit localization and antibody selectivity could also 
contribute to the incongruity between anatomical and electrophysiological 
observations. While the GluK2 subunit is expressed throughout the 
hippocampus, GluK3 expression is essentially restricted to the DG (Bureau et al., 
1999; Darstein et al., 2003). The present study utilized an antibody that targeted 
both GluK2 and GluK3 KAR subunits. Therefore, while conclusions reached 
about GluK2/3 immunoreactivity and expression in area CA1 and CA3 are 
reflective of the GluK2 subunit, the presence of GluK3 within the DG complicates 
our results. It is possible that our findings actually represent a reduction in GluK2 
or GluK3 subunit expression, while the other subunit may actually increase or 
remain unaltered. More selective antibodies or analysis of mRNA expression 
could be used to determine which low affinity KAR subunit is actually impaired in 
animals post-SE.  
 
4.5.3 TEMPORAL ALTERATIONS IN KAR SUBUNIT EXPRESSION WITHIN THE DG 
 Through western blot analysis we observed distinct alterations in KAR 
subunit expression following the induction of SE. These time-sensitive changes 
were most apparent within the DG. In this region at 60d post-SE we observed 
significant reduction in the expression of the GluK2/3 subunit only. However, by 
200d post-SE all three subunits, GluK2/3, GluK4 and GluK5 were significantly 
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reduced. By 60d post-SE animals were extremely likely to experience 
spontaneous seizures, so the decrease at 200d post-SE was likely not due to 
seizure activity. However, it has been suggested that seizure frequency and 
severity increases in chronically epileptic animals (Loscher and Brandt, 2010), 
which may further impact KAR subunit expression in this region. 
 Another possible, and more likely, explanation for the delay in KAR 
subunit expression may involve the process of neurogenesis, the generation of 
new neurons. This process has been well established within the DG as the 
appearance of newly formed DGCs persists into adulthood (Eriksson et al., 1998; 
Gould et al., 1999; Cameron and McKay, 2001; Kempermann, 2002). It has been 
demonstrated that SE significantly increases the number of DGCs by increasing 
the process of neurogenesis 5 – 10x following the latent period of SE (Parent et 
al., 1997; Gray and Sundstrom, 1998). However by 3 – 4 weeks post-SE the rate 
of DGC proliferation returns to baseline (Parent et al., 1997), and by 5 months 
post-SE there is a significant reduction in adult dentate granule cell proliferation 
believed to be associated with chronic epilepsy (Hattiangady et al., 2004).  
Based on these studies we suggest that at 60d post-SE animals likely 
experience fairly robust neurogenesis. Porter et al. (2006) determined that GluK2 
subunit expression was significantly reduced in newly born DGCs following SE. 
In agreement with this study we also observed a reduction in GluK2/3 expression 
at 60d post-SE. However, by 200d post-SE the process of neurogenesis in our 
animals was likely significantly impaired. Thus the reduction in KAR subunit 
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expression could be affected. In addition, the observed reduction could also be 
due to fewer DGCs than what is seen at 5 or 60d post-SE.  
 
4.5.4 ASTROCYTE PROLIFERATION IN ANIMALS POST-SE 
 Astrocytes are star-shaped glial cells that essentially cover the entire 
CNS. While not widely discussed, astrocytes are believed to play a prominent 
role in synaptic transmission through their release and regulation of active 
molecules including glutamate and GABA (Nedergaard et al., 2003; Halassa et 
al., 2007; Shigetomi et al., 2008; Perea et al., 2009). The extent of their role has 
given rise to the term ‘tripartite synapse’ which proposes that astrocytes play an 
essential role in regulating synaptic neurotransmission (Araque et al., 1999; 
Halassa et al., 2007; Perea et al., 2009). Both human and animal models of 
epilepsy have demonstrated robust increases in astrogliosis (Babb et al., 1996; 
Binder and Steinhauser, 2006), even as early as one week post-SE (Schmidt-
Kastner and Ingvar, 1996; Vargas et al., 2013). In agreement with these previous 
studies we observed significant increases in GFAP labeling of astrocytes in all 
three hippocampal brain regions at all time-points explored.  
It should be noted that a recent publication also demonstrated an increase 
in GFAP labeling post kainate-induced SE but also reported colocalization of 
KAR subunits GluK1, GluK2/3, GluK4 and GluK5 in GFAP-positive astrocytes in 
area CA1 (Vargas et al., 2013). In direct contrast, we did not observe any 
immunoreactivity in cells resembling astrocytes in any brain region at any of the 
three time-points explored.  Several factors could contribute to these apparent 
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differences. Vargas et al. (2013) utilized the kainate model of SE as well as 
enriched astroglial tissue fractions for western blot analysis. The current study 
employed the pilocarpine model of SE, thus avoiding direct activation of KARs. In 
addition we performed western blot analysis on crude plasma membrane 
fractions not enriched with astroglia and were still able to detect dramatic 
increases in GFAP labeling in tissue collected from animals post-SE. While our 
findings regarding the increase in GFAP labeling are in agreement with previous 
findings, we do not have any evidence supporting the notion that KAR 
subunitsare colocalized with astrocytes (Vargas et al., 2013). 
 
4.5.5 KAR SUBUNIT EXPRESSION AND COMORBIDITIES 
 While epilepsy is first and foremost considered a seizure disorder, it is 
also accompanied by a variety of comorbidities including alterations in psychiatric 
and cognitive functioning. The diagnosis of psychiatric comorbidities is 
significantly increased in patients with epilepsy, with nearly 50% of patients 
reporting depressive-like symptoms (Jackson and Turkington, 2005). In addition, 
patients commonly report impairments in memory, attention and describe a 
feeling of general mental slowness (van Rijckevorsel, 2006). Studies examining 
the role of hippocampal KARs have begun to elucidate a possible correlation 
between KARs and comorbidities associated with epilepsy.  
Of note is the recent identification that the GluK4 subunit is likely involved 
in regulating anxiety and depressive-like phenotypes (Catches et al., 2012), 
however findings from this study do not rule out the likely role of the GluK5 
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subunit. The GluK4 subunit has also been linked to response to antidepressant 
treatment in patients (Paddock et al., 2007). In addition to the possible correlation 
between altered KAR subunit expression and disorders associated with epilepsy, 
KARs have also been linked to other severe disorders such as bipolar disorder 
and schizophrenia (for review see Lerma and Marques, 2013). Given the role of 
KARs in a variety of diseases, the findings of this study suggest that the dramatic 
reduction in KAR subunit expression we identified may be implicated in epilepsy 
comorbidities. Thus, KARs may serve as potential targets for treatment of these 
disorders.  
 
4.5.6 ALTERED KAR SUBUNIT EXPRESSION AND CA3 NEUROTRANSMISSION 
POST-SE 
In the current study we observed significant reductions in both GluK2/3 
and GluK4 subunit expression in area CA3 from epileptic animals (60d and 200d 
post-SE).  Previous studies have demonstrated that the GluK5 subunit contains 
several endoplasmic reticulum (ER) retention motifs that block surface 
expression unless bound to a GluK1 – 3 subunit, thus promoting the formation of 
heteromeric KARs (Gallyas et al., 2003; Ren et al., 2003).  However, recent 
findings have demonstrated that agonist binding to the GluK5 subunit was 
sufficient to promote heteromeric receptor trafficking (Fisher and Housley, 2013). 
In light of these studies we suggest that in epileptic animals there may be fewer 
functional KARs, and that the KARs that do remain likely contain GluK2/5 
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subunits, a shift from predominately GluK2/4-containing receptors in control 
animals. The potential shift from Glu2/4 to GluK2/5-containing KARs would 
dramatically impact receptor pharmacology as well as the kinetics of the KAR- 
 mediated current. 
 
4.6 SIGNIFICANCE 
 The results of this study demonstrate that pilocarpine-induced SE 
produces dramatic alterations in KAR subunit expression in both a region- and 
time-specific manner. Hippocampal KARs have been implicated in seizure 
disorders as well as comorbidities such as anxiety and depression (Catches et 
al., 2012; Lerma and Marques, 2013). The observed alterations in KAR subunit 
expression following SE may shed light on the role of individual KAR subunits in 
the generation and propagation of seizures as well as observed comorbidities.  
We suggest that these alterations likely influence KAR-mediated 
neurotransmission in both the DG and area CA3 following pilocarpine-induced 
SE, a topic explored in detail in Chapter 5. Together these results provide further 
evidence that healthy and diseased brains are strikingly different and that 
understanding these differences may be the key to the development of 








ALTERATIONS IN KAINATE RECEPTOR MEDIATED NEUROTRANSMISSION AT 




Kainate receptors (KARs) are ionotropic glutamate receptors that mediate 
fast excitatory neurotransmission. Functional KARs are tetramers that can be 
composed of a homomeric combination of the low glutamate affinity GluK1 – 3 
subunits. The GluK4 and GluK5 subunits have higher glutamate sensitivity and 
only form functional receptor complexes when paired with GluK1 – 3 subunits. 
KARs are widely distributed throughout the CNS with the strongest expression 
noted within the dentate gyrus (DG) and area CA3 of the hippocampus (Wisden 
and Seeburg, 1993; Bahn et al., 1994; Darstein et al., 2003). 
The role of hippocampal KARs has been most strongly characterized at 
the mossy fiber – CA3 synapse. In this region postsynaptic KARs mediate a 
small excitatory current with slow decay kinetics, which allows for temporal 
summation and serves to enhance the depolarization envelope (Castillo et al., 
1997; Vignes and Collingridge, 1997; Frerking and Ohliger-Frerking, 2002). 
These characteristics of postsynaptic KARs emphasize their potential 
contribution to a hyperexcitable network. In contrast to their widespread role in 
area CA3, KARs have not been found to contribute to synaptic transmission in       
the naïve DG. The lack of KAR-mediated transmission within the DG is also 
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noted in area CA1, where despite an abundance of KAR subunits there is no 
synaptic contribution (Bureau et al., 1999).  
The DG has been identified as the ‘gatekeeper’ of the hippocampus, 
acting to restrict excitatory transmission entering area CA3, a region prone to 
hyperexcitability and epileptiform activity (Nadler et al., 1978). An anatomical 
hallmark of epilepsy is the appearance of sprouted mossy fibers in the inner 
molecular layer of the DG (Tauck and Nadler, 1985; Represa et al., 1987; Sutula 
and Dudek, 2007). In addition to this axonal rewiring, KARs have been implicated 
in mediating a portion of the newly formed excitatory circuit in the epileptic brain 
(Epsztein et al., 2005). Most notably, KARs located on these aberrant mossy 
fibers have been shown to increase the hyperexcitability and synchronization of 
DGCs by altering their intrinsic firing pattern (Artinian et al., 2011). These actions 
significantly impair the ability of the DG to properly gate excitatory 
neurotransmission in epilepsy.  
 These alterations in the ‘gatekeeper’ function of the DG likely impact 
transmission and epileptiform activity throughout the other regions of the 
hippocampus, most notably, area CA3. In addition, given the dramatic shift in the 
role of KARs within the epileptic DG, it is likely that KARs located in area CA3 are 
also modified. The goal of this study was to explore these possible alterations in 
KAR-mediated neurotransmission at the mossy fiber – CA3 synapse in epileptic 
animals.  Findings from this study have provided the first in-depth look at the 
impact of epilepsy on the function of KARs localized to area CA3 and provide 




 Anatomical data presented in Chapter 4 demonstrated a robust and 
significant decrease in both GluK2/3 and GluK4 subunit expression in area CA3 
in epileptic animals. Based upon these data we hypothesize that KAR-mediated 
neurotransmission in the mossy fiber – CA3 pathway will be reduced in epileptic 
animals. Given the significant increase in excitatory drive within the DG, the 
observed reduction in KAR-mediated transmission in area CA3 of epileptic 
animals may serve as a compensatory modification to limit hyperexcitability and 
the generation of epileptiform activity.  
 
5.3 MATERIALS AND METHODS 
5.3.1 ANIMAL MODEL OF SE 
All animal care and use procedures were carried out in accordance with 
protocols written under the guidance of the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals and approved by the Institutional Animal 
Care and Use Committee at the University of South Carolina. Following induction 
of SE, rats were housed 1 per cage with ad libitum access to food and water. 
Rats were housed in a climate controlled facility with a light/dark cycle of 12/12 
hours. 
           SE was induced in adult male Sprague-Dawley rats (Harlan, Indianapolis, 
IN). Animals received intraperitoneal (i.p.) injections of scopolamine methyl 
bromide and terbutaline hemisulfate (2 mg/kg) followed 30 – 45 min later by 
pilocarpine hydrochloride (390 mg/kg). After 2 hours of continuous SE, seizures 
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were terminated by diazepam (DZP, 25 mg/kg). This group of animals served as 
the ‘pilo’ group. A separate group of animals received identical treatment with the 
exception of receiving saline (390 mg/kg) instead of pilocarpine hydrochloride. 
This group of animals served as the ‘sham’ group. More detailed methods 
concerning induction of SE are described in Chapter 2.3. 
 
5.3.2 WHOLE CELL ELECTROPHYSIOLOGY 
Transverse (300 µM thick) hippocampal slices were prepared from sham- 
and pilocarpine-treated adult male Sprague-Dawley rats as described in detail in 
Chapter 2.6. Briefly, animals were deeply anesthetized with isoflurane and 
transcardially perfused with a sucrose-based aCSF. Slices were prepared in ice 
cold (4°C) sucrose-based aCSF and incubated in room-temperature oxygenated 
(95% O2 / 5% CO2) NaCl-based solution. 
Excitatory postsynaptic currents (EPSCs) recorded from dentate granule 
cells from animals 169 ± 10 days post-treatment were evoked with a 50 ms puff 
of 10 µM domoate applied every 60 seconds through a Pneumatic PicoPump 
(PV800, WPI, Sarasota, FL), located approximately 70 µM from the recorded cell. 
EPSCs were pharmacologically isolated in an antagonist cocktail containing 
bicuculline methochloride (Bic, 15 µM), CGP (1 µM), MK-801 (10 µM) and TTX (1 
µM).  KAR-mediated currents were isolated using GYKI53655 (50 µM). CNQX 
(100 µM) was applied at the end of the experiments to block any residual 
glutamatergic transmission. All drugs were purchased from Abcam with the 
exception of bicuculline methochloride (Ascent Scientific). 
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5.3.3 FIELD POTENTIAL ELECTROPHYSIOLOGY 
Transverse (500 µM thick) hippocampal slices were prepared from sham- 
and pilocarpine-treated adult male Sprague-Dawley rats as described in detail in 
Chapter 2.7. Briefly, animals were deeply anesthetized with isoflurane and 
transcardially perfused with a sucrose-based aCSF. Slices were prepared in ice 
cold (4°C), and then incubated for 30 minutes in heated (37°C) oxygenated (95% 
O2 / 5% CO2) sucrose-based aCSF prior to a gradual transition to room-
temperature oxygenated (95% O2 / 5% CO2) NaCl-based solution.  
 Field EPSPs (fEPSPs) were evoked from animals 157 ± 9 days post-
treatment in the DG and area CA3 using two distinct paradigms. 1) Mossy fiber – 
CA3 fEPSPs were evoked in the dentate gyrus granule cell layer every 30 sec 
and recorded in CA3 stratum lucidum. 2) Recurrent mossy fiber fEPSPs in the 
dentate gyrus of epileptic animals were evoked in the inner one-third of the 
molecular layer every 60 sec and recorded in the granule cell layer. Figure 2.2 
depicts each of the two experimental paradigms utilized, blue and green 
electrodes, respectively.  fEPSPs were evoked at 50% of the maximal response 
determined through an I/O curve. fEPSPs evoked from mossy fibers were 
identified based upon their large paired pulse facilitation (PPF) as well as 
inhibition by the group II metabotropic glutamate receptor antagonist DCG-IV, 
which selectively inhibits mossy fiber-evoked, but not fEPSPs evoked from 
stimulation of associational/commissural fibers (Yeckel et al., 1999). In our hands 
DCG-IV (1 µM) blocked 91.8 ± 1.2% of the response in sham (n = 6), and 88.9 ± 








Figure 5.1. Selective inhibition of fEPSPs.  A. DCG-IV (1 µM) inhibited 
AMPA-fEPSPs evoked from selective stimulation of the mossy fiber – CA3 
pathway in sham (n = 6) and pilo-treated animals (n = 6). Control waveforms 
evoked from sham and pilo-treated animals demonstrate large PPF (black 
traces) and inhibition by DCG-IV (gray traces). B. UBP310 (3 µM) inhibits KA-
fEPSPs evoked from stimulation of the mossy fiber – CA3 pathway in both sham 
(n = 7) and pilo-treated animals (n = 5). Control waveforms evoked from sham 
and pilo-treated animals demonstrate PPF (black traces) and inhibition by 








willardine derivative UBP310 to inhibit KAR-mediated transmission (Jane et al., 
2009; Perrais et al., 2009; Pinheiro et al., 2013). We demonstrated that UBP310 
(3 µM) blocked 93.9 ± 0.8% of the response in sham-treated animals (n = 7), and 
93.0 ± 2.0% in pilo-treated animals (n = 5; Figure 5.1B). 
 fEPSPs were pharmacologically isolated in an antagonist cocktail 
containing bicuculline methochloride (Bic, 20 µM) and MK-801 (10 µM). AMPA 
receptors were blocked by application of GYKI53655 (50 µM), and KARs were 
blocked by UBP310 (3 µM) or ACET (300nM). Residual transmission was 
blocked by application of CNQX (100 µM). All drugs were purchased from Abcam 




5.4.1 KAR-MEDIATED TRANSMISSION IS INCREASED IN THE DENTATE GYRUS OF 
EPILEPTIC ANIMALS 
Puff application of the glutamate receptor agonist domoate (10 µM) in the 
inner molecular layer of the DG elicited a large current mediated by the 
extrasynaptic receptor population. Application of the AMPA receptor (AMPAR) 
antagonist GYKI53655 (50 µM) revealed a large KAR-mediated component 
(Figure 5.2A). This suggests that functional extrasynaptic KARs are present and 
fail to contribute to synaptic neurotransmission, a finding similar to what has been 
observed in area CA1 (Bureau et al., 1999).  KARs have been shown to 









Figure 5.2. KARs mediate transmission in dentate granule cells from 
epileptic animals. A. EPSCKA amplitude is significantly increased in pilo-treated 
animals following puff application of domoate (10 µM) on dentate granule cells (n 
= 6). No change in the EPSCAMPA amplitude between sham and pilo-treated 
animals was observed (n = 6). Waveforms evoked by domoate in sham (black 
traces) and pilo-treated animals (gray traces) demonstrate an increase in 
ESPCKA but not EPSCAMPA. B. Stimulation of recurrent mossy fibers elicits a 
KAR-mediated fEPSP in pilo-treated animals (n = 5). No change in the 
fEPSPAMPA amplitude was observed between sham and pilo-treated animals (n = 
5 – 6). Waveforms evoked by stimulation of the inner molecular layer 
demonstrate the appearance of a fEPSPKA in pilo-treated animals (gray traces), 
and no change in the amplitude of the fEPSPAMPA. C. The KA:AMPA amplitude 
ratio is significantly increased in pilo-treated animals due to the appearance of a 







fibers into the inner molecular layer of the DG in epileptic animals (Epsztein et 
al., 2005). Therefore we explored the effects of 10 µM domoate on DGCs from 
pilo-treated animals. We determined that the amplitude of the current was 
significantly increased following application of 10µM domoate (169.7 ± 16.3% of 
control, n = 6; p < 0.01; Figure 5.2A), while the EPSCAMPA was unaltered (108.3 ± 
16.4% of control, n = 6; p > 0.05; Figure 5.2A). These findings were further 
explored using field potential electrophysiology.  
 fEPSPs were elicited with a stimulating electrode placed in the inner 
molecular layer of the DG with the recording electrode placed within the granule 
cell layer (Figure 2.2, green electrodes). In sham-treated animals we evoked a 
large fEPSP that was completely inhibited by GYKI53655, a finding in agreement 
with previous observations demonstrating a lack of synaptic KAR-mediated 
transmission in the DG. However, in epileptic animals we observed a GYKI-
resistant component that was sensitive to the KAR antagonist UBP310 (3 µM), 
demonstrating the appearance of KAR-regulated synaptic transmission in the DG 
of pilo-treated animals (740.8 ± 107.3% of control, n = 5; p < 0.001; Figure 5.2B). 
Furthermore, we determined that transmission mediated by AMPARs was 
unaltered (127.3 ± 15.2% of control, n = 5 – 6; p > 0.05; Figure 5.2B), 
demonstrating a selective increase in KAR-mediated transmission.  In agreement 
the KA:AMPA amplitude ratio was significantly increased in pilo-treated animals 
(sham: 0.006 ± .0001, n = 5; pilo: 0.04 ± 0.007, n = 6; p < 0.01; Figure 5.2C).       
Input-output (I/O) curves were conducted to examine the impact of 
stimulation intensity on the observed increase in KAR-mediated transmission. 
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The fEPSPKA amplitude increased with stimulation strength in pilo-, but not sham-
treated animals (n = 3 – 6, Figure 5.3A). At maximal stimulation strength the 
fEPSPKA evoked from pilo-treated animals was significantly greater than that 
from sham-treated animals (sham: 31.1 ± 11.5 µV; pilo: 136.4 ± 28.8 µV, n = 3 – 
5; p < 0.05; Figure 5.3A). In agreement with our observation that the increase in 
KAR-mediated transmission is a selective modification, no difference in the 
amplitude of the fEPSPAMPA was observed over many stimulus intensities, even 
at the highest intensity (sham: 187.6 ± 84.3 µV; pilo: 237.2 ± 56.2 µV, n = 3 – 5, p 
> 0.05; Figure 5.3B). These findings are in agreement with observations by 
Epsztein et al. (2005) demonstrating the appearance of a KAR-mediated 
response in the inner molecular layer of the DG in epileptic animals. 
 
5.4.2 SYNAPTIC INTEGRATION IS IMPAIRED IN THE DENTATE GYRUS OF EPILEPTIC 
ANIMALS  
As fast synaptic transmission enters the DG it must be synaptically 
integrated by the intrinsically sparse firing DGCs, a process that serves to limit 
transmission (Jung and McNaughton, 1993; Schmidt-Hieber et al., 2007). In 
epilepsy, the KARs located on aberrant mossy fibers create a shift in the firing  
properties of DGCs from sparse firing to sustained, rhythmic firing thus 
increasing the window for synaptic integration and increasing hyperexcitability 
(Artinian et al., 2011). We examined the contribution of AMPA and KA-receptor 
mediated transmission at varying frequency intensities in pilo-treated animals. 






Figure 5.3. I/O curves of fEPSPs in the dentate gyrus demonstrate 
the appearance of KAR-mediated transmission in epileptic animals. A. At 
stimulus intensities of 50µA and above a KAR-mediated fEPSP is apparent in 
pilo-treated animals (closed gray squares, n = 5 – 6) but not sham-treated 
animals (open circles, n = 3 – 5). Representative waveforms from sham-treated 
(black traces) illustrate the lack of a fEPSPKA in sham-treated animals, and the 
development of a fEPSPKA in pilo-treated animals (gray traces). B. The amplitude 
of the fEPSPAMPA evoked from pilo-treated animals (closed gray squares, n = 5 – 
6) is not significantly different that the fEPSPAMPA evoked from sham-treated 
animals (open circles, n = 3 – 5) at any of the stimulus intensities examined. 
Representative waveforms from sham-treated (black traces) and pilo-treated 









area of the fEPSPAMPA/KA at all frequencies explored (Figure 5.4A) representative 
of an increase in synaptic integration. In addition, the area of the fEPSPAMPA/KA 
induced by higher frequencies (10 – 100 Hz) was significantly greater than the 
area of very low (0.017 Hz) stimuli. We specifically examined a 5 pulse, 50 Hz 
train, which increased the total MF-evoked area in pilo-treated animals (sham: 
26.5 ± 3.9 mV/ms, n = 5; pilo: 60.4 ± 7.1 mV/ms, n = 5; p < 0.01; Figure 5.4B). 
We further explored the isolated fEPSPKA and fEPSPAMPA in response to a 50 Hz 
train and determined that the increase in area was due solely to the appearance 
of a KAR-mediated component (pilo: 20.4 ± 4.6 mV/ms, n = 5; Figure 5.4C) as 
the area of the isolated AMPAR-mediated train was unaltered (sham: 26.2 ± 2.8 
mV/ms; pilo: 28.6 ± 3.1 mV/ms, n = 5; p > 0.05; Figure 5.4C). 
To further exemplify the appearance of a KAR-mediated response in pilo-
treated animals we used the same 5 pulse, 50 Hz train to elicit a substantial 
KAR-mediated component and examined inhibition produced by the KAR 
antagonist UBP310 (Pinheiro et al., 2013).  We determined that 3 µM UBP310 
significantly inhibited the response in pilo-treated (32.2 ± 8.9% of control, n = 4; p 
< 0.01; Figure 5.5), but not sham-treated animals (91.9 ± 6.8% of control, n = 4; p 
> 0.05; Figure 5.5). These findings were in agreement with Pinheiro et al. (2013) 
in which UBP310 significantly blocked EPSCKA elicited in dentate granule cells at 
recurrent mossy fiber synapses in epileptic animals.  We also explored the ability 
of a different KAR antagonist, ACET, to block the KAR-mediated response in 
pilo-treated animals. Our initial data suggested that ACET (300 nM) blocks the 








Figure 5.4. Synaptic integration is impaired in the dentate gyrus of 
epileptic animals. Trains were evoked by stimulation of the inner molecular 
layer of the dentate gyrus. A. The area of the fEPSPAMPA/KA was significantly 
increased at all frequencies examined in pilo-treated animals (n = 5 – 7). The 
area evoked by higher frequencies (10 – 100 Hz) was significantly increased 
relative to the lowest frequency examined. B. The fEPSPAMPA/KA area of a 5 
pulse, 50 Hz train was significantly increased in pilo-treated animals (n = 5). 
Representative waveform demonstrates the increased area and decay of the 
fESPSAMPA/KA in sham (black trace) and pilo-treated animals (gray trace). C. Area 
of the fEPSPAMPA is not different between sham and pilo-treated animals (n = 5). 
There is the appearance of a KAR-mediated fEPSP in pilo-treated animals (n = 
5). Waveforms illustrate no change in the fEPSPAMPA in sham (black trace) and 
pilo-treated animals (gray trace) and the appearance of a fEPSPKA in pilo-treated 










Figure 5.5. UBP310 inhibits KAR-mediated transmission at recurrent 
mossy fiber synapses. The selective KAR antagonist UBP310 is ineffective in 
sham-treated animals (n = 4), but significantly inhibits fEPSPs evoked from the 
recurrent mossy fibers of pilo-treated animals (n = 4). This demonstrates the 
appearance of a KAR-mediated response in the dentate gyrus of pilo-treated 
animals. Representative waveforms illustrate the lack of inhibition by UBP (gray 
traces) on control responses (black traces) in sham-treated animals, and the 











control, n = 2, p = 0.08, data not shown).  These data further demonstrate that a 
UBP310-sensitive KAR-mediated response appears within the inner molecular 
layer of pilo-treated animals and contributes to the excitatory circuit. In addition, 
we demonstrated that this new KAR component significantly contributes to both 
high and low frequency transmission, which likely contributes to hyperexcitability 
and the generation of epileptiform activity within the DG. 
 
5.4.3 KAR-MEDIATED TRANSMISSION AT THE MOSSY FIBER – CA3 SYNAPSE IS 
SIGNIFICANTLY REDUCED IN EPILEPTIC ANIMALS 
Mossy fiber – CA3 fEPSPs were elicited with a stimulating electrode 
placed along the hilar border of the dentate granule cell layer with the recording 
electrode placed within CA3 stratum lucidum (Figure 2.2, blue electrodes). In 
direct contrast to the increase in KAR-mediated transmission observed in the 
DG, we observed that the fEPSPKA was significantly reduced in pilo-treated 
animals (48.9 ± 5.0% of control, n = 7 – 8; p < 0.001; Figure 5.6A). This dramatic 
decrease in KAR-mediated transmission is selective, in that the fEPSPAMPA was 
not different in pilo-treated animals (98.3 ± 20.2% of control, n = 5 – 9; p > 0.05; 
Figure 5.6A). In support of these findings, we observed that the KA:AMPA 
amplitude ratio was significantly reduced (sham: 0.274 ± 0.026, n = 4; pilo: 0.146 
± 0.02, n = 5; p < 0.01; Figure 5.6B), as well as the KA:AMPA area ratio (sham: 
6.63 ± 0.86, n = 3; pilo: 1.71 ± 0.61, n = 5; p < 0.01; Figure 5.6C). I/O curves at 
stimulus intensities from 10 – 400 µA were performed on isolated KA- and 







Figure 5.6. KAR-mediated transmission is significantly reduced in 
the mossy fiber – CA3 pathway of epileptic animals. A. The amplitude of the 
mossy fiber evoked KAR-mediated fEPSP is significantly reduced in pilo-treated 
animals (n = 7 – 8). No change in the AMPAR-mediated fEPSP was observed 
between sham and pilo-treated animals (n = 5 – 9). Waveforms evoked by 
stimulation of the mossy fiber pathway demonstrate the reduction in fEPSPKA 
amplitude in sham (black traces) and pilo-treated animals (gray traces), with no 
apparent change in fEPSPAMPA amplitude. B. The KA:AMPA amplitude ratio is 
significantly reduced in pilo-treated animals due to the decrease of a KAR-
mediated response (n = 4 – 5). C. The KA:AMPA area ratio is also significantly 










amplitude of the fEPSPKA between sham and pilo-treated animals at stimulus 
intensities of 70 µA and above (Figure 5.7A). At maximal stimulation the fEPSPKA 
evoked from pilo-treated animals was significantly smaller than that of sham-
treated animals (sham: 177.8 ± 33.2% of control, n = 3; pilo: 59.6 ± 10.2% of 
control, n = 4; p < 0.05; Figure 5.7A). In support of the selective alteration in 
KAR-mediated transmission we did not observe any difference in the amplitude 
of the fEPSPAMPA at any stimulus intensity (Figure 5.7B). These findings 
demonstrate that there is a downregulation in excitatory neurotransmission 
mediated by KARs, but not AMPARs. These findings are supported by the 
anatomical data collected in Chapter 4 demonstrating a significant reduction in 
GluK2/3 and GluK4 subunit expression in area CA3 of animals 60 and 200d post-
SE, Figure 4.3 – 4.4). 
 
5.4.4 SYNAPTIC INTEGRATION AT THE MOSSY FIBER – CA3 SYNAPSE OF 
EPILEPTIC ANIMALS IS IMPAIRED 
 The ability of CA3 pyramidal cells to properly integrate information 
stemming from the DG and synapsing via the mossy fiber pathway is believed to 
be an integral step in the process of encoding and retrieving episodic memory 
(Herrmann et al., 2004; Bartos et al., 2007). In addition higher frequency, gamma 
oscillations have been demonstrated to be necessary for induction of long-term 
potentiation (LTP), a synaptic correlate of learning (Rosenzweig et al., 1997; 
Traub et al., 1998). Given the significant decrease in KAR-mediated 






Figure 5.7. I/O curves of mossy fiber evoked fEPSPs demonstrate a 
selective decrease in KAR-mediated transmission. A.  The amplitude of the 
fEPSPKA evoked from pilo-treated animals (closed gray squares, n = 4 – 6) is 
significantly reduced compared to the fEPSPKA evoked from sham-treated 
animals (open circles, n = 3 – 6) at stimulus intensities of 70 – 400 µA. 
Representative waveforms from sham-treated (black traces) and pilo-treated 
(gray traces) demonstrate the reduced potentiation of fEPSPKA at two different 
stimulus intensities. B. The amplitude of the fEPSPAMPA evoked from pilo-treated 
animals (closed gray squares, n = 3 – 5) is not significantly different that the 
fEPSPAMPA evoked from sham-treated animals (open circles, n = 4 – 10) at any of 
the stimulus intensities examined. Representative waveforms from sham-treated 
(black traces) and pilo-treated (gray traces) are not different at two different 









integration at several different frequencies within the mossy fiber – CA3 pathway 
(Figure 5.8A). We determined that at lower frequencies (0.03 – 10 Hz) there was 
no difference in area of fEPSPAMPA/KA. However at higher frequencies, closer to 
that of gamma frequency (30 – 100 Hz), there was a significant decrease in the 
fEPSPAMPA/KA, indicative of a reduction in signal integration within the mossy fiber 
– CA3 pathway in pilo-treated animals. Similar to data collected from the DG, we 
examined a 5 pulse, 50 Hz train and concluded that the area of the train was 
significantly reduced in pilo-treated animals (sham: 56.8 ± 6.2% of control, n = 8; 
pilo: 27.6 ± 5.0% of control, n = 5; p < 0.01; Figure 5.8B). As anticipated we 
discovered that this decrease was attributed to the selective reduction in the 
fEPSPKA (sham: 35.7 ± 4.3 mV/ms, n = 7; pilo: 18.6 ± 3.1 mV/ms, n = 6; p < 0.01; 
Figure 5.8C) as the fEPSPAMPA remained unaltered (sham: 10.9 ± 2.0 mV/ms, n = 
5; pilo: 11.1 ± 2.1 mV/ms, n = 5; p > 0.05; Figure 5.8C). 
We examined the ability of the KAR antagonist UBP310 to inhibit the 
fEPSPAMPA/KA induced by a 5 pulse, 50 Hz train stimuli. Given the large KAR-
mediated component at the mossy fiber – CA3 synapse in sham-treated animals, 
we observed a significant inhibition following application of 3 µM UBP (33.5 ± 
6.6% of control, n = 5; p < 0.01; Figure 5.9), a finding in agreement with a 
previous study demonstrating inhibition of postsynaptic KARs at mossy fiber – 
CA3 synapses (Pinheiro et al., 2013).Given the significant reduction in KAR-
mediated transmission in pilo-treated animals we anticipated that UBP310 (3µM) 
would produce less inhibition of the fEPSPAMPA/KA. We found that UBP310 still 







Figure 5.8. Frequency dependent alterations in synaptic integration 
at the mossy fiber – CA3 synapse of epileptic animals. Trains were evoked 
by stimulation of the mossy fiber – CA3 pathway. A. Frequency-dependent 
alterations in KAR-mediated transmission were observed in the mossy fiber – 
CA3 pathway (n = 4 – 8). Significant reduction in the area fEPSPAMPA/KA was 
observed in pilo-treated animals at higher frequencies (30 – 100 Hz). B. The 
fEPSPAMPA/KA area of a 5 pulse, 50 Hz train was significantly reduced in pilo-
treated animals. Representative waveform demonstrates the decrease in area 
and decay of the fEPSPAMPA/KA in sham (black trace) and pilo-treated animals 
(gray trace). C. Area of the fEPSPAMPA is not different between sham and pilo-
treated animals (n = 5). There is a significant decrease in the fEPSPKA in pilo-
treated animals (n = 6 – 7). Waveforms illustrate the lack of change in the 
fEPSPAMPA in sham (black trace) and pilo-treated animals (gray trace) and the 
significant decrease in the area fEPSPKA in pilo-treated (gray trace) relative to 












Figure 5.9. UBP310 inhibits KAR-mediated transmission at mossy 
fiber – CA3 synapses in sham and epileptic animals. The selective KAR 
antagonist UBP310 significantly inhibits fEPSPs evoked by stimulation of the 
mossy fiber – CA3 pathway in sham (n = 5) and pilo-treated animals (n = 4).  
There was a trend towards a significant reduction in UBP310 inhibition in pilo- 
compared to sham-treated animals (p = 0.087). Representative waveforms 
illustrate the inhibition produced by UBP310 (gray traces) compared to control 









of control, n = 4, p < 0.05; Figure 5.9). While not significant, we did observe a 
trend towards the reduced inhibition by UBP310 in pilo- vs. sham-treated animals 
(p = 0.087).  Similar to the actions of UBP310, we observed a significant 
inhibition by ACET (300nM) on the fEPSPAMPA/KA in both sham (27.2 ± 6.6% of 
control, n = 4; p < 0.05) and pilo-treated animals (28.3 ± 2.9% of control, n = 3; p 
< 0.05; data not shown). Together these data demonstrate that KAR-mediated 
transmission within the mossy fiber – CA3 pathway is significantly reduced in 
pilo-treated animals. This finding is in direct opposition to the observed increase 
in KAR-mediated transmission within the DG. We suggest that this decrease may 
serve as a compensatory mechanism to limit hippocampal excitability and the 
development of seizures within the highly epileptogenic CA3 region. 
 
5.4.5 PAIRED PULSE FACILITATION IS NOT ALTERED IN EPILEPTIC ANIMALS 
 A prominent feature of the mossy fiber – CA3 synapse is extremely large 
PPF (Henze et al., 2000), thought to be mediated in part by KARs (Kamiya et al., 
2002).  We explored whether PPF at the mossy fiber – CA3 synapse is altered in 
pilo-treated animals. We determined in sham-treated animals that the paired-
pulse ratio (PPR) at 50 ms was significantly increased in both isolated AMPA (1.7 
± 0.1, n = 8; p < 0.001), and KA-receptor mediated fEPSPs (1.2 ± 0.1, n = 8; p < 
0.05; Figure 5.10A). In addition the PPR mediated by the KAR was significantly 
lower than that of the AMPAR (p < 0.01). These findings are supported by 
previous studies and have been demonstrated to hold true for a variety of 






Figure 5.10. Paired pulse facilitation is not altered epileptic animals. 
Alterations in the paired pulse ratio at an interval of 50 ms were examined at the 
mossy fiber – CA3 synapse (A. and B.) and in the dentate of sham and pilo-
treated animals (C.). A. In sham-treated animals the fEPSPKA  (n = 8) and the 
fEPSPAMPA (n = 8) PPR50 were significantly increased. The ratio of the 
fEPSPAMPA was significantly greater than that observed for the fEPSPKA. 
Representative waveforms illustrate PPF mediated by KA and AMPA-receptors. 
B. Relative to sham-treated animals there was no difference in the PPR50 for 
fEPSPKA (n = 5) or fEPSPAMPA (n = 5) elicited from pilo-treated animals. 
Representative waveforms demonstrate similar levels of PPF in pilo-treated 
animals to what was observed in sham-treated animals. C. The fEPSPAMPA 
PPR50 was not significantly different in sham (n = 5) or pilo-treated animals (n = 
6). Representative waveforms illustrate the lack of PPF or PPD observed within 








facilitation than AMPARs at the mossy fiber synapse (Contractor et al., 2001; Ito 
et al., 2004). In pilo-treated animals we observed that the PPR for fEPSPKA and 
fEPSPAMPA were not different than those noted in sham-treated animals (KA: 98.5 
± 11.0% of sham, n = 5; p > 0.05; AMPA: 112.5 ± 13.4% of sham, n = 5; p > 
0.05; Figure 5.10B). We also explored the ability of UBP310 (3 µM) to alter PPF. 
In agreement with Perrais et al. (2009), UBP310 had no effect on the PPF in 
either sham-treated (97.1 ± 3.7, n = 7; p > 0.05) or pilo-treated animals (89.6 ± 
68% of control, n = 5; p > 0.05), suggesting that presynaptic KARs are composed 
of the UBP310-insensitive heteromeric GluK2/3, or homomeric GluK2- subunit 
combination.  Together these data demonstrate that the relative contribution of 
AMPARs and KARs to the presynaptic regulation of PPF is not altered in 
epilepsy. It should be noted that this observation is in contrast to the report that 
the PPR of the fEPSPAMPA/KA at the mossy fiber synapse is significantly reduced 
in kainate-treated animals several weeks post-SE (Goussakov et al., 2000).  
Unlike the distinct PPF observed at the mossy fiber – CA3 synapse, 
stimulation of the perforant path input in the DG is not as well-defined. A general 
consensus reveals that stimulation of the lateral perforant path input results in 
PPF, while stimulation of the medial perforant path produces paired-pulse 
depression (PPD) (McNaughton, 1980; Christie and Abraham, 1992b, a; Colino 
and Malenka, 1993; Froc et al., 2003). However, these findings have been widely 
scrutinized and in general it is believed that simply relying on observed PPF or 
PPD is not sufficient to demonstrate proper stimulation of the lateral or medial 
perforant path (Petersen et al., 2013). We briefly examined whether the PPR of 
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fEPSPAMPA was altered in the DG of epileptic animals and determined that the 
PPR at a 50 ms interval was unaltered in sham-treated (0.9 ± 0.05, n = 5, p > 
0.05) and pilo-treated animals (0.91 ± 0.06, n = 6, p > 0.05; Figure 5.10C).  
 
5.5 DISCUSSION 
 The results of this study provide the first examination of specific alterations 
in KAR-mediated neurotransmission in area CA3 of epileptic animals. Despite the 
abundance of KARs in this region and the significant role they play in both pre- 
and postsynaptic regulation of neurotransmission there are no reports exploring 
their function in epilepsy. In agreement with previous studies in the DG of 
epileptic animals we observed the appearance of a KAR-mediated response 
(Epsztein et al., 2005). In direct contrast to this increase within the DG, we 
observed for the first time, a significant reduction in KAR-mediated transmission 
in area CA3 in pilo-treated animals. We believe that these effects are limited to 
KARs located on postsynaptic CA3 pyramidal cells, as we did not observe any 
difference in presynaptic regulation of PPF. The results of this study suggest that 
the observed reduction in KAR-mediated transmission in area CA3 may serve as 
a compensatory modification in response to the significant increase in 
synchronization and excitatory transmission observed in the DG of epileptic 
animals. Figure 5.11 summarizes the principal finding of this study, the reduction 









Figure 5.11. Summary of findings detailed in Chapter 5. Epilepsy differentially 
alters KARs at two synapses of the same axon. In epileptic animals aberrant 
mossy fiber sprouting (light blue), is associated with an appearance in KAR-
mediated transmission.  In contrast, transmission mediated by KARs at the 
mossy fiber – CA3 synapse is significantly reduced. Sham fEPSPKA: black traces; 











5.5.1 KAR-MEDIATED TRANSMISSION IS REDUCED AT THE MOSSY FIBER – CA3 
SYNAPSE 
 In pilo-treated animals we observed a selective reduction in the mossy 
fiber evoked fEPSPKA, as the fEPSPAMPA remained unaltered. In agreement, we 
observed significant reduction in the fEPSPKA of epileptic animals over several 
different stimulus intensities while the fEPSPAMPA was not changed. This finding 
clearly demonstrates that KAR-, but not AMPAR-mediated transmission, is 
significantly reduced in epilepsy. These data are in contrast to the report by 
Goussakov et al. (2000) in which the mossy fiber evoked fEPSP was increased 
in the kainate model of SE. The discrepancy between these studies is likely 
attributed to several factors. The most likely rationale is the age of the animals 
and their epileptic background. The current study utilized animals considered to 
be chronically epileptic (189 ± 9 days post-SE), while Goussakov et al. (2000) 
examined alterations in animals only several weeks post-SE. It is widely noted  
that while anatomical alterations and neuronal rewiring can occur within days 
following SE, many of these changes do not plateau until many months after the 
event (Loscher and Brandt, 2010). Thus it is likely that the current study and that 
conducted by Goussakov et al. (2000) examined different hippocampal networks. 
 
5.5.2 POTENTIAL ALTERATIONS IN HIPPOCAMPAL KAR SUBUNIT COMBINATION 
 An underlying goal of this study was to determine if the KAR subunit 
composition at postsynaptic CA3 cells was altered in the epileptic brain. This type 
of alteration could have a dramatic impact on receptor agonist affinity, 
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biophysical properties of the receptor, and the development of potential 
therapeutics. Given the lack of subunit selective KAR antagonists we attempted 
to use UBP310 and ACET to determine if KAR subunit composition was altered 
in area CA3 of epileptic animals. 
The willardine-derivative UBP310 has been identified as a potent 
antagonist at homomeric GluK3 and heteromeric GluK2/5-containing KARs 
(Perrais et al., 2009; Pinheiro et al., 2013). Furthermore, this compound was 
shown to be ineffective at blocking homomeric GluK2-containing KARs and 
heteromeric GluK2/3-containing KARs (Perrais et al., 2009). We observed rapid 
and robust inhibition of KAR-mediated transmission in area CA3 from both sham 
and pilo-treated animals following application with UBP310. Furthermore, 
UBP310 did not affect presynaptically regulated PPF. In agreement with previous 
studies, these data suggest that presynaptic KARs are likely composed of 
homomeric GluK2-containing KARs and/or heteromeric GluK2/3-containing 
KARs, as UBP310 failed to inhibit the response (Perrais et al., 2009; Pinheiro et 
al., 2013).  
In regards to postsynaptic KARs, the observed inhibition by UBP310 
suggests they contain GluK2/5 subunits (Pinheiro et al., 2013). However, the 
ability of UBP310 to inhibit GluK2/4-containing KARs has not been explored, and 
thus it is quite possible that KARs localized to postsynaptic CA3 cells may 
contain an abundance of GluK2/4-contaning receptors. In addition, anatomical 
data from Chapter 4 demonstrated a significant reduction in GluK2/3 and GluK4 
subunits, suggesting that residual KARs in area CA3 may be composed of 
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GluK2/5 subunits. In an attempt to elucidate this possibility we utilized the KAR 
antagonist ACET. While ACET was initially developed as a GluK1 antagonist 
(Dolman et al., 2007; Dargan et al., 2009), preliminary data from our lab has 
suggested that it may selectively inhibit GluK2/4-containing KARs. However, we 
observed similar inhibition by ACET in both sham and pilo-treated animals. This 
finding could demonstrate a lack of ACET selectivity, or demonstrate that the 
KAR subunit composition on the membrane surface is not altered in area CA3 of 
pilo-treated animals. Given the differences that the GluK4 and GluK5 subunits 
bestow upon the receptor, having a clear understanding of their expression is 
essential. However, this lies within our ability to develop subunit-selective KAR 
antagonists which as of yet has proved quite challenging.  
 
5.5.3 ALTERATIONS IN PRESYNAPTIC KAR-MEDIATED TRANSMISSION AT THE 
MOSSY FIBER – CA3 SYNAPSE 
 In addition to their postsynaptic localization KARs are also located on 
presynaptic mossy fiber terminals where they have been shown to regulate 
several forms of both short-term and long-term synaptic plasticity (Nicoll and 
Malenka, 1995; Salin et al., 1996). Synaptically released glutamate can activate 
these presynaptic KARs to facilitate or depress glutamate release and have also 
been shown to be integral in the induction of mossy fiber LTP (Bortolotto et al., 
1999; Contractor et al., 2001; Lauri et al., 2001; Schmitz et al., 2001a; Schmitz et 
al., 2003; Pinheiro et al., 2007; Scott et al., 2008). In the current study we 
examined possible alterations in the presynaptic regulation of PPF at the mossy 
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fiber – CA3 synapse and did not observe any difference in pilo-treated animals, 
thus attributing the observed decrease in KAR-mediated transmission to 
postsynaptic modifications. In contrast to this finding, Goussakov et al. (2000)  
reported a decrease in PPF at the mossy fiber – CA3 pathway from kainate 
treated animals. As previously discussed this discrepancy is likely due to the 
substantial difference in the length in which epilepsy progressed following 
induction of SE, weeks vs. months.  
Previous studies have demonstrated that differential alterations in 
presynaptically regulated processes such as PPF and frequency facilitation can 
be observed (Contractor et al., 2001; Fernandes et al., 2009). These 
observations led to the suggestion that two populations of presynaptic KARs may 
exist; those that mediate a single release event, and those responsible for 
mediating low frequency stimulations (Fernandes et al., 2009). While data 
collected in the current study as well as anatomical data presented in Chapter 4 
are supportive of a postsynaptic alteration in KAR function, the possibility that 
other presynaptically mediated processes, such as frequency facilitation or even 
mossy fiber LTP, may be altered cannot be completely excluded.  
 
5.5.4 IMPACT OF COMPROMISED DENTATE GYRUS ‘GATEKEEPER’ FUNCTION 
 The concept that the DG may serve as a gate to limit or filter transmission 
into the hippocampus was first established in the 1960s (Andersen et al., 1966). 
This role was re-examined following the observation that in both patients and 
animal models of SE there is abnormal sprouting of mossy fibers into the DG 
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which creates an excitatory network (Tauck and Nadler, 1985; Represa et al., 
1987; Sutula and Dudek, 2007). In addition to regulating excitatory 
neurotransmission mossy fibers, including those sprouted into the DG, release 
extremely high levels of synaptically sequestered zinc (Perez-Clausell and 
Danscher, 1985). This release of zinc has been found to accelerate and increase 
epileptiform bursting within the DG (Timofeeva and Nadler, 2006). More recently 
it was demonstrated that KARs located on sprouted mossy fibers contribute to 
regulation of glutamatergic activity and actually alter the intrinsic firing properties 
of dentate granule cells (Epsztein et al., 2005; Artinian et al., 2011). The switch 
from the normal sparse firing to more sustained activity significantly increases the 
synchronization of dentate granule cells and reduces their ability to properly 
integrate transmission entering from the entorhinal cortex (Artinian et al., 2011). 
 In agreement with these reports the data in the current study revealed an 
increase in KAR-mediated transmission with the DG and subsequent impairment 
of synaptic integration, as demonstrated by a significant increase in the area of 
the fEPSPKA at varying frequencies.  This well-established increase in excitatory 
transmission within the DG could have huge consequences for the generation of 
epileptiform activity in area CA3. We suggest that the observed decrease in 
KAR-mediated transmission in area CA3 may serve as a compensatory 
mechanism to limit the impact of synchronous activity in the DG. Of particular 
note in this study is the observation that on two different synapses of the same 
axon we have observed opposite alterations of the same receptor population. 
Aberrant mossy fibers synapsing into the inner molecular layer of the DG exhibit 
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increased KAR-mediated transmission, while mossy fibers synapsing into area 
CA3 exhibit decreased KAR-mediated transmission.  A similar finding has not 
been observed in other synapses or brain regions, adding to the uniqueness of 
hippocampal mossy fibers. 
 
5.5.5 COMORBIDITIES AND EPILEPSY 
As previously discussed epilepsy is associated with severe comorbidities 
and recent literature has suggested that KARs and alteration in subunit 
expression may be implicated. We suggest that the apparent downregulation of 
KAR subunit expression and KAR-mediated transmission within area CA3, while 
likely a compensatory modification, may be associated with noted comorbidities. 
As previously elaborated upon, the reduction in KAR function may be a 
compensatory mechanism to limit excitability. However the trade-off may be the 
occurrence of comorbidities, particularly those linked to the mossy fiber – CA3 
pathway. While controversy surrounds mossy fiber induced LTP (Henze et al., 
2000), it is apparent that the mossy fiber – CA3 synapse demonstrates the ability 
to undergo long-term or even permanent alterations. The observed decrease in 
KAR function at this synapse may likely contribute to cognitive impairment, 
specifically associated with memories. The process of encoding and retrieving 
memories has been associated with gamma frequencies, ~30 – 80 Hz (Herrmann 
et al., 2004; Bartos et al., 2007).  In the current study we observed a selective 
reduction in the area of the fEPSPKA at frequencies of 30 – 100Hz, those similar 
to gamma frequency. This finding suggests that the impairment of signal 
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integration at frequencies responsible for memory and learning may contribute to 
the cognitive comorbidities associated with epilepsy.  
 
5.6 SIGNIFICANCE 
 The results of this study demonstrate that in the epileptic brain KARs 
localized to mossy fibers are differentially altered. We demonstrated for the first 
time that KAR-mediated transmission is significantly reduced in area CA3. In 
stark contrast to the decrease in KARs at the mossy fiber – CA3 synapse, we 
observed a significant increase in KARs localized to aberrant mossy fibers 
synapsing in the DG, a finding in agreement with previous reports (Epsztein et 
al., 2005). We suggest that the reduction in KAR-mediated excitatory 
transmission in area CA3 is a compensatory modification in response to the 
dramatic increase in DGC synchronization and inability of the DG to properly 
integrate transmission. In addition we suggest that this compensatory decrease 
in KAR-mediated transmission may precede the development of comorbidities 
associated with epilepsy, including anxiety, depression and cognitive impairment. 
Given the vast alterations in KAR-mediated transmission within the DG and area 
CA3, and the potential impact of those alterations on cognitive and psychiatric 
comorbidities, KARs may prove to be valuable therapeutic targets. However, 
further investigation into subunit composition and the relationship between KARs 






ALTERATIONS IN KAINATE RECEPTOR MEDIATED REGULATION OF AXON 
EXCITABILITY IN EPILEPTIC ANIMALS 
 
6.1 INTRODUCTION 
 Excitatory neurotransmission mediated by kainate receptors (KARs) has 
been most thoroughly examined at the hippocampal mossy fiber – CA3 synapse. 
At this synapse KARs localized to postsynaptic CA3 cells regulate a small, but 
slowly decaying excitatory current that significantly contributes to temporal 
summation and a large depolarizing envelope (Castillo et al., 1997; Vignes and 
Collingridge, 1997; Frerking and Ohliger-Frerking, 2002). KARs localized to 
presynaptic mossy fiber (MF) terminals have been shown to contribute to forms 
of both short-term and long-term plasticity, including paired-pulse facilitation, 
frequency facilitation and long-term potentiation (Bortolotto et al., 1999; 
Contractor et al., 2001; Lauri et al., 2001; Schmitz et al., 2001a; Kamiya et al., 
2002; Pinheiro et al., 2007). Several studies have also examined the role of 
presynaptic KARs in regulating glutamate release at the MF terminal. These 
studies report that low concentrations of the KAR agonist kainate (KA) facilitate 
the release of glutamate, while higher concentrations of glutamate depress 
transmitter release (Contractor et al., 2000; Kamiya and Ozawa, 2000; Schmitz 
et al., 2001a). In support of these findings utilizing exogenously applied kainate, it 
was found that released glutamate following brief and prolonged trains produces 
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was found that released glutamate following brief and prolonged trains produces 
similar effects on presynaptic KAR regulation of transmitter release (Bettler et al., 
1990; Schmitz et al., 2000; Schmitz et al., 2001a).  
 In addition to these diverse pre- and postsynaptic roles of KARs at the 
mossy fiber – CA3 synapse, KARs are thought to be present along the length of 
mossy fibers as well as along the axons of CA3 pyramidal cells where they have 
been shown to regulate axon excitability (Kamiya and Ozawa, 2000; Schmitz et 
al., 2000; Frerking et al., 2001). Similar to the findings of presynaptic KAR-
regulated glutamate release, it has been determined that KARs located along 
MFs regulate excitability in a bidirectional manner, as low concentrations of 
kainate facilitate and higher concentrations depress axon excitability (Kamiya 
and Ozawa, 2000; Schmitz et al., 2000). Whereas KARs localized to MFs 
demonstrate bimodal actions, those receptors along the axons of CA3 pyramidal 
cells have been shown to purely reduce axon excitability in a concentration 
dependent manner (Frerking et al., 2001; Mott et al., 2008). It should be noted 
that KAR regulation of axon excitability, determined through observation of 
orthodromic fiber volleys or antidromic action potentials is a separate and 
distinguishable phenomenon than that of presynaptic regulation of glutamate 
release. However, alterations in axon excitability are typically consistent with 
observed presynaptic changes in glutamate release. 
 KARs localized to MF or CA3 axons are likely key regulators of 
glutamatergic transmission and may ultimately serve to govern excitatory drive 
through the hippocampus, specifically area CA3 and CA1 via the mossy fiber and 
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CA3 axons, respectively. Given observations of dramatic alterations in KAR 
subunit expression in the hippocampus of status epilepticus-experienced animals 
(Lason et al., 1997; Tandon et al., 2002; Zhang et al., 2004; Ullal et al., 2005; 
Porter et al., 2006) and Chapter 4, in conjunction with the hyperexcitable and 
epileptogenic nature of CA3, it is conceivable that KAR-regulation of axonal 
excitability may be altered. Therefore the goal of this study was to determine 
possible alterations in KAR-regulation of axon excitability in epileptic animals.  
 
6.2 HYPOTHESIS 
 We previously observed significant alterations in KAR subunit expression 
and localization throughout the hippocampus, specifically a reduction in GluK2/3 
and GluK4 within the mossy fibers terminating in CA3 stratum lucidum (Chapter 
4). In addition, in Chapter 5, we suggested that in epileptic animals the increase 
in the excitatory circuitry of the dentate gyrus may lead a compensatory 
downregulation of KAR-mediated excitatory in area CA3. Based on these 
observations, we hypothesize that the ability of KARs to regulate axon excitability 
will be reduced in the epileptic brain. This potential outcome could serve to either 
recover or exacerbate the epileptic condition.  
 
6.3 MATERIALS AND METHODS 
6.3.1 ANIMAL MODEL OF SE 
All animal care and use procedures were carried out in accordance with 
protocols written under the guidance of the National Institutes of Health Guide for 
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the Care and Use of Laboratory Animals and approved by the Institutional Animal 
Care and Use Committee at the University of South Carolina. Following induction 
of SE, rats were housed 1 per cage with ad libitum access to food and water. 
Rats were housed in a climate controlled facility with a light/dark cycle of 12/12 
hours. 
           SE was induced in adult male Sprague-Dawley rats (Harlan, Indianapolis, 
IN). Animals received intraperitoneal (i.p.) injections of scopolamine methyl 
bromide and terbutaline hemisulfate (2 mg/kg) followed 30 – 45 min later by 
pilocarpine hydrochloride (390 mg/kg). After 2 hours of continuous SE, seizures 
were terminated by diazepam (DZP, 25 mg/kg). This group of animals served as 
the ‘pilo’ group. A separate group of animals received identical treatment with the 
exception of receiving saline (390 mg/kg) instead of pilocarpine hydrochloride. 
This group of animals served as the ‘sham’ group. More detailed methods 
concerning induction of SE are described in Chapter 2.3. 
 
6.3.2 FIELD POTENTIAL ELECTROPHYSIOLOGY  
Transverse (500 µM thick) hippocampal slices were prepared from sham- 
and pilocarpine-treated adult male Sprague-Dawley rats 145 ± 10 days post-
treatment as described in detail in Chapter 2.7. Briefly, animals were deeply 
anesthetized with isoflurane and transcardially perfused with a sucrose-based 
aCSF. Slices were prepared in ice cold (4°C), and then incubated for 30 min in 
heated (37ºC) oxygenated (95% O2 / 5% CO2) sucrose-based aCSF prior to a 
gradual transition to room-temperate oxygenated Na-Cl based solution. 
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In contrast to orthodromic stimulation in which action potentials travel 
away from the soma, antidromic stimulation involves stimulation of the dendrite 
or axon as the action potential travels backwards towards the soma. This type of 
stimulation paradigm is commonly used to examine dendritic or axonal 
projections. The current project utilized antidromic spikes to directly explore KAR-
mediated hippocampal axon excitability. Antidromic population spikes were 
evoked in two distinct pathways. 1) Mossy fibers were stimulated in CA3 stratum 
lucidum and the response was recorded in the dentate granule cell layer. 2) CA3 
axons were stimulated in stratum radiatum and the response was recorded in the 
CA3 pyramidal cell layer. Figure 2.2 depicts each of these two experimental 
paradigms utilized, purple and red electrodes, respectively.  Antidromic spikes 
were pharmacologically isolated in an antagonist cocktail containing bicuculline 
methochloride (Bic, 20 µM) and MK-801 (10 µM). KAR antagonists, UBP310 (3 
µM), ACET (300 nM), and kynurenic acid (KYN, 3 mM) were used to explore 
kainate-induced axon excitability or depression. All drugs were purchased from 
Abcam with the exceptions of Bic (Ascent Scientific), ACET (Tocris Bioscience), 
and KYN (Sigma-Aldrich).  
 
6.4 RESULTS 
6.4.1 KAR- MEDIATED FACILITATION, BUT NOT DEPRESSION OF MOSSY FIBER 
EXCITABILITY IS REDUCED IN EPILEPTIC ANIMALS 
 KARs located along mossy fibers regulate MF excitability in a bimodal 
manner, as low concentrations facilitate and high concentrations of kainate 
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depress excitability (Kamiya and Ozawa, 2000; Schmitz et al., 2000). Alterations 
in the ability of KARs to properly regulate this action would dramatically impact 
the excitatory drive into area CA3 resulting in alterations in both short-term and 
long-term plasticity at this synapse. Antidromic spikes were evoked by 
stimulation of the mossy fibers in CA3 stratum lucidum and recorded in the 
dentate granule cell layer (Figure 2.2, purple electrodes).  
In agreement with previous studies we observed concentration-dependent 
effects on axon excitability following bath application of KA with low 
concentrations potentiating the amplitude of the MF antidromic spike, and higher 
concentrations inhibiting the spike amplitude (Figure 6.1A). However, in pilo-
treated animals we found that while depression induced by high KA was intact, 
the facilitation produced by low KA was completely absent (Figure 6.1A). Based 
on these studies we further examined alterations in MF excitability produced by 
0.3 µM KA due to its selective activation of the KAR at this low concentration 
(Mulle et al., 1998). We concluded that 0.3 µM KA significantly increases the 
amplitude (121.5 ± 2.9% of control, n = 7; p < 0.001; Figure 6.1B) and area 
(117.6 ± 4.4% of control, n = 7, p < 0.01; Figure 6.1C) of the MF antidromic 
spike. In contrast, the actions of 0.3 µM KA were significantly different in pilo-
treated animals, as KA produced no effect on the amplitude (98.9 ± 2.8% of 
control, n = 5, p > 0.05; Figure 6.1B) or area (95.3 ± 2.0% of control, n = 5; p > 
0.05; Figure 6.1C) of the antidromic spike.  We also examined possible 
alterations in the half width of the antidromic spike following application of 0.3 µM 





Figure 6.1. KAR-mediated facilitation but not depression of mossy 
fiber excitability is reduced in epileptic animals. A. Kainate concentration 
response curves from sham-treated (black squares, n = 5 – 7) and pilo-treated 
animals (gray circles, n = 4 – 7). Facilitation produced by low KA was significantly 
reduced in pilo-treated animals. Depression produced by high KA was not 
different between groups. Right, Waveforms from sham and pilo-treated animals. 
Baseline antidromic spikes (Con, light gray traces), were potentiated by 0.3 µM 
KA in sham, but not pilo-treated groups (black traces), and depressed by 10 µM 
KA (dark gray traces). Application of 0.3 µM significantly increased the amplitude 
(B.) and area (C.) of sham-treated, but not pilo-treated animals. KA (0.3 µM) had 
no effect on the half width of the MF antidromic spike (D.) **p < 0.01; ***p < 
0.001; ##p < 0.01; ###p < 0.001, t-test. 
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6.1D) and pilo-treated animals (101.2 ± 3.2% of control, n = 5; p > 0.05; Figure 
6.1D). These findings demonstrate that bimodal regulation of axon excitability is 
absent in epileptic animals as low concentrations of KA now produce more 
inhibitory than facilitatory effects. Furthermore we suggest that this loss of KAR-
mediated facilitation of MF excitability may be due to a decrease in GluK4 
subunit expression in area CA3 (Chapter 4). In support of this notion, it has been 
reported that facilitation of MF excitability is significantly reduced in GluK4-/- 
animals (Catches et al., 2012). 
 
6.4.2 UBP310 SELECTIVELY BLOCKS KA-INDUCED FACILITATION, BUT NOT 
DEPRESSION OF MOSSY FIBER EXCITABILITY 
 We next explored whether the observed facilitation of MF excitability by 
low kainate (0.3 µM) or the depression by high KA could be blocked by 
application of a KAR antagonist. The selective KAR antagonist UBP310, while 
originally characterized as a GluK1 antagonist, has been shown to potently block 
current at homomeric GluK3 and heteromeric GluK2/5-containing KARs, while it 
is ineffective at homomeric GluK2 and heteromeric GluK2/3-containing KARs 
(Perrais et al., 2009; Pinheiro et al., 2013). It should be noted that while it has not 
been reported, it is likely that UBP310 also antagonizes GluK4-containing 
receptors. We first demonstrated that UBP310 (3 µM) was capable of reversing 
the facilitation produced by 0.3 µM KA in sham-treated animals (Figure 6.2A). We 
next explored the ability of UBP310 to prevent KA-induced facilitation or 




Figure 6.2. UBP310 blocks KA-induced facilitation but not depression 
of mossy fiber excitability. A. Representative time-course experiment 
demonstrating facilitation induced by low KA (0.3 µM) and reversal by 3 µM 
UBP310. Sample waveforms illustrate the antidromic spike at each point during 
the experiment. B. Bar graphs demonstrate that that application of 3 µM UBP did 
not alter the baseline amplitude of the MF-antidromic spike but was able to block 
the ability of low (0.3 µM KA) to facilitate excitability in sham-treated animals. 
Depression by high KA (10 µM) was not prevented by UBP310. Sham-treated 




(106.3 ± 1.0% of control, n = 5; p > 0.05; Figure 6.2B) and pilo-treated animals 
(101.3 ± 1.4% of control, n = 5; p > 0.05; Figure 6.2B), bath application of 
UBP310 (3 µM) had no effect on the baseline antidromic spike amplitude. 
However, we determined that in sham-treated animals pre-application of UBP310 
significantly blocked the anticipated facilitatory effects of 0.3 µM KA (without 
UBP310: 121.5 ± 2.9% of control; n = 7; with UBP310: 108.7 ± 3.1% of control, n 
= 5; p < 0.01; Figure 6.2B). In pilo-treated animals the presence of UBP310 did 
not affect the observed lack of potentiation produced by 0.3 µM KA (p > 0.05; 
Figure 6.2B). 
Given the capacity of UBP310 to block KA-induced facilitation by low KA 
we also examined its ability to block depression induced by high KA (10 µM). We 
found that pre-application of UBP310 (3 µM) was unable to block the significant 
depression induced by 10 µM KA in sham (without UBP: 15.5 ± 8.0% of control, n 
= 5; with UBP: 8.9 ± 0.8% of control, n = 5; p > 0.05) and pilo-treated animals 
(without UBP: 14.3 ± 2.2% of control, n = 5; with UBP: 13.1 ± 5.2% of control, n = 
5; p > 0.05;Figure 6.2B). Given that UBP310 selectively inhibits KARs over 
AMPA or NMDA-receptors (Perrais et al., 2009; Pinheiro et al., 2013), these 
findings demonstrate that facilitation by low KA is in fact KAR-mediated. In 
addition we suggest that the KARs located on mossy fibers are likely composed 
of heteromeric GluK2/4 or GluK2/5-containing receptors and possibly homomeric 
GluK3-cotaining receptors.  However, this is less likely as GluK3 subunit 
expression is restricted to the dentate gyrus (Wisden and Seeburg, 1993; Bureau 
et al., 1999; Darstein et al., 2003). 
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6.4.3 ACET SELECTIVELY BLOCKS KA-INDUCED FACILITATION, BUT NOT 
DEPRESSION OF MOSSY FIBER EXCITABILITY 
Similar to UBP310, the compound ACET (UBP316) was originally 
characterized as an antagonist of GluK1-containing KARs (Dolman et al., 2007; 
Dargan et al., 2009). However studies have suggested that ACET may also 
antagonize KARs composed of homomeric GluK3 subunits (Perrais et al., 2009), 
and has even shown to be partially effective in blocking transmission at the 
mossy fiber – CA3 synapse (Pinheiro et al., 2013). In addition, to these studies 
preliminary data from our lab has suggested that ACET may demonstrate 
increased selectivity for GluK2/4, over GluK2/5-containing KARs. We examined 
the ability of ACET to prevent KA-induced facilitation and/or depression of mossy 
fiber excitability. 
A time course experiment demonstrates the ability of ACET (1 µM) to 
block the facilitation produced by 0.3 µM KA in sham-treated animals (Figure 
6.3A). We next explored the ability of ACET to prevent the observed facilitation 
and depression of MF excitability produced by KA (Figure 6.3B), and found 
results essentially identical to those produced by application of UBP310. Briefly, 
bath application of ACET (1 µM) had no effect on the baseline amplitude of the 
antidromic spike in either sham (99.7 ± 2.4% of control, n = 5; p > 0.05; Figure 
6.3B) or pilo-treated animals (109.5 ± 6.8% of control, n = 3; p > 0.05; Figure 
6.3B). In agreement with our results with UBP310, we found that ACET 
significantly prevented the facilitatory action of 0.3 µM KA in sham-treated 





Figure 6.3. ACET blocks KA-induced facilitation but not depression 
of mossy fiber excitability. A. Representative time-course experiment 
demonstrating facilitation induced by low KA (0.3 µM) and reversal by 1 µM 
ACET. Sample waveforms illustrate the antidromic spike at each point during the 
experiment. B. Bar graphs demonstrate that that application of 1 µM ACET did 
not alter the baseline amplitude of the MF antidromic spike but was able to block 
the ability of low KA (0.3 µM) to facilitate excitability. Depression by high KA (10 
µM) was not prevented by ACET. Sham-treated group: black bars (n = 4 – 5); 
pilo-treated group: gray bars (n = 2 – 3). ***p < 0.001, t-test.  
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of control, n = 5; p < 0.001; Figure 6.3B). The lack of potentiation by 0.3 µM in 
pilo-treated animals was not significantly different in the presence of ACET (p > 
0.05; Figure 6.3B). In addition, we determined that ACET (1 µM) was not able to 
prevent the depression induced by 10 µM KA in sham (without ACET: 15.5 ± 
8.0% of control, n = 5; with ACET: 23.8 ± 6.9% of control, n = 5; p > 0.05) or pilo-
treated animals without ACET: 14.3 ± 2.2% of control, n = 5; with ACET: 6.0 ± 
1.3% of control, n = 2; p > 0.05; Figure 6.3B).  
The above findings are not surprising given the similarities in the UBP310 
and ACET pharmacological profiles. However, the possibility of distinguishing  
whether the actions of KA on mossy fiber excitability were mediated by GluK2/4-  
or GluK2/5-containing KARs was encouraging. Regardless, the results from 
these experiments support the idea that KARs located on mossy fiber axons are 
likely comprised of the GluK2/4- and/or GluK2/5 subunit combination. However, 
the inability of either UBP310 or ACET to prevent inhibition by 10 µM KA 
suggests either that the inhibition is mediated by AMPA receptors and not KARs, 
or perhaps that the observed inhibition occurs through a metabotropic function.  
 
6.4.4 KYN BLOCKS BOTH KA-INDUCED FACILITATION AND DEPRESSION OF 
MOSSY FIBER EXCITABILITY 
 While UBP310 and ACET were originally designed as KAR antagonists, 
kynurenic acid (KYN) has been characterized as a more general glutamate 
receptor antagonist (Ganong et al., 1983; Alt et al., 2004). In regards to KARs, it 
has been demonstrated that KYN has a much higher affinity for GluK2 over 
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GluK5 KAR subunits (Alt et al., 2004). KYN has also been shown to potentiate 
current at recombinant GluK2/5 and GluK3/5 KARs, through its removal of GluK2 
or GluK3-induced desensitization (Fisher and Mott, 2011).  We explored the 
actions of KYN on KA-induced potentiation and depression of MF excitability.  
We first demonstrated that KYN (3 mM) was able to reverse the 
potentiation observed by 0.3 µM KA in sham-treated animals (Figure 6.4A). 
Similar to previous experiments we then wanted to determine if pre-application of  
KYN was able to prevent the observed facilitation or depression of MF excitability 
by 0.3 µM (Figure 6.4B). In agreement with our previous experiments, we found 
that KYN (3 mM) did not significantly alter the amplitude of the MF antidromic 
spike in sham (95.7 ± 2.2% of control, n = 5; p > 0.05) or pilo-treated animals 
(100.7 ± 2.7% of control, n = 5; p > 0.05; Figure 6.4B). Similar to our studies of 
UBP and ACET, we found that KYN significantly prevented the expected 
facilitation induced by 0.3 µM KA in sham-treated animals (without KYN: 121.5 ± 
2.9% of control, n = 7; with KYN: 95.7 ± 1.6% of control, n = 5; p < 0.001; Figure 
6.4B). In addition the lack of potentiation observed by 0.3 µM KA in pilo-treated 
animals was not significantly different in the presence of CNQX (p > 0.05; Figure 
6.4B).  
In stark contrast to the inability of both UBP and ACET to block the 
depressive effects of high KA, we observed that pre-application of 3 mM KYN 
significantly blocked the depression induced by 10 µM KA in pilo-treated animals 
(without KYN: 14.3 ± 2.2% of control, n = 5; with KYN: 87.5 ± 8.0% of control, n = 




Figure 6.4. Kynurenate prevents KA-induced facilitation and 
depression of mossy fiber excitability. A. Representative time-course 
experiment demonstrating facilitation induced by low KA (0.3 µM) and reversal by 
3 mM KYN. Sample waveforms illustrate the antidromic at each point during the 
experiment. B. Bar graphs demonstrate that that application of 3 mM KYN did not 
alter the baseline amplitude of the MF antidromic spike but was able to block the 
ability of low KA (0.3 µM) to facilitate excitability. In the presence of KYN, 10 µM 
KA significantly increased the MF-antidromic spike amplitude in sham-treated 
animals, and prevented inhibition in pilo-treated animals. Sham-treated group: 




animals, in the presence of 3 mM KYN, 10 µM KA actually significantly increased 
the amplitude of the MF antidromic spike (without KYN: 15.5 ± 8.0% of control, n 
= 5; with KYN: 122.6 ± 8.4% of control, n = 5; p < 0.001; Figure 6.4B). 
 Based upon the data collected from experiments using UBP310 and 
ACET, we anticipated the ability of KYN to block the facilitation of MF excitability 
induced by 0.3 µM KA. Blockade of KA-induced depression by KYN may be 
reflective of its more general antagonistic action of glutamate receptors, as 
opposed to selectively targeting KARs. The observed increase in MF excitability 
in sham-treated animals in the presence of KYN is perplexing, and likely involves 
a more intricate interaction between KYN and the KAR and/or AMPAR 
complexes. Nevertheless, this set of experiments clearly demonstrates that 
depression induced by high KA can be blocked and is perhaps regulated by 
AMPA receptors.  
 
6.4.5 CNQX SELECTIVELY BLOCKS KA-INDUCED FACILITATION, BUT NOT 
DEPRESSION OF MOSSY FIBER EXCITABILITY 
 To explore the possibility that KA-induced depression is possibly mediated 
by AMPA receptors, we utilized CNQX, an extremely potent antagonist at AMPA 
receptors with an IC50 of ~400 nM (Honore et al., 1988; Sheardown et al., 1990). 
To ensure absolute blockade of both AMPA and KA-receptors we utilized 100 µM 
CNQX, an extremely high concentration. Very surprisingly, we found that similar 
to UBP and ACET, CNQX (100 µM) was able to block the facilitation, but not the 
depression of MF excitability induced by KA. Bath application of CNQX (100 µM) 
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did not significantly alter the baseline MF antidromic spike amplitude in sham 
(103.5 ± 9.0% of control, n = 5; p > 0.05) or pilo-treated animals (101.5 ± 7.3% of 
control, n = 3; p > 0.05; Figure 6.5). Furthermore, similar to UBP and ACET, we 
determined that CNQX significantly blocked the ability of 0.3 µM KA to potentiate 
the antidromic spike (without CNQX: 121.5 ± 2.9% of control, n = 7; with CNQX: 
100.3 ± 3.0% of control, n = 5; p < 0.001; Figure 6.5). In addition, the lack of 
potentiation by 0.3 µM KA in pilo-treated animals was not significantly different in 
the presence of CNQX (p > 0.05; Figure 6.5). We next explored the actions of 10 
µM KA in the presence of CNQX, fully anticipating CNQX to prevent the dramatic 
depression induced by high KA. However, we determined that CNQX (100 µM) in 
fact did not prevent the depression in sham (without CNQX: 15.5 ± 8.0% of 
control, n = 5; with CNQX: 48.0 ± 17.0% of control, n = 5; p > 0.05) or pilo-treated 
animals without CNQX: 14.3 ± 2.2% of control, n = 5; with CNQX: 40.7 ± 14.8% 
of control, n = 3; p > 0.05; Figure 6.5).  
It is worthwhile noting that in the presence of CNQX the observed 
depression in both sham and pilo-treated animals by high KA was quite variable. 
In sham-treated animals, in the presence of CNQX, inhibition by 10 µM KA 
ranged from a minimal 4.6% to almost complete inhibition at 91.5%. Similarly in 
pilo-treated animals, in the presence of CNQX, inhibition by 10 µM KA ranged 
from 44.5 – 89%. We suggest that perhaps with additional experiments it would 
become clear that while CNQX does not completely block the depressive action 
of 10 µM KA, it is likely that it would at least limit the extent of this depression. 







Figure 6.5. CNQX blocks KA-induced facilitation but not depression 
of mossy fiber excitability. Application of CNQX (100 µM) did not affect the 
baseline amplitude of the mossy fiber antidromic spike, but was able to prevent 
the facilitation of low KA (0.3 µM) in sham-treated animals. In the presence of 
100 µM CNQX, high KA (10 µM) continued to significantly reduce axon 
excitability in both sham and pilo-treated animals. Representative waveforms 
from a sham-treated animal demonstrate the lack of effect of CNQX (100 µM) on 
the amplitude of the antidromic spike, its blockade of 0.3 µM KA-induced 
facilitation, and the continued depressive actions of 10 µM KA. Sham-treated 








(0.3 µM) are extremely likely to be occurring through KARs, while the depressive 
actions by 10 µM KA are likely not ionotropic, or are at least partially mediated 
through a second-messenger metabotropic function. 
 
6.4.6 KAR-MEDIATED DEPRESSION OF CA3 AXON EXCITABILITY IS 
SIGNIFICANTLY REDUCED IN EPILEPTIC ANIMALS 
 In contrast to the bidirectional regulation of MF excitability, KARs localized 
to the axons of CA3 pyramidal cells reduce excitability in a concentration-
dependent manner (Frerking et al., 2001; Mott et al., 2008). Similar to the issues 
mentioned with alterations in MF excitability, the inability of KARs to properly 
regulate axon excitability in area CA3 could have huge implications in the 
epileptic brain and increase hyperexcitability. Antidromic spikes from the axons of 
CA3 pyramidal cells were evoked by stimulation of CA3 stratum radiatum and 
recorded in the CA3 pyramidal cell layer (Figure 2.2, red electrodes).  
 In agreement with Mott et al. (2008) we observed concentration-
dependent inhibition of CA3 axons with bath applied kainate (Figure 6.6A). 
However, in pilo-treated animals we found that while depression remained intact 
it was significantly less than that observed in sham-treated animals at 0.1 µM (p 
< 0.01), 1 µM (p < 0.001) and 10 µM (p < 0.001).  We found that 0.1 µM KA 
significantly reduces the amplitude (59.9 ± 8.7% of control, n = 6; p < 0.001; 
Figure 6.6B) and area (87.6 ± 5.0% of control, n = 5; p > 0.05; Figure 6.6C) of the 
CA3 axon antidromic spike in sham-treated animals. However in pilo-treated 




Figure 6.6. KAR-mediated depression of CA3 axon excitability is 
impaired in epileptic animals. A. Kainate concentration response curves from 
sham-treated (black squares, n = 4 – 6) and pilo-treated animals (gray circles, n 
= 2 – 6). Depression produced by low KA was significantly reduced in pilo-treated 
animals. Right, Waveforms from sham and pilo-treated animals. Baseline 
antidromic spikes (Con, light gray traces) were depressed by 0.1 µM KA (black 
traces), and further depression induced by 10 µM KA (gray traces). Depression 
by 0.1 µM and 10 µM KA was significantly reduced in pilo-treated animals. 
Application of 0.1 µM significantly decreased the amplitude (B.) of both sham- 
and pilo-treated animals. KA significantly reduced the area (C.) of sham-treated, 
but not pilo-treated animals. KA (0.1 µM) significantly increased the half-width in 




and was significantly different than that observed in sham-treated animals (91.5 ± 
2.7% of control, n = 5; p < 0.05; Figure 6.6B). In addition, we did not observe any 
change in the area of the CA3 axon antidromic spike with 0.1 µM, a finding also 
different from sham-treated animals (101.3 ± 1.2% of control, n = 5; p < 0.01; 
Figure 6.6C). We also examined possible alterations in the half width of the CA3 
antidromic spike and determined that it was significantly increased in both sham-
treated (141.6 ± 9.5% of control, n = 6; p < 0.01) and pilo-treated animals (110.6 
± 3.1% of control, n = 4; p < 0.05; Figure 6.6D), but to significantly different levels 
(p < 0.05; Figure 6.6D). This finding of an increase in the half width of the CA3 
antidromic spike by KA is in agreement with Mott et al. (2008). Overall these 
findings demonstrate that KA-induced depression of CA3 axon excitability is 
significantly impaired in epileptic animals. Thus we suggest that in the epileptic 
brain the inhibitory tone of CA3 axonal projections is reduced, and may lead to 
increased hyperexcitability and potentially increased transmission into area CA1.  
 
6.4.7 UBP310 BLOCKS KA-INDUCED DEPRESSION OF CA3 AXON EXCITABILITY 
 Similar to previous experiments with MF excitability, we examined the 
ability of the KAR antagonist UBP310 to block the KA-induced depression in 
sham- and pilo-treated animals (Figure 6.7). We found that in both sham (102.6 ± 
9.0% of control, n = 3; p > 0.05; Figure 6.7) and pilo-treated animals (102.0 ± 
2.2% of control, n = 2; p > 0.05; Figure 6.7) bath application of UBP310 (3 µM) 
had no effect on the amplitude of the CA3 antidromic spike. However, we 







Figure 6.7. UBP310 blocks KA-induced depression of CA3 axon 
excitability. Application of UBP310 (3 µM) did not affect the baseline amplitude 
of the CA3 axon antidromic spike in sham or pilo-treated animals. The presence 
of UBP310 was sufficient to block the depression by low 0.1 µM KA observed in 
sham-treated animals. Representative waveforms from a sham-treated animal 
demonstrate the lack of effect of UBP310 (3 µM) on the amplitude of the CA3 
antidromic spike as well its blockade of 0.1 µM KA-induced depression. Sham-






blocked the anticipated depression by 0.1 µM KA (without UBP310: 59.9 ± 8.7% 
of control, n = 6; with UBP310: 106.0 ± 13.4% of control, n = 3; p < 0.05; Figure 
6.7). In pilo-treated animals the presence of UBP310 appeared to block the 
depressive actions of 0.1 µM KA, however the difference was not significant likely 
due to variability and a low n-value (without UBP: 91.5 ± 2.7% of control, n = 2; 
with UBP310: 101.6 ± 4.1% of control, n = 2; p > 0.05; Figure 6.7). The 
selectively of UBP310 for KARs demonstrates that the depression of CA3 axon 
excitability is mediated by KARs. In Chapter 4 we observed a significant 
reduction in KAR subunit expression in area CA3 at both 60d and 200d post-SE. 
This reduction in KAR subunit expression likely serves as a rationale for the 
observed decrease in KAR-regulation of CA3 axon excitability. 
 
6.5 DISCUSSION 
 Together the results of this study provide the first known examination of 
alterations in KAR-mediated regulation of hippocampal axon excitability in 
epileptic animals. In agreement with previous studies we determined 
concentration-dependent actions of KA on both MF and CA3 axon excitability in 
sham-treated animals (Kamiya and Ozawa, 2000; Schmitz et al., 2000; Mott et 
al., 2008). These results are in line with the observation that low concentrations 
of KA induce opposing actions on MF and CA3 axons, as low KA facilitates MF 
excitability and reduces CA3 axon excitability (Mott et al., 2008). In epileptic 
animals we observed that the facilitation of MF excitability by low KA (0.3 µM) 
and depression of CA3 axon excitability by low KA (0.1 µM) were both 
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significantly impaired. This finding suggests the possibility that synaptic 
transmission, including into areas CA3 and CA1, may be critically impaired in 
epileptic animals. In addition these changes may reflect compensatory changes 
to limit network excitability in the epileptic brain.  
 
6.5.1 POSSIBLE ROLE OF METABOTROPIC KARS  
  KARs localized to presynaptic mossy fiber terminals have been reported 
to regulate transmission in a bidirectional, concentration-dependent manner, 
where low concentrations of KA facilitate, and high concentrations of KA depress 
the EPSC (Contractor et al., 2000; Kamiya and Ozawa, 2000; Schmitz et al., 
2000; Schmitz et al., 2001a). In agreement with these findings KA has also been 
shown to have the same bidirectional control on axon excitability, with low KA 
facilitating and high KA depressing MF excitability (Kamiya and Ozawa, 2000; 
Schmitz et al., 2000). While these two functions of KARs are distinct from one 
another, KA does appear to have the same effect. Therefore, alterations in KAR-
regulation of axon excitability can likely be extrapolated to suggest similar 
findings in transmitter release.  
 While the actions of KA on axon excitability and presynaptic transmitter 
release are well documented, the mechanism regulating these actions is not as 
clear. The facilitatory effects of KA on axon excitability are likely due to a slight 
depolarization of the axon with serves to increase excitability (Schmitz et al., 
2000). This is observed as a potentiation of the antidromic spike or orthodromic 
fiber volley, as well as an increase in transmitter release and potentiation of the 
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EPSC. In contrast, the decrease in axon excitability by high concentrations is not 
as straight-forward. Some studies have suggested that the depression is due to a 
substantial increase in depolarization resulting in the inactivation of Na+ channels 
and a subsequent blockade of action potentials (Contractor et al., 2000; Kamiya 
and Ozawa, 2000; Schmitz et al., 2000). In support of this line of reasoning is 
that the effects of KA  on transmitter release can be mimicked by raising 
extracellular K+ levels to increase depolarization (Schmitz et al., 2000). These 
findings support an ionotropic mechanism of KA-induced facilitation and 
depression of axon excitability as well as presynaptic regulation of transmitter 
release.  
 A metabotropic mechanism has also been identified as a possible 
explanation of high KA-induced depression of presynaptic transmitter release, 
and likely also explains the decrease in axon excitability observed in the current 
study. Negrete-Diaz et al. (2006) reported that KA-induced depression of 
transmitter release could be blocked by application of the G-protein inhibitor 
pertussis-toxin (PTX), a finding indicative of a metabotropic action. In support of 
this mechanism, while high K+ does in fact produce significant depression of 
transmitter release, it recovers to baseline fairly quickly, while the depressive 
actions of KA are significantly longer lasting.  
While Negrete-Diaz et al. (2006) demonstrated a metabotropic mechanism 
of high KA-induced depression of transmitter release, we believe that these 
findings can be generalized to our examination of axon excitability. We found that 
while facilitation induced by low concentrations of KA was blocked by all 
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antagonists examined, the depressive actions were much more complicated. 
Most surprising was the inability of the glutamate receptor antagonist CNQX to 
block the depression. While we did not directly explore a metabotropic action, we 
feel that our findings are suggestive of this mechanism. Therefore, we propose 
that while facilitation of axon excitability is mediated by ionotropic KARs, the 
depression induced by high KA is likely through a metabotropic action.  
 
6.5.2 ACTIONS OF KYN ON MF EXCITABILITY 
 We observed that facilitation of MF excitability by low concentrations of KA 
was readily blocked by all antagonists we examined. In contrast, the KA-induced 
depression of MF excitability by high KA was only inhibited by KYN. As 
previously mentioned, KYN is commonly used as a more global glutamate 
antagonist and at high concentrations inhibits AMPA, NMDA, and KA-receptors 
(Ganong et al., 1983; Alt et al., 2004). While KYN does demonstrate some KAR 
subunit selectively, by preferentially blocking the GluK2 subunit, its most notable 
action at KARs is potentiating current from GluK2/5-containing KARs (Fisher and 
Mott, 2011). Regardless of these actions of KYN the ability of this compound to 
not only block but potentiate axon excitability with 10 µM KA is perplexing. One 
possible explanation, although improbable, could be that if depression is 
mediated through a metabotropic action, which we believe is likely, that perhaps 
the high concentration of KYN (3 mM) used in the current study had inhibitory 
effects on metabotropic glutamate receptors. This would explain the ability of 
KYN, but not CNQX, UBP or ACET to inhibit the KA-induced depression of MF 
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excitability. It should also be noted that many of the studies examining 
antagonistic properties of not only KYN, but most compounds, have utilized 
glutamate as the agonist (Ganong et al., 1983; Alt et al., 2004; Fisher and Mott, 
2011).  It is entirely possible, and quite likely, that the antagonistic actions of KYN 
are significantly different when kainate is used as the agonist.  
 
6.5.3 ROLE OF ZINC ON MOSSY FIBER KARS 
  High quantities of zinc are found within the hippocampus, particularly 
within the hippocampal mossy fibers (Maske, 1955; McLardy, 1962). Within the 
mossy fiber terminals zinc is actually co-localized with glutamate and is released 
in a Ca2+-dependent manner (Assaf and Chung, 1984; Howell et al., 1984). Zinc 
has also been reported to play critical roles in cognition and aging (Szewczyk, 
2013). Furthermore, synaptically released zinc has been shown to inhibit both 
NMDA and GABAA receptors (Vogt et al., 2000; Ueno et al., 2002; Ruiz et al., 
2004), but seemingly has minimal effects on AMPA receptors (Mayer et al., 1989; 
Dreixler and Leonard, 1994; Lin et al., 2001; Mott et al., 2008). More recently it 
was demonstrated that synaptically released zinc inhibits postsynaptic KARs 
localized to the mossy fiber – CA3 synapse, and preferentially acts on GluK4, or 
GluK5-contaiing KARs (Mott et al., 2008).  
 In addition to a significant role in regulating synaptic transmission at the 
mossy fiber – CA3 synapse, zinc has also been shown to regulate axon 
excitability. Mott et al. (2008) demonstrated that facilitation of MF excitability 
produced by low concentrations of KA could be prevented by exogenously 
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applied zinc. In contrast, zinc did not appear to effect the depressive actions of 
KA on CA3 axons.  Increases in synaptic activity, as noted in epilepsy, as well as 
the aberrant sprouting of mossy fibers, have been shown to increase levels of 
zinc (Assaf and Chung, 1984; Howell et al., 1984; Li et al., 2001a; Li et al., 
2001b; Lin et al., 2001).  
In the current study we determined that facilitation, but not depression of 
MF excitability is significantly reduced in epileptic animals. In light of the current 
studies, we suggest that this may be due to the apparent increase in the 
concentration of zinc in the MFs, which serves to block the facilitatory effects of 
KA. In regards to CA3 axons, we observed that KA-induced depression is 
significantly reduced in epileptic animals. While Mott et al. (2008) demonstrated 
that zinc was not able to block KA-induced depression of CA3 axons in control 
animals, we cannot rule out the possibility that the increased levels of zinc in 
epilepsy may now function to inhibit KA-induced depression. To explore these 
possibilities experiments utilizing a zinc chelator would be beneficial, and allow 
us to essentially lower the levels of zinc in epileptic slices back to baseline levels 
and determine if we see the appropriate KA-induced facilitation of MF excitability 
and KA-induced depression of CA3 axon excitability.  
 
6.5.4 POSSIBLE CHANGES IN KAR SUBUNIT COMPOSITION 
 While the possibility that increased levels of zinc may be responsible for 
the lack of observed KA-induced facilitation of MFs and depression of CA3 axons 
in epileptic animals, based on our previous data, we suggest that alterations in 
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KAR subunit expression may also serve as an explanation. In regards to MF 
excitability we determined that facilitation, but not depression was absent in 
epileptic animals. We also observed that expression of the GluK4 subunit was 
significantly reduced in area CA3 of animals 60 and 200d post-SE (Chapter 4), 
suggesting that the lack of facilitation may be due to the reduction in GluK4 
subunit expression. In support of this proposition, studies utilizing knockout 
animals have demonstrated that animals lacking the high affinity GluK4 and/or 
GluK5 subunits display impaired facilitation, but not depression (Contractor et al., 
2003; Fernandes et al., 2009; Catches et al., 2012). Therefore, we believe that 
the loss of KA-induced facilitation of MF axon excitability is most likely due to the 
significant reduction in GluK4 subunit expression. 
 While many studies have explored the KAR subunit composition 
responsible for MF facilitation and depression, few studies have examined KAR-
regulation of CA3 axon excitability. Mott et al. (2008), reported that zinc 
preferentially inhibits GluK4 or GluK5-containing KARs and that zinc did not block 
the KA-induced depression of CA3 axon excitability. This suggests that KARs 
localized to CA3 axons are likely GluK2/3-containing KARs. Our anatomical data 
from epileptic animals (Chapter 4), demonstrated a significant decrease in 
GluK2/3 expression in area CA3. If KA-induced depression of CA3 axons is in 
fact mediated by GluK2/3-containing KARs, our observation of reduced inhibition 
could be explained via alterations in subunit expression. However, we still cannot 
rule out the possibility that increased levels of zinc may contribute to these 
findings. In addition, it should be noted that auxiliary proteins, such as Neto1 and 
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Neto2, have been demonstrated to dramatically impact KAR trafficking and 
pharmacology. As the current study did not directly explore the interaction 
between Neto1 and/or Neto2 on KARs, we cannot rule out the possibility that 
observed alterations are not due to changes in expression of the Neto proteins.  
   
6.6 SIGNIFICANCE  
 The findings of this study provide the first look at alterations in KAR-
mediated regulation of hippocampal axon excitability in epileptic animals.  We 
demonstrated that facilitation of MF excitability is absent in epileptic animals, 
likely due to alterations in KAR subunit expression. This reduction in facilitatory 
drive into area CA3 of epileptic animals could serve as a compensatory 
mechanism to limit epileptogenic activity. Alternatively, it also reveals that the 
mossy fiber pathway, the main source of communication between the dentate 
gyrus and area CA3, is significantly impaired in epileptic animals. In addition this 
study suggests that the depressive actions of high KA on MF excitability are likely 
through a metabotropic action, a finding supported by previous studies (Cunha et 
al., 1999; Negrete-Diaz et al., 2006). Furthermore, we report that KA-induced 
depression of CA3 axon excitability is significantly impaired in epileptic animals, 
likely due to alterations in KAR subunit expression.   This reduced inhibition of 
CA3 axons would likely contribute to bursting within the highly interconnected 
CA3 network and would most likely increase synaptic input into area CA1 in the 
epileptic brain. Overall we suggest that the observed changes in axon excitability 
in both the mossy fibers and area CA3 are due to the reduction in KAR subunit 
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expression in the epileptic brain. Further studies would need to be conducted to 
solidify the impact that the observed changes would have on network excitability 






GENERAL DISCUSSION AND SIGNIFICANCE 
7.1 DISCUSSION 
 The data collected from these studies significantly contribute to the 
scientific literature regarding the impact of status epilepticus and the 
development of epilepsy on alterations in both inhibitory and excitatory networks. 
We have demonstrated that while GABAAR subunit composition is dramatically 
altered following a prolonged SE event, agents such as stiripentol remain 
effective in terminating SE, and thus may serve as potential therapeutic targets. 
We also examined changes in excitatory neurotransmission mediated by the 
kainate receptor and demonstrated a significant decrease in receptor subunit 
expression and a subsequent decrease in KAR-mediated transmission in the 
epileptic brain. We feel that these studies are extremely valuable to our 
understanding and knowledge of SE and epilepsy, as well as anatomical 
changes that occur in the brain. These studies may serve as building blocks for 
potential therapeutic targets for the treatment of epilepsy and/or associated 
comorbidities.  The findings revealed in this document are summarized in Tables 
7.1 – 7.4. 
 SE is a neurologic emergency which requires prompt medical attention 
and immediate therapeutic intervention. As nearly 50% of SE cases occur in 






Table 7.1 Summary of results detailed in Chapter 3 
 
Question Hypothesis Findings Impact/Significance 










 Actions of STP  
do not require γ2-
containing GABAARs 
 
 Is STP effective  
in terminating SE 
when resistance to 
BZDs has 
developed? 
 STP will  
remain effective 
in a model of 
BZD-resistant SE 
 STP terminates brief and  
prolonged SE 
 
 Less pharmacoresistance  
develops to STP than to DZP 
 
 STP potentiates GABAergic  
transmission in an age-
dependent manner 
 
 STP does not act through 
the BZD-binding site 
 
 STP, not DZP, potentiates  
phasic and tonic GABAergic 
transmission after prolonged 
SE 
 
 STP, not DZP, potentiates  
mIPSCs after prolonged SE 
 STP remains  
effective in terminating 
BZD-resistant prolonged SE 
 
 STP is effective in all  
age groups examined but is 
most effective in younger 
animals 
 
 STP alone, or in  
conjunction with other 
AEDs would be effective in 
the treatment of brief and 
prolonged SE 
 
 Development of  
additional therapeutics with 
pharmacological profiles 






Table 7.2 Summary of results detailed in Chapter 4 
 
Question Hypothesis Findings Impact/Significance 
 KARs have 
been implicated in 
seizure disorders as 
well as their 
comorbidities 
 
 KARs are widely 
expressed throughout 
the hippocampus, a 
region prone to 
seizure generation and 
propagation 
 
 How does the 
progression of 
epilepsy alter the 







be observed in 
hippocampal 
regions DG, CA3 
and CA1 
 








5d-     GluK2/3 & GluK5 
60d-    GluK2/3 
200d-    GluK2/3, GluK4 & GluK5 
 
CA3: 
5d-     GluK2/3 & GluK5 
60d-    GluK2/3 & GluK4 
200d-    GluK2/3 & GluK4 
 
CA1: 
5d-     GluK2/3 & GluK5 
60d-    GluK2/3 
200d-    GluK2/3  
 
 GFAP expression increased  
at all time-points in all regions 
 
 Reduced GluK2/3 expression  
is restricted to limbic regions 
 
 Pilo-induced SE  
produces significant 
alterations in KAR subunit  
expression 
 
 Alterations are  
independent of region 
and duration of epilepsy 
 





 Likely correlated to  
observed comorbidities of 
epilepsy i.e., cognition, 






      Table 7.3 Summary of results detailed in Chapter 5 
 
Question Hypothesis Findings Impact/Significance 
 KAR-mediated  
transmission is increased 
in DG of epileptic animals 
 
 KARs regulate  
transmission in area CA3 
 
 KAR subunit  
expression is significantly 
reduced in area CA3 of 
epileptic animals 
 
 Is KAR-mediated  
transmission at the mossy 
fiber – CA3 synapse 
altered in the epileptic 
brain? 
 Neurotransmission  
mediated by KARs will 
be significantly 
reduced at the  
mossy – fiber CA3 
synapse of epileptic 
animals  
In epileptic animals: 
 KAR-mediated  
transmission at mossy 
fiber – CA3 synapse is 
significantly reduced 
 
 Synaptic integration at  
this synapse is impaired 
 
 Reduction is specific  




 Presynaptic regulation  
of  PPF was not different  
 Epilepsy generates  
opposing alterations in 
KAR-mediated 
transmission at two 
different synapses of 
the same axon 
 
 Observed reduction  
is likely a compensatory 
mechanism resulting 
from the increased 
excitatory circuit in DG 
 
 Reduction may  








Table 7.4 Summary of results detailed in Chapter 6 
 
Question Hypothesis Findings Impact/Significance 




 KAR-mediated  
axon excitability is 
subunit dependent 
 
 KAR subunit  
expression is 
significantly 
reduced in epileptic 
animals 
 
 Is KAR-  
mediated regulation 
of axon excitability 
altered in epileptic 
animals? 
 The ability of  
axonal KARs to 
regulate excitability 
will be reduced in the 
epileptic brain  
Mossy fibers: 
 Facilitation but not  
depression is absent in 
epileptic animals 
 
 Facilitation is blocked  
by KAR antagonists 
 
 Depression is likely   




 Depression is  
significantly reduced in 
epileptic animals 
 
 Depression is  
blocked by a KAR antagonist 
 KAR regulation of  
axon excitability is  
impaired in epileptic 
animals 
 






 In CA3 axons,  
reduction likely contributes 
to epileptogenic activity  
 
 Alterations likely  
influence synaptic 




is essential. Our data demonstrates that in a model of prolonged SE, when 
resistance to BZDs develops, STP continues to terminate SE, in an age-
dependent manner. Of note from this study was the observation that the actions 
of STP are independent of the BZD-binding site of the GABAA receptor, a finding 
in agreement with a previous study (Quilichini et al., 2006). While this allows for 
STP to work in conjunction with additional AEDs, such as clobazam, the exact 
mechanism of STP remains elusive. It remains a possibility that STP may act on 
a separate and distinct site of the GABAA receptor. In addition we feel that the 
ability of STP to potentiate tonic GABAergic transmission, a mechanism which is 
maintained following prolonged SE, greatly contributes to its anticonvulsant 
effects. As extrasynaptic δ-containing receptors are not altered during prolonged 
SE (Goodkin et al., 2008), this population of GABAA receptors provide a unique 
target for the development of new AEDs. The findings provided in Chapter 3 are 
the first examination of the ability of STP to terminate BZD-resistant SE.  
KARs have been implicated in several disease states, specifically 
epilepsy, where systemic administration of kainate induces SE and the 
development of spontaneously occurring seizures through activation of GluK2-
containing KARs (Mulle et al., 1998; Fritsch et al., 2014). KAR subunits GluK1 – 
5 are expressed throughout the brain and hippocampus, specifically at the mossy 
fiber – CA3 synapse, a region considered to be highly epileptogenic and 
sensitive to excitotoxicity. Despite the relationship between KARs and seizure 
disorders, few studies have explored KARs in the epileptic brain.  Furthermore, 
the studies that have explored this interaction have focused on the DG, a region 
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characterized by aberrant mossy fiber sprouting in epilepsy. As a whole, the 
experiments discussed in Chapters 4 – 6 provide the first in-depth examination of 
KAR subunit expression and neurotransmission in epilepsy.  
 One aspect of KAR-mediated neurotransmission that we did not explore in 
the current study is the role of the auxiliary transmembrane proteins Neto1 and 
Neto2. While both proteins are expressed in the hippocampus, data suggests 
that expression of Neto1 is more abundant and appears restricted to area CA3 
and the DG (Copits et al., 2011; Straub et al., 2011b). In addition, studies utilizing 
Neto1-/- animals have demonstrated that KAR-mediated ionotropic and 
metabotropic transmission is significantly impaired at the mossy fiber – CA3 
synapse (Straub et al., 2011b; Tang et al., 2011; Wyeth et al., 2014). Reportedly 
this reduction in KAR-mediated transmission is due to a decrease in surface 
trafficking of the GluK2/3 subunit to the postsynaptic CA3 cell (Wyeth et al., 
2014). In the current study we observed a rapid and sustained decrease in 
GluK2/3 expression in hippocampal regions, specifically area CA3 which was 
also accompanied by a reduction in KAR-mediated transmission. Due to 
limitations in antibody availability and selectivity we did not explore alterations in 
Neto1 or Neto2 expression in epileptic animals. It is possible that Neto1 may be 
significantly impaired in animals following SE and this reduction impairs proper 
trafficking of the GluK2/3 subunit and thus reduces transmission.  
 The current study focused predominately on the ionotropic actions of 
KARs. While we suggest that the depression of mossy fiber excitability induced 
by high KA (10 µM) is likely through a metabotropic action we did not specifically 
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explore this possibility. Nevertheless, the concept that KARs mediate both 
ionotropic and metabotropic transmission in the hippocampus should be 
appreciated. In addition to their role in regulating excitatory transmission, 
activation of KARs by kainate has been demonstrated to depress GABA release 
at inhibitory synapses (Rodriguez-Moreno et al., 1997). This inhibition was 
determined to occur through a presynaptic activation of metabotropic KARs 
linked to the inhibitory Gi/o protein, representing the first identification of 
metabotropic KARs (Rodriguez-Moreno and Lerma, 1998). The ability of KARs to 
regulate metabotropic transmission prompted additional studies which eventually 
established that glutamate release at the Schaffer collateral – CA1 synapse is 
regulated by metabotropic KARs (Frerking et al., 2001), and that the depression 
of axon excitability and glutamate release observed at the mossy fiber – CA3 
synapse likely involves metabotropic KARs (Negrete-Diaz et al., 2006). In 
addition, it is well documented that KARs mediate postsynaptic excitability 
through metabotropic regulation of the slow and medium AHP (Melyan et al., 
2002; Melyan et al., 2004; Fisahn et al., 2005; Grabauskas et al., 2007). Overall 
these studies emphasize the diverse role of KARs within the hippocampus and 
demonstrate their ability to regulate both excitatory and inhibitory transmission 
through ionotropic and metabotropic mechanisms.  
 
7.2 IMPACT OF REDUCED KAR-MEDIATED TRANSMISSION ON HIPPOCAMPAL NETWORK 
EXCITABILITY 
Our data concerning altered expression of KARs likely has significant  
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implications for hippocampal network activity. SE and the progression to 
spontaneous seizures is associated with an increase in network excitability within 
the DG due to sprouting of aberrant mossy fibers and the subsequent 
development of an excitatory circuit partially mediated by KARs (Cronin et al., 
1992; Wuarin and Dudek, 1996; Sutula et al., 1998; Epsztein et al., 2005). To 
compensate for this increase in excitability, we suggest that KAR subunit 
expression is reduced in area CA3 leading to a decrease in excitatory 
transmission in this region. This decrease in excitatory transmission in area CA3 
was specific to KARs, as AMPAR-mediated transmission was unaltered. In 
addition, facilitation but not depression of MF excitability, which likely influences 
presynaptic glutamate release was also reduced in epileptic animals. These 
studies suggest that the reduction in KAR subunit expression and function serves 
to limit network excitability in area CA3 of epileptic animals. 
At the Schaffer collateral – CA1 synapse, activation of KARs by kainate or 
domoate has been reported to depress glutamate release in area CA1, thus 
reducing excitatory transmission (Chittajallu et al., 1996; Kamiya and Ozawa, 
1998; Vignes et al., 1998; Frerking et al., 2001). Our observation that KAR-
mediated depression of CA3 axon excitability is reduced in epilepsy suggests 
that excitatory transmission into area CA1 may be increased. Thus while the 
reduction in KAR subunit expression and function at the mossy fiber – CA3 
synapse may help reduce network excitability, the reduction in KAR regulation of 
CA3 axons may increase network excitability at the Schaffer collateral – CA1 
synapse. However, this concept is based solely on our studies of CA3 axon 
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excitability, and thus additional studies would need to be conducted to further 
determine the impact of this alteration on CA1 network excitability. 
 
7.3 FUTURE DIRECTIONS  
 Our data demonstrating that STP is effective in terminating BZD-resistant 
status epilepticus could potentially impact the treatment algorithms currently used 
for refractory SE. However, in order for STP to be used clinically to treat SE 
additional studies need to be performed. While our data clearly demonstrates 
that STP effectively terminates both brief and prolonged SE, these findings were 
based purely on the appearance of behavioral convulsions. While these 
behavioral affects are correlated to electrographic activity (Racine, 1972), we did 
not specifically explore this relationship. In addition, the ability to demonstrate 
that STP is effective over several animal models of SE would add tremendous 
validity to our findings. Therefore, future studies would need to determine the 
impact of STP on EEG activity as well as determine the effectiveness of STP in 
additional models of SE. Furthermore, STP is commonly utilized in conjunction 
with other compounds such as clobazam (CLB) (Chiron et al., 2000; Ng and 
Collins, 2007). While the current study did explore the ability of STP and CLB to 
potentiate GABAergic transmission in SE-experienced animals, we did not 
examine the impact of these compounds together on behavioral seizures, 
something that would provide direct clinical relevance to the method in which 
STP is currently utilized.  
 Our anatomical data demonstrates that KAR subunit expression is  
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significantly reduced in all brain regions post-SE. The electrophysiological data 
collected from area CA3 is in agreement with these anatomical alterations, 
particularly the observed decrease in GluK2/3 and GluK4 subunit expression. 
However, in the DG we observed a significant increase in KAR-mediated 
transmission, a finding in agreement with a previous study (Epsztein et al., 2005). 
However, this does not correlate with the decreases in KAR subunit expression 
in the DG. Future experiments should be aimed at understanding this 
discrepancy, which likely involves the process of neurogenesis which is unique to 
the DG. We feel that anatomical data collected from epileptic animals may be 
hindered by the massive increase, and subsequent decrease, in neurogenesis 
that takes place post-SE (Parent et al., 1997; Gray and Sundstrom, 1998; 
Hattiangady et al., 2004). Future studies should be aimed at unraveling the 
impact of neurogenesis on KAR subunit expression. Similarly, a previous study 
has suggested that KARs are colocalized with astrocytes (Vargas et al., 2013). 
While the current study did not observe the appearance of any astrocytic labeling 
in immunohistochemical analysis of KAR subunit expression this possibility 
should be explored further, as we did find significant increases in GFAP 
expression in all brain regions, and all time-points explored. As previously 
discussed the current study did not explore potential alterations in Neto1 and 
Neto2 expression in the epileptic brain. Given the apparent role of Neto1 in 
trafficking of KAR subunits, particularly in area CA3 (Copits et al., 2011; Straub et 
al., 2011b; Wyeth et al., 2014), future experiments should unquestionably explore 
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the impact of SE and epilepsy on expression of the auxiliary proteins Neto1 and 
Neto2 in regulating KAR subunit expression and function.  
 We concluded that the apparent decrease in KAR-mediated excitatory 
neurotransmission in area CA3 may be a compensatory modification. This notion 
was based on our finding, in agreement with other studies, that KAR-mediated 
transmission is increased in the DG, and that this increase significantly impairs 
the ability of the DG to properly integrate transmission entering the hippocampus 
(Epsztein et al., 2005; Artinian et al., 2011). Thus KARs in area CA3 are reduced 
in an attempt to limit transmission into this hyperexcitable region. Future 
experiments should be specifically aimed at determining if transmission entering 
the DG via the perforant path produces a weakened KAR-mediated current in 
area CA3. This finding would add support to the idea of a compensatory 
downregulation of KARs in epileptic animals. Additionally, we made several 
claims that the reduction in KAR subunit expression and the functional impact of 
these changes could precede the development of comorbid conditions common 
in epilepsy, such as anxiety, depression and cognitive impairment. A recent study 
has concluded that the GluK4 subunit may play a role in anxiety and depressive-
phenotypes in animals (Catches et al., 2012). However, future experiments 







7.4 HYPOTHESIS REVISITED 
 The overarching hypothesis that served as the catalyst for the studies 
outlined in this manuscript was that status epilepticus and the development of 
epilepsy produce striking alterations in GABAA and kainate receptor populations. 
Furthermore, that these alterations significantly impact receptor pharmacology 
and neurotransmission in the SE-experienced brain.  
 The findings detailed in Chapters 3 – 6 of this document support this 
hypothesis. Briefly, previous studies had demonstrated that SE resulted in 
subunit selective internalization of the GABAA receptor resulting in the 
development of pharmacoresistance to commonly prescribed BZDs (Walton and 
Treiman, 1988; Kapur and Macdonald, 1997; Jones et al., 2002; Goodkin et al., 
2008). In conjunction with these studies we demonstrated that the 
pharmacological profile of STP, a compound utilized as add-on therapy for 
treatment of Dravet syndrome, was effective in terminating both brief and 
prolonged SE by sustaining its potentiation of GABAergic transmission. In 
addition we studied alterations in excitatory neurotransmission mediated by the 
KAR following induction of SE. We demonstrated that SE produces significant 
and region specific reductions in the expression of KAR subunits, and that these 
alterations yield a significant decrease in KAR-mediated transmission at the 
mossy fiber – CA3 synapse, as well as reducing the ability of KARs to properly 
regulate axon excitability. Together these studies support our hypothesis that SE 
and the development of epilepsy, significantly alters both the pharmacology and 
physiology of hippocampal receptor populations.  
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7.5 SIGNIFICANCE REVISITED 
Status epilepticus, characterized as a prolonged seizure, is an extremely 
serious event that requires immediate medical attention.  Nearly 40% of people 
who experience a single SE event go on to develop epilepsy, making it the most 
challenging long-term consequence associated with SE (Hesdorffer et al., 1998). 
While several lines of treatment options for SE are available, approximately 20 – 
40% of people prove refractory to these agents, significantly increasing their risk 
for development of epilepsy, associated comorbidities and death (French, 2007). 
In light of the staggering impact that SE and seizure disorders can impart, the 
development of more effective therapeutics is essential. However, in order to 
develop these drugs we must better understand the impact that SE and the 
development of epilepsy have on the brain, particularly how receptor populations 
are altered and the impact of those alterations on neurotransmission.  
The studies in this document provide new and essential information 
regarding how both GABAergic and glutamatergic receptor populations are 
altered following SE. While BZDs are considered the first-line of therapy for 
treatment of SE, they develop significant pharmacoresistance that can put 
patients in extreme danger as the seizures progress. We have demonstrated that 
STP, a compound already clinically used for Dravet syndrome, is highly effective 
in terminating SE and develops less pharmacoresistance. This finding will 
hopefully lead to further exploration of STP as a potential treatment method in 
the patient population. In addition, our findings demonstrate the types of 
compounds and their pharmacological profiles that are effective in treating BZD-
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resistant SE, and suggest that the development of additional compounds with 
similar profiles may be advantageous.  
The final set of studies explored alterations in KAR subunit expression and 
neurotransmission. Our understanding of KARs and their role in hippocampal 
neurotransmission has dramatically increased over the past couple decades. 
Emerging from these studies was the relationship between KARs and epilepsy. 
The studies outlined in this document further this field by demonstrating that SE 
and the progression of epilepsy significantly alter the expression of KAR subunits 
throughout the three central regions of the hippocampus- DG, CA3 and CA1. In 
support of the reduction in KAR subunit expression we observed a significant and 
selective decrease in KAR-mediated transmission, as transmission mediated by 
AMPA receptors was unaltered. These findings likely demonstrate a 
compensatory downregulation of KAR-mediated excitatory neurotransmission in 
the epileptic brain. However, a consequence of this reduction to limit 
epileptogenic activity may be the development of comorbidities associated with 
epilepsy. In addition these studies could potentially serve as a rationale for the 
selective targeting of KARs for therapeutic agents. Together these studies 
contribute new and exciting information to our knowledge concerning the impact 
of SE and the development of epilepsy on the inhibitory and excitatory systems 
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